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Abstract 
Coronary heart disease (CED) is the major cause of mortality in Western societies. 
The main risk factors are plasma lipoprotein concentrations, smoking, blood pressure and 
family history. The effect of family history implies a genetic contribution to the aetiology, 
support for which has also come from twin, and other heritability studies. The genetic 
component of CHID may be studied by the candidate gene approach, whereby the genes of 
products most likely to be involved in the processes leading to CHD, and in its risk factors, 
are analysed. The plasma concentration of apolipoprotein (apo) B, the major protein 
component of low density lipoprotein (LDL), is positively correlated with the risk of 
developing CHD. 
In this research, the gene for apo B was analysed for restriction enzyme fragment 
length polymorphisms (RFLPs). A RFLP is caused by a sequence change in the DNA, and 
results in length variation in the fragments. RFLPs for apo B have been shown to be 
associated with CHD and the plasma concentrations of cholesterol, triglycerides and apo B 
in some population studies. However, other studies have failed to confirm these relations. 
The work described in this thesis was designed to overcome some of the problems which 
niay have produced these inconsistencies. A random sample of 300 men, aged 49-65 years, 
residing in South Wales was studied. RFLPs determined in these individuals were used to 
generate genotypes and haplotypes (arrangements of specific alleles on a single 
chromosome). Significant associations were found between some genotypes and some 
haplotypes with altered concentrations of plasma total cholesterol and LDL cholesterol and 
with risk of CHD and/or with obesity. Presence of Xbal site (X2X2 genotype) was 
significantly associated with higher concentrations of plasma LDL cholesterol (p=0.0 19). 
Absence of Mspl site (M 1) was associated with significantly elevated concentrations of 
plasma total and LDL cholesterol (p < 0.05) by both the techniques of genotype and 
haplotype analysis. EcoRl RFLP (absence of the site - El) was the minimum haplotype 
necessary to detect a significant association with decreased plasma cholesterol 
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concentrations (p < 0.05). Genotypes generated from alleles defined by the Mspl-EcoRl 
RFLPs were associated with significant variation in serum cholesterol concentration (p < 
0.03), showing a stratification of concentration with the highest being associated with loss 
of the Mspl site and the lowest with the presence of the EcoRl site. Both these RFLPs result 
in charged aminoacid alterations, and lie close to the LDL receptor binding domain of apo 
B. The minimum haplotype necessary for detection of apo B with CHD was Xbal-Mspl (p 
< 0.05). The minimum haplotype associated with obesity was the RFLP pair Pvull-Xbal (p 
< 0.05). 
Further examination for mutations of the CpG dinucleotide which may influence 
cholesterol metabolism was undertaken by screening around the putative LDL receptor- 
binding domain (RBD) of the apo B gene. One variant was detected for aminoacid residue 
3500 (Arg,,,,, 4 Gln) mutation, and two variants for aminoacid residue 3611 which also 
corresponds to the MspI mutation (Arg,,, ,4 Gln). 
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Quoted from the'TheBhagavadGita ', Krishna speaking toArjuna. 
(translated from the Sanskrit by Juan Mascaro) 
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Purpose of the Study 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in the 
affluent industrialised western societies accounting for 40%-50% of deaths (WHO expert 
committee 732,1986). Coronary heart disease (CHD) is usually a consequence of 
atherosclerosis of the coronary vessels. The underlying lesion is the atheroma, which is 
responsible for angina and myocardial infarction when coronary arteries are involved. 
Various biochemical and epidemiological studies have shed considerable insight on the 
mechanism of atherosclerosis. However, factors that affect an individual's susceptibility to 
atheroma formation are poorly understood. The progression of the atherosclerosis and the 
consequent risk of developing CHD are determined by the interaction of several genetic 
and environmental factors known as the'risk factors'. Major risk factors for CHD include 
raised serum cholesterol, smoking, hypertension and diabetes mellitus. Familial and twin 
studies have provided evidence for a strong inherited component in the aetiology of the 
disease. The nature of genetic factors predisposing to the disease are not fully understood. 
Only a small proportion of CHD cases result from a single gene defect e. g. familial 
hypercholesterolaernia. The majority of the cases are polygenic, i. e. several different genes 
interact cumulatively with multiple environmental factors to produce the disease, thus 
having a multifactorial inheritance. For any one individual, the expression of the disease 
may be dependent on the expression of one or more genes and the presence of certain 
1+ nviroruneffl-l - 10.0. 
T A: fr fact rs I hus, the multifac-torial aetiology ofthe disorder makes It U1111CUIL 
to identify the genetic factors. The candidate gene approach may help to identify some of 
the genetic components involved in the disease, by determining whether associations exist 
with alleles of the candidate locus and the presence of the disease and or its risk factors. 
Intermediates involved in lipoprotein metabolism are potential candidates involved in the 
aetiology of the disease. For example, apolipoprotein B (apo B) is an essential structural 
component of low density lipoprotein (LDL), the major cholesterol transport lipoprotein in 
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the plasma. Elevated concentrations of LDL and apo B are positively correlated with an 
increased risk of premature CHD. LDL predisposes to atheroma formation by favouring 
foam cell formation. Various studies have shown an association with genetic variation at 
the apo B gene locus and risk of CHD and its risk factors such as plasma cholesterol and 
LDL. Other studies have however, reported contradictory results. The work described in 
this thesis was undertaken to re-examine the genetic variation at the apo B gene locus in 
relation to the presence of CHD and some of its risk factors by controlling for confounding 
variables which might have been responsible for the previous discordant findings. 
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Introduction 
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Epidemiology of coronary heart disease 
Coronary heart disease (CHD) is the most common cause of death in the Western 
countries, accounting for almost 30%-40% of the deaths (Reitsma, 1979). In the United 
Kingdom, approximately 160 000 deaths occur per annum as a result of coronary artery 
disease (Weatherall, 1987). The disease manifests as angina pectoris, myocardial 
infarction (M. I. ), sudden death or heart failure. The incidence of M. I. in the United 
Kingdom is 5/1000, affecting approximately 200 000 people per annum. A third of the men 
suffer premature death from coronary heart disease before the age of 65 years. The 
frequency ofthe disease is lower in pre-menopausal women, although it increases with age 
in both sexes (Dodu, 1984) 
There is considerable variation in the incidence of mortality from CHD between 
countries (Simons et al., 1986): Northern Ireland is the highest followed by Scotland, 
Finland, Czechcoslovakia, Ireland, Hungary, and then England & Wales, whilst France 
and Japan have the lowest mortalities. Some of the differences may be accounted for by the 
social and dietary habits. The prevalence and mortality of CHD are higher in lower socio- 
economic classes than in non-manual workers. Various epidemiological studies have 
shown the association of 'risk factors'with incidence of CHD (Hopkins et al., 198 1; Kannel 
et al., 1986; Anderson et al., 1987). The major risk factors associated with CHD include 
elevated plasma cholesterol concentrations, low HDL (high density lipoprotein) 
A X-11 -II cholesterol,, hypertension, and cigarette smoking (Golubouit et aL, Miller ei al., 
1977). There is a continuous risk gradient with changing values of these risk factors. Other 
risk factors are blood triglycerides, obesity, diabetes mellitus, male gender, family history 
of CHID, physical activity, and personality type (Ball, 1987). Elevated blood cholesterol 
and/or triglyceride at or above the 95th percentile (or 90th percentile) is defined as 
hyperlipidaemia (Motulsky, 1976) and is present in one in three survivors of M. I. 
Risk factors can be conveniently divided into those which are altered by the 
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environment and those which are genetically determined. Most risk factors fall into both 
categories. Blood cholesterol concentrations, for example, can be modified by altering the 
intake of fats, but in some individuals, in spite of a reduction in saturated fat intake, 
cholesterol concentrations remain elevated, suggesting a strong genetic contribution in 
regulation of lipid levels. Studies of migrants have shown that the risks change in 
accordance with new environment and lifestyle. Japanese, living in Japan have low serum 
cholesterol concentrations paralleled with a low incidence of CHD: but Japanese emigrants 
to Hawaii, have much higher concentrations of cholesterol, due to increased intake of 
saturated fats, and increased incidence of CHD (Kato et al., 1973; Robertson et al., 1977). 
Similarly Eskimos living in Denmark had a higher incidence of CHD than Greenland 
Eskimos in spite of having the same genetic background (Bang et al. 197 1). 
A decline in mortality during the past three decades has been achieved in certain 
industrialised countries by national campaigning to increase public awareness to alter 
certain lifestyle factors, such as reducing dietary fat intake and cigarette smoking and 
increasing intake of polyunsaturated fats and physical exercise (Office of population 
censuses and Surveys, series DH12, No. 12,1985, England and Wales). 
In England and Wales between 1972 and 1982, a decline of 11.5% and 7.1% 
occurred respectively in males and females for CHD mortality, whilst cardiovascular 
mortality rates declined by 17% and 20% respectively (WHO expert committee, 1986). 
Despite a downward trend in the mortality rate of CHD in the United Kingdom, it still ranks 
poorly --- pared to t I, - otlwr countries 
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Pathology of coronary heart disease 
Coronary heart disease (CHD) is a consequence of the formation of atherosclerosis in 
the coronary arteries. Atherosclerosis involves the build-up of lipid and other substances. 
The process begins in childhood, and progresses through young adulthood, and usually 
presents with clinical symptoms in the middle age (Ross, 1986; Tsukada et al., 1986). The 
events leading to atherosclerosis have been studied in animal models (Faggiotto et al., 
1984) and cell culture (endothelial, smooth muscle, platelets). 
The earliest lesion is a fatty streak, composed of lipid-laden smooth muscle 
cells and macrophages. This progresses to a fibrous plaque, composed of increased 
content of smooth muscle cells and macrophages plus collagen, elastic fibres, 
proteoglycans and lipids. The final'complicated lesion' involves the development of the 
fibrous plaque into a fibrous cap by the process of calcification, cell necrosis and 
thrombosis (Ross, 1986). This results in narrowing of the lumen, consequently reducing 
the blood flow, and leading to ischaernia, manifest as angina, or (when there is total 
occlusion due to thrombosis or haemorrhage) to myocardial infarction. 
Various mechanisms have been proposed for the development of the atherosclerotic 
lesions. The Response to Injury Hypothesis (Ross, 1986) states that injury to the 
endothelium, either mechanical or chemical (LDL, viruses, toxins, immunological), 
initiates the process of atherogenesis. The Monoclonal Hypothesis proposed by Benditt 
and Benditt ( It 973) states that atherosclerotic plaques arise from either viral or chemica-1111-y 
transformed cells that are monoclonal in origin and are benign smooth muscle cell 
tumours. 
Penn et al. (1986) showed that human atherosclerotic plaques contain transforming 
gene sequences which behave in an analogous manner to oncogenes in cancer cells; when 
injected into nude mice, such transformed cells elicit turnours which contain human 
sequences. 
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Plasma cholesterol and coronary heart disease 
The positive association between plasma cholesterol concentration and 
cardiovascular morbidity and mortality has been established in many studies conducted 
in different populations and in many countries (Kannel et al., 1971; Castelli et al., 1986; 
Simons, 1986; Reed et al., 1986; Shaper et al., 1985; Medalie et al., 1973). Although some 
studies have suggested that there is a threshold for CHD risk (200mg/dl or 5.18 mmol/1) 
(Grundy et al., 1984), others have suggested that there is a continuous gradient of 
increasing risk with increasing cholesterol concentrations (Motulsky, 1976; Simons, 
1986; Rhoads et al., 1976). 
Drug Prevention trials have also provided evidence of an association between 
increasing serum cholesterol concentrations and death from CHD, for example, MRFIT 
(Multiple Risk Factor Intervention Trial) (Kannel et al., 1986). 
Drug and dietary intervention trials have shown that the risk of CHD in 
hypercholesterolaernic men can probably be reduced by reducing the concentration of 
plasma cholesterol. In the LRCCPT (Lipid Research Clinics Coronary Primary 
Prevention Trial) a cholestyramine induced reduction in serum cholesterol of 9% was 
accompanied by a 24% reduction in CHD incidence (Lipid Research Clinics Program 
1984a & 1984b). Using Clofibrate to lower cholesterol, a 20% reduction in incidence of 
CHD was achieved (Report ftom the Committee of principal investigators, 1978), 
asSOCiC 1, , LLedd with a OzOllu- reduction 
in serum cholesterol concentratlons. 1, he Helsinki I ea 11 IL 
Study trial, also showed a reduction in the incidence of CHD after five years treatment of 
otherwise healthy hyperlipidaernic men with gernfibrozil (Frick et al., 1987). However, 
some other trials have shown no definite beneficial effects from the manipulation of risk 
factors (Kannel, 1986). The Seven Countries Study (Keys, 1970) and the British Regional 
Heart (BRH) (Shaper et al., 1985) study also illustrated a good correlation between serum 
cholesterol and CHD. Low average saturated fat intake was associated with low mean 
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serum cholesterol concentrations and low incidence of CHD. Although dietary 
intervention can influence plasma cholesterol concentrations, not all individuals show 
such a response. This differential response may reflect, at least in part, inherited traits, 
which influence the response of plasma cholesterol to diet. Evidence that the concentration 
of plasma cholesterol is to some extent under genetic control has been provided by 
heritability estimates in family and twin studies. 
Genetics of coronary heart disease and its risk factors 
The aetiology of CHD has a substantial genetic component (Berg, 1983), as 
evidenced by family history (Rissanen, 1979b; Rissanen, 1979a; Friedlander, 1985) and 
twin studies, the concordance rate for the disease being higher in monozygotic twins 
(identical) than in dizygotic twins (fraternal) (Berg, 1984). For females, concordance in 
monozygotic twins is 44%, and only 14% in dizygotic twins. 
A positive family history of premature (before the age of onset of 55 years for men 
and before 65 years for women) CHD increases the chance of developing CHD 2- to 5- fold 
compared to those with a negative history. This effect may be independent of age, plasma 
total cholesterol and hypertension (Friedlander et al., 1985), although not all studies have 
supported this possibility (Conroy et al., 1985). 
Familial clustering of risk factors such as hyperlipidaernia and hypertension 
usualb, ace Omp. -Iiies aggregation of ICHD in xf, tD rSt degree relatives kinissarien L)L 
Nikkila, 1977; Slack & Evans, 1966; Rissanen, 1979b). The familial clustering of CHD 
and its risk factors, such as cholesterol, is related not only to shared environment and 
shared family habits, but also to inherited genes, as is evident from familial correlation and 
heritability studies (see later chapter for details). Familial correlations for lipids have 
provided evidence for significant genetic and environmental contributions to the normal 
variance in lipid concentrations. Relatives who share a greater proportion of their genes 
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tend to have higher concordance, i. e. their lipid concentrations tend to show resemblance. 
Both maternal and paternal plasma cholesterol have been shown to be significantly 
correlated with the plasma cholesterol concentrations of their children (Garrison et al., 
1979). Significant sib-sib correlations were also found for cholesterol, even after 
adjustment for covariates (age, body weight, alcohol consumption, cigarette smoking). 
Because correlations between cholesterol concentrations of various relatives are roughly 
half of those expected if genes were entirely responsible, the variation of cholesterol 
values in a population must also be influenced by environmental factors, i. e. it is 
multifactorial (Motulsky, 1976). However, in unrelated individuals (e. g. spouse pairs) 
no significant correlation was observed, suggesting that familial resemblance of 
cholesterol levels in relatives may be due in part to environmental factors shared earlier 
in life. Shared family environment did not seem to make a large contribution to familial 
aggregation of lipids. In contrast, a study by Feinleib et al. (1977) suggested that familial 
similarities in cholesterol were not due to genetic effects, but to shared environmental 
factors. 
Heritability of plasma cholesterol 
Heritability studies in populations, families, and twin pairs have provided 
quantitative evidence for a genetic contribution to the determination of variation in lipid 
concentrat' t--ý lno/ CAO/ bons. I Win and i'a-1-11ily studies have shhown that 30/o-50/o offthe varld-601-1 III 
circulating cholesterol concentrations is inherited (Christian et aL, 1976; Berg, 1984; Berg, 
1983; Whitfield& Martin, 1983). 
Heritability is defined as the proportion of total phenotypic variance (genetic and 
nongenetic) which is due to additive genetic variance (Emery, 1986). Heritability (hl) is 
expressed as a percentage, and gives a rough estimate of the involvement of a genetic 
component in the phenotypic variation of a particular characteristic. It does not give an 
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indication of the number of genes involved or the genetic mechanism (Vogel & 
Motulsky, 1979). The greater is h', the greater is the genetic contribution to the 
determination of the trait. 
Genetic (hl) and cultural heritability (cl) have been estimated by various statistical 
modelling methods. After adjustment for concomitant variables such as age and sex, 
correlations obtained are used for quantifying the genetic and environmental 
contributions. The path analysis model assumes that a quantitative trait P can be 
partitioned into both transmissible (genetic + cultural) and non-transmissible 
(environmental) factors: P=A+B+E, where P is the quantitative trait; A+13 are additive 
genetic and cultural factors which can be transmitted from parents to the offspring; E 
represents nontransmissible environmental factors. 
The phenotypic variance (VP) is composed of both transmissible variance (t') and 
non-transmissible variance (el): V1, = t2 +e2 
(a) Population and family studies 
In a French Canadian population (Perusse et al., 1989) heritability estimate for 
cholesterol was 0.55, suggesting a significant contribution of genetic factors to the 
phenotypic variance of cholesterol. Slightly higher estimates were obtained for families 
either ascertained through randomly selected probands who were part of a larger 
prevalence study, h'=0.62 (Rao eta!., 1098822ý orthrough survivors ofmyocardial i-E-r-tion .7) -- --V 11IXULýL1%J11 
(< 45 years), h 
2=0 
. 
64 (Hamsten et al., 1986). 
(b) Twin studies 
Twin studies provide a good discrimination between genetic and environmental 
contributions to lipid concentrations, using intra-pair (within) and inter-pair (between) 
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variances and correlations. For a continuous variable such as plasma cholesterol, if the 
intra-pair variance is greater in dizygotic than in monozygotic twins, it suggests a role of 
hereditary factors in its control. Also, the correlations would be highest for monozygotic 
twins, whose gene make-up is identical. Any differences between them must therefore 
reflect the environmental contribution, possibly due to shared family habits or family 
environment. Twin studies tend to give an overestimation of heritability, because of 
shared environment (especially in utero). To overcome this, studies have been done on 
twins reared together and apart. A study by Whitfield & Martin (1983) provided an 
heritability estimate of 55% responsible for the variance in plasma cholesterol in both 
monozygotic and dizygotic twins. A lower heritability of 0.34 was determined in 
Norwegian twins, although this increased to 0.52 when only monozygotic pairs were 
considered (Berg, 1984). The effect of the common environment C2 was 0.18 for both 
monozygotic and dizygotic pairs. 
To determine if a particular gene interacts with environmental factors (e. g., diet) to 
influence cholesterol concentration, one needs to study monozygotic twins living apart. 
For example, in twins lacking the MNs gene for the blood group system, the within-pair 
difference is greater than in twins possessing the M gene. Thus the M gene seems to have a 
restrictive effect on variability of cholesterol concentrations caused by nutritional or 
lifestyle factors (Magnus etal., 1981). 
This may explain the differential response of individuals to diet (in some 
individuals, %- 
1-. *Ist *- -L-- 
-1 I, c tary lffi-t results in higher %, 11U1C; ýLC; 1V1 %, V11%, %: -, 11Lra-Uons, whi III UL11VIN UlrL- 
induced hyperlipidaemia is negligible). It is possible that hyper-responders have genes 
which do not have a direct effect on cholesterol concentrations but influence variability 
by interaction with environmental factors. Only variability due to environmental factors 
which differ between twin pairs is investigated in this way. 
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Multifactorial inheritance 
The genetic contribution to coronary heart disease is not well defined. Hence, the 
mode of inheritance remains uncertain. First-degree relatives of affected patients have a 
two- to six-fold increased risk of developing the disease, compared to relatives of 
unaffected patients (Rissanen, 1979b). Despite a greater frequency of affected relatives 
in the families of probands than in the general population, the frequency is smaller (<5%) 
than would be expected with Mendelian segregation (Emery, 1986), where at least 50% 
of the relatives would be affected (e. g. familial hypercholesterolaemics) (Motulsky, 
1976). The lower frequency of expected affected individuals may be explained by other 
modes of inheritance, namely multifactorial inheritance. This implies that the aetiology is 
partly environmental and partly genetic, with the genetic contribution probably consisting 
of many different genes, i. e. polygenic. In polygenic inheritance several genes (each 
having a small effect) at different loci interact cumulatively, and the superimposition of the 
environment results in a multifactorial inheritance. These genes probably occur with 
variable frequencies in the population and still remain to be identified. 
Similarly, the variation in cholesterol concentrations has a multifactorial basis. 
Although first degree relatives of affected individuals have high concentrations of 
circulating lipids, the proportion of individuals affected is smaller (10%-15%) than 
expected by Men-16an Jnhcr- nce t250/ and 500/ -P-- dominant '-*sor'ers UU IVI U 11 1 4a ý--) /U U -)V/O IUI ICAIC.; ýýIvv aUIL UI U 
respectively). As for CHD, circulating lipid concentrations in most individuals may 
therefore be determined not by a single gene, but by several genes as in polygenic 
inheritance (Galton, 1985; Galton et al., 1985) i. e. it involves cumulative interaction of 
several genes acting at several loci involved in lipid metabolism. 
The nature and the number of genes influencing the risk of CHD or variation of 
circulating cholesterol concentrations is not known. Of an estimated 50,000 to 100,000 
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structural genes in humans, at least one third (17,500 to 33,000) exist in more than one 
form (each form being termed an allele), i. e., they are polymorphic (Vogel and Motulsky, 
1979). Some of these polymorphic genes would give rise to variant proteins and enzymes, 
which could be involved in the control of interindividual variations of lipids and risk of 
CHD, and which would exert their effect in the heterozygous state. But the nature of such 
variant proteins and enzymes is not known. Besides polymorphic alleles (present in 
frequencies equal to or greater than 1%), rare alleles will also contribute, but to a lesser 
extent, some of which will be inherited in Mendelian fashion. To try and identify these 
polygenes, various studies have adopted the 'candidate gene' approach. Candidate genes 
are genes of products which may affect risk factor levels and consequently the 
development of the disease. Before identifying potential candidates involved in the 
regulation of circulating cholesterol concentration and CHD, a brief review of lipoprotein 
metabolism follows. 
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Metabolism of lipoproteins 
Cholesterol and triglycerides in plasma are transported as components of lipoprotein 
particles, which are water soluble complexes, composed of a hydrophobic core of 
cholesteryl esters and triglycerides, surrounded by a hydrophilic surface coat of proteins 
(called apolipoproteins), phospholipids and unesterified cholesterol. 
Based on their flotation properties in the ultracentrifuge, lipoproteins have been 
classified as very low density lipoprotein (VLDL), intermediate density lipoprotein 
(IDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) (Table 1). 
Each class contains one or more apolipoproteins in varying concentrations and distribution 
(Table 2). All apolipoproteins except apo B-100 and apo B-48 exchange between 
lipoproteins. Apo B-48 and apo B-100 are the two forms of apo B present in mammals 
(Kane et al. 1980; Kane et al., 1983). Based on their apparent molecular weights on SDS- 
polyacylamide gels, the larger hepatic species was named apo B- 100, whilst the smaller 
intestine-derived species was called apo B-48. Both proteins are products of the same 
gene, being produced by a novel RNA editing mechanism (Powell et al., 1987; Higuchi et 
al., 1988; Hospattanker, 1987). Structural comparison studies have suggested apo B- 48 to 
be homologous over its entire length with apo B- 100, representing 47% of the amino 
terminal sequence of apo B- 100 (Hardman et al., 1987; Innerarity et al., 1987b). Apo B-48 
is a structural component of chylomicrons, which transport dietary triglyceride from the 
intestine tLO +Lll- -4 11%, tJ%, l lphe-ICtIl tissues. 
A schematic diagram of lipoprotein metabolism is shown in Figure 1. Apo B- 100 is 
essential for the hepatic assembly and secretion of VLDL, which carries endogenously 
synthesised triglyceride (Eisenberg, 1975). VLDL is triglyceride-rich consisting mainly 
of apo C-11 and apo E acquired from HDL (Sparks & Sparks, 1985). Apo C-11 has been 
suggested to prevent the premature uptake of the nascent VLDL particle by the liver 
(Havel, 1985). It also activates the endothelial-bound lipoprotein lipase to hydrolyse the 
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triglyceride of VLDL, producing smaller and denser, cholesterol-rich particles, the 
VLDL remnant (also called IDL). The released surface components (cholesterol, 
phospholipids, and apoA-1) are transferred to HDL, which converts to the less dense 
HDL, (Eisenberg, 1984). Apo B -100 and apo E on IDL particles interact with the hepatic 
apo B, E receptors (Goldstein & Brown, 1974) for uptake and degradation or the IDL are 
converted to the denser (d 0.019- 1.063g/ml), spherical, cholesterol-rich LDL by the 
continued action of lipoprotein lipase. 
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Table 1. Physicochemical Properties and Composition of Human Plasma 
Lipoproteins * 
Properties Chylomicrons Very Low Intermediate Low High Density High Density 
Densit-, Density Density Lipoprotein 2 Lipoprotem 3 
Lipoprotein Lipoprotein Lipoprotein (HDL 2) (HDL 3) 
(VLDL) (IDL) (LDL) 
Solvent 0.93 0.93 - 1.006- 1.093 - 1.063 - 1.125 - 
Density 1.006 1.019 1.063 1.125 1.210 
(g/ml) 
Molecular 50- 10- 5- 2.3 0.36 0.175 
Weight 1,000 80 10 
(x 10 ') I L 
Diameter 75 - 30 - 25 - 18 - 9- 5- 
(nm) 1,200 80 35 25 12 9 
Electrophoretic Origin Pre- P Slow Pre-P P P P 
Mobility 
Chemical 
Composition 
Free Cholesterol 7 9 8 5 4 
Phospholipids 18 19 22 33 35 
Apolipoprotein 2 8 19 22 40 55 
Triglycerides 86 55 23 6 5 3 
Cholesteryl Esters 3 12 29 42 17 13 
Source: Havel and Kane, 1989 
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Table 2. Properties and Distribution of Some Human Plasma Apolipoproteins * 
Properties A-I A-11 A-IV B-48 B-100 C-I C-11 C-111 D E-11 
E-111 
E-IV 
Plasma 100- 50- 4- 50 80- 5- 3- 7- 7- 4- 
Conc. 150 70 15 120 10 5 12 12 14 
(mg/dl) 
Molecular 29,016 17,414 44,465 240,800 512,723 6,630 8,900 8,800 19,000 34,415 
Weight 
Distribution 
(M01%) : 
VLDL 22 30 20 20 
IDL -81 10 10 
20 
LDL --- 82 -- 10 - 
10 
HDL 100 100 35@ - 97 60 60 100 50 
Sources: Havel and Kane (1989) and Edelstein (1986). 
Source Lagrost et al (1990); Value obtained using gel permeation 
chromatography; however, using ultracentrifugation, more than 90% of apo A-IV is 
localised in the lipoprotein free fraction. 
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Figure 1. Lipoprotein Metabolism. 
A schematic diagram showing the relationship of the liver, peripheral tissues and 
the gut in lipoprotein metabolism. A, B, C and E refer to the corresponding apoproteins; 
FC is free cholesterol, PL is phospholipid; Rem is chylomicron remnant; VLDL is very 
low density lipoprotein; IDL is intermediate density lipoprotein; HDL, and HDL, are 
high density lipoproteins; LPL is extrahepatic lipoprotein lipase which is activated by 
apo C-11 to hydrolyse chylomicron to chylomicron remnants and VLDL to IDL; HPL is 
hepatic lipoprotein lipase which may be involved in the hydrolysis of IDL to LDL; LDL 
is in turn catabolised by the LDL receptor. For more details see text. Adapted from 
Thompson, 1984. 
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Apolipoprotein 13- 100 and low density lipoprotein metabolism 
LDL particles are spherical, and heterogeneous in size (21-25 nm) with a core of 
cholesteryl esters and surface apo B-100 (Mills etal., 1984) (Tables 1,2). LDL comprises 
about two-thirds of plasma cholesterol, and its main function is to transport cholesterol to 
the liver and the peripheral tissues (Brown et al., 1981). Uptake into these tissues is 
mediated by the LDL receptors, localised in the 'coated pits' of the plasma membrane. 
Goldstein and Brown provided the first evidence for the existence of the LDL receptors in 
cultured human skin fibroblasts (Goldstein & Brown, 1974). Similar receptors have been 
identified in cultured smooth muscle cells, vascular endothelium, lymphocytes, HEP G-2 
cells, and rat H-35 cells (Havel, 1986). 
Uptake of LDL is initiated by interaction of apo B- 100 with the receptor. Positively 
charged amino acids lysine and arginine residues on apo B and apo E interact with the 
negative charges on the receptor (Mahley & Innerarity, 1983). LDL binds to the high 
affinity receptor irreversibly. Binding is followed by invagination of the pits into the cell to 
form vesicles, which are endocytosed into lysosomes. In the lysosomes apo B 100 is 
degraded into trichloroacetic acid-soluble fragments, whilst the cholesteryl ester is 
hydrolysed by acid lipase. The free cholesterol so released suppresses hydroxy methyl 
glutaryl coenzyme A (HMG-CoA) reductase activity, thereby inhibiting cholesterol 
synthesis; enhances cholesterol esterification by activating microsomal fatty acyl CoA: 
cholesterolacyl transterase (ACAT); and suppresses synthesis of the ILDDL receptors and 
further uptake of LDL (Goldstein & Brown, 1977). After dissociation of the lipoprotein, 
the LDL receptor recycles to the cell surface. The gene for the LDL receptor has been 
mapped to chromosome 19. The cDNA (5.3 kb) for LDL receptor has been isolated, and the 
structure of the protein elucidated (Yamamoto et al., 1984; Sudhof et al., 1985). 
The cholesterol thus accumulating in peripheral cells by uptake of LDL is eventually 
transferred to HDL for transport to, and elimination by, the liver by the process of reverse 
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cholesterol transport (Miller, 1984; Reichl & Miller, 1986). HDL is formed from the 
surface remnants of lipolysed VLDL and chylomicrons enriched with apo C; and from 
apo E and apo A-1 enriched discoidal particles secreted by hepatic and intestinal cells 
(Eisenberg, 1984; Miller, 1984a). On entering the blood, the discoidal particles are rapidly 
converted to mature spherical HDL particles, as a consequence of esterification of 
cholesterol by lecithin: cholesterol acyltransferase (LCAT) Glomset et al., 1970; Glomset, 
1968), an HDL-associated enzyme which catalyses the transfer of linoleic acid from the C- 
2 position of lecithin to the 3- hydroxyl position of cholesterol (Glomset, 1968). The esters 
so formed move into the core of the particle or are transferred to trigy1ceride-rich 
lipoproteins and their remnants in exchange for triglycerides (Barter, 1984) by the 
cholesteryl ester transfer protein (CETP) (Hesler et al., 1987), also known as lipid transfer 
protein-I (LTP-1) (Zilversmit, 1984; Tall, 1986). The cholesteryl esters are subsequently 
transferred to the liver by several mechanisms: (1) Endocvtosis of remnant lipoproteins 
and LDL. (2) Endocytosis of HDLs. (3) Direct transfer from HDLs to hepatocytes without 
particle uptake. The second and third processes may involve interaction with hepatocyte 
receptors for HDLs, though these have not yet been clearly defined. The principal site of 
catabolism of HDL particles is probably the liver, with the kidney being the second most 
important (Pittman & Steinberg, 1984). The mechanism of renal catabolism has not been 
elucidated. 
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Candidate genes and coronary heart disease 
Defects in any of the steps of lipoprotein metabolism may result in abnormal 
lipoprotein levels, giving rise to either hypolipidaernia or hyperlipidaemia, associated in 
some cases with atherosclerosis leading to premature CHD. Some of the hyperlipidaernias 
have a well defined genetic component while in others the genetic component is 'ill- 
defined'and requires environmental factors to fully manifest the disease (Galton, 1985). 
A small percentage (5%) of the cases of CHD are associated with familial 
hypercholesterolaemia (FH) (Goldstein & Brown, 1983; Goldstein & Brown, 1978; 
Motulsky, 1976), in which deficiency of LDL receptors results in elevated plasma LDL 
cholesterol concentrations. FH is an example of a single gene disorder, in which a mutation 
at a single locus has a clinically manifest effect on the phenotype. In the general population 
I in 500 individuals is heterozygous and I in 1,000,000 is homozygous for the receptor 
locus mutation. At the molecular level the defect is related to deletions in the LDL receptor 
gene (Langlois, 1988). Four classes of ten different mutations have been identified for both 
homozygous and heterozygous FH (Goldstein & Brown, 1984). Class I mutations result in 
failure of receptor synthesis and represent the 'null' alleles. Class 11 mutations result in 
failure of transportation of the receptors to the Golgi apparatus to be modified to the mature 
form. Class III mutations produce defective binding of the receptor to LDL. With Class IV 
mutations there is normal receptor synthesis, processing and binding, but failure of the 
+ receptors tLO CIIUS+L%-, -I 11-1 LVaL%., U PILS, anU Lhc,, 1U1%. LU 111L%ýIIMHSC. 
Single gene disorders such as FH are rare and relatively easy to detect and analyse. 
However, in the majority of the cases, as already mentioned, the disease develops as a result 
of the interaction of two or more genes, where the effect may comprise a major gene effect 
plus a small number of genes having a minor effect, or it may involve a large number of 
genes each having a minor effect. In such cases identification of the genetic component 
involved in the risk of CHD and control of its associated risk factors, in particular plasma 
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cholesterol, can be studied by employing the 'candidate gene' approach (Humphries, 
1988), whereby genetic variation in the gene most likely to be involved in influencing the 
risk factor is selectively studied. Candidate genes are potentially involved in the aetiology 
of the disease, usually because they code for the proteins involved in the metabolic 
pathways related to the disease. Various candidate genes have been identified in the 
aetiology of atherosclerosis. The field of lipid metabolism has several potential candidates 
which are likely to be involved in the control of cholesterol concentration and the risk of 
CHD, such as apolipoproteins B, C, E, A-1 and A-11, LDL receptor, cholesteryl ester 
transfer protein (CETP), lecithin cholesterol: acyltransferase (LCAT). 
The characterisation of mutations at these loci is important in assessing their effects 
on atherosclerosis and its risk factors. The search for allelic variation at these known 
candidate loci is likely to reveal mutations that have small effects on the development of 
atherosclerosis. However, a substantial proportion of the risk is probably attributable to 
genetic loci that remain to be identified. 
From the previous section on metabolism, it is clear that most of the circulating 
cholesterol is transported by apolipoprotein 13- 100, the major protein of LDL, and also 
essential for its interaction with the LDL receptor. It was the aim of the present study to 
investigate the association of genetic variation at the candidate gene locus for apo 13- 100, 
with the risk of CHD and associated risk factors, such as plasma cholesterol 
concentrations, obesity, and plasma triglycerides. 
Apolipoprotein 13- 100 and low density lipoprotein cholesterol 
Apo B and LDL cholesterol have both been correlated with the risk of CHD 
(Sniderman et al., 1980), although apo B has been suggested to be the better discriminator 
(Durrington, et al., 1986,1988; Avogaro et al., 1979; Onitri et al., 1980), especially at 
similar or lower LDL and plasma cholesterol concentrations (Durrington et al., 1988; 
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Whayne el al.. 1981; Kladetzsky et al., 1980). In spite of normal cholesterol 
concentrations, patients with a history of myocardial infarction (Avogaro et al., 1978) or 
with angiographically documented CAD (Whayne et al., 198 1) had higher concentrations 
of apo B compared to a control group of patients with apparently normal coronary arteries. 
Immunofluoreseence and immunohistochernical studies have shown the presence of 
LDL cholesterol and apoB in the atherosclerotic plaque (Hoff et al., 1975a; Hoff et al., 
1975b; Morton el al., 1986). The LDL was of similar lipid composition to plasma LDL, but 
more electronegative (Hoff et al., 1982), a property which may be implicated in its uptake 
by cultured macrophages in the formation of foam cells. Foam cells in the lesions are 
derived from circulating nionocytes, which enter the subendothelial space and take up 
LDL to become cholestcryl estcr-loaded macrophages (Brown & Goldstein, 1983). In 
vitro, native LDL is taken up at a low rate by macrophages, and cannot induce foam cell 
formation. In contrast, several chemically modified forms of LDL (acetylated, 
acetoacetylated, malondialdehyde) are taken up rapidly by a specific scavenger receptor. 
Acetylation increases the net negative charge on LDL, which enhances binding to this Z=1 
receptor. Unlike the LDL receptor, synthesis of scavenger receptors is not suppressed by 
cholesterol, resulting in the formation of foam cells in vitro (Goldstein et al., 1979,1983). 
The existence of a physiological ligand in vivo for the acetyl LDL receptor is not 
certain. However, it has been suggested that lipid peroxidation of LDL in vivo can produce 
a ligand resembling acetyl LDL. Evidence that this occurs in vivo is based on the isolation 
from plasma of a modified form of LDL (mLDL) with increased negative charge. This 
mLDL was taken up by cultured macrophages, but at a lower rate than was acetyl LDL 
(Avogaro et al., 1988). Incubation of LDL in the presence of endothelial cells (Henriksen et 
at, 1981), smooth muscle cells and rnacrophages enhances the oxidative modification of 
LDL to a form recognised by the scavenger receptors (Steinberg el al., 1989). zn 
The scavenger receptor has also been identified in cultured bovine endothelial cells, 
and has been cloned (Kodama el al., 1990) from the bovine lung. 
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Lipoprotein(a) and coronary heart disease 
Lipoprotein (a) (Lp(a)), an apo B-100 containing lipoprotein has also been 
implicated in atherosclerosis. High plasma concentrations of Lp(a) have shown to be 
associated with increased risk of premature atherosclerotic heart disease (Kostner et al., 
1981) and may predispose to arterial thrombosis (Durrington etal., 1988). Durrington etal. 
(1988) have proposed that serum apo (a) concentrations could be substituted for a 
knowledge of parental history of early cardiac ischaernia, (i. e. men with high serum apo 
(a) concentrations had either one or both parents with a history of early ischaernic heart 
disease), suggesting a genetic involvement in the determination of serum apo (a) 
concentrations. Lp(a) consists of an LDL particle, the apo B-100 molecule of which is 
linked covalently to a glycoprotein molecule, apo(a). It has been suggested that there is an 
interaction between Lp(a) and LDL cholesterol concentrations to increase the risk of CHD 
(Armstrong et al., 1986). However, unlike LDL it is unable to induce foam cell formation. 
In transgenic mice fed a high fat diet, free circulating apo(a) was associated with 
development of fatty lesions in arteries (Lawn et al., 1992). Lp(a) was first identified 
immunochemically as a genetic variant of LDL, using rabbit antiserurn (Berg, 1963). The 
cDNA for apo(a) has been cloned (McLean et al., 1987) and has been shown to be 
structurally homologous to plasminogen, a precursor of the enzyme plasmin which digests 
fibrin, hence it might be involved in thrombus formation. It has multiple copies of a kringle 
4-like domain, and one copy homologous to the kringle-5 domain of plasminogen. 
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Molecular genetics of apolipoprotein 13- 100 
Structure of apolipoprotein B- 100 gene 
The determination of the structural and biochemical characteristics of apo B was 
hampered by its large size, instability and insolubility in aqueous media. However, with the 
advent of recombinant DNA techniques, the gene for apo B was cloned by screening two 
genomic libraries with apo B cDNA and oligonucleotide probes (Blackhart et al., 1986). 
Isolation of overlapping cDNA clones from liver and HepG2 cDNA libraries enabled the 
cDNA and protein sequence of apo B to be determined (Knott et al., 1986b; Knott et al., 
1986a; Chen et al., 1986; Yang et al., 1986; Cladaras et al., 1986; Law et al., 1986b; 
Mehrabianet al., 1985). 
The gene for apo B was mapped to the p24 region of the short arm of chromosome 2 
(Knott et a/., 1985; Law etal., 1985). It is expressed mainly in the liver and to a small extent 
in the small intestine. The apo B gene is 43kb long comprising of 28 introns and 29 exons. 
The cDNA codes for one of the largest mammalian proteins, which is synthesised as a 4563 
amino acid precursor protein. Cleavage of a 27 residue signal peptide gives a mature 
protein of 4536 amino acids (Blackhart et al., 1986). The distribution of the introns is 
extremely asymmetric, in that 24 out of 28 occur in the 5' amino terminus encoding the T4 
thrombolytic peptide. T4 encompasses 31.3kb of the genomic DNA, a small portion 
0891 nucleotides') ot Whic'n encodes for the '14 peptide, thus representing 22,99/o of the 
mature protein. Most of the 6.2 kb of the genomic DNA in the middle portion of the gene 
codes for the T3 peptide encoded by a cDNA of 5856 nucleotides. Only one intron 
interrupts T3, whilst T2 representing the carboxy terminal has three introns. T2 is encoded 
by 5.3 kb of genomic DNA and a cDNA of 3861 nucleotides. Although the whole of the 
cDNA has been sequenced, not all of the introns have been sequenced completely. 
The 5' and 3' untranslated regions are 128 and 304 bp respectively. Apo B also 
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contains at least six Alu-type repeats in the gene. In the 5'flanking sequence, 29 nucleotides 
5'of the transcription start site is the TATA box and a CAAT box, 31 nucleotides 5' of the 
TATA box. Two GC boxes, with a consensus sequence AGCCCGCC, are also present 3' of 
the transcription initiation site in the untranslated region. This is a binding site for 
transcription factors e. g. Sp I in other genes; its function in apo B is unsure. 
Structure of apolipoprotein B- 100 protein 
The protein sequence of apoB has been deduced both from the cDNA sequence and 
by directly sequencing the tryptic peptides (Knott et al., 1985; Knott et al., 1986b; Knott et 
al., 1986a; Yang et al., 1986; Chen et al., 1986). Apo B is synthesised on polysomes bound 
to the rough endoplasmic reticulum membrane (Olofsson et al., 1987). Synthesis is 
completed in 14 minutes, (HEP G2 cells), while secretion occurs 30 minutes later, after 
being intracellularly transported through the rough endoplasmic reticulum (10 minutes) 
and through the Golgi apparatus (20 minutes). Apo B is synthesised as a precursor protein 
of 4563 amino acids, with relative molecular mass (M, ) of 514K. Cleavage of a 
hydrophobic 27 residue signal peptide yields a mature protein of M, 512K, which is 
required for the assembly of the nascent VLDL particle in cisternae of the rough 
endoplasmic reticulurn and secretion into the circulation. 
Sequencing data have confirmed that there is only one apo B molecule per LDL 
particle. T wenty potential N-glycosylation sites are distributed throughlout the sequence 
(Knott et al., 1986b), sixteen of which are glycosylated. One of the original Asn sites has 
now been excluded as a potential site. Seven of the glycosylated sites occur between 
residues 3071-4100, a region which contains the putative receptor binding domain as well 
as some of the heparin- binding sites (Yang et al., 1989; Yang et al., 1986; Chen et al., 
1986). Thus, glycosylationmay have structural and functional implications. 
Compared to other apolipoproteins, apo B is very hydrophobic, particularly the 
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carboxy-terminal region. Whilst most apolipoproteins have no B-sheet, the secondary 
structure of apo B is predicted to contain a high content of both a-helices (43%) and B- 
sheets (21%). The amphipathic nature of both a-helical and the B-sheets which contain 
alternating hydrophobic and hydrophilic amino acids may be involved in lipid binding. 
The tertiary structure of apo B may involve disulphide bond formation of cysteine residues. 
Of the twenty-five cysteines present in the mature protein, 15 are located in the T4 peptide. 
Three disulphide linkages have been located in the N- terminal domain (Yang et al., 1989). 
Apo B-100 contains internal repeats of about 70 amino- acid residues (Yang et al., 
1986; DeLoof et aL, 1987), although there is only up to 20% homology between individual 
repeats. Homologous structures also present in other apolipoproteins are thought to be 
involved in lipid binding. 
Two basic sequences representing the putative receptor binding domain have been 
located near the T3/T2 junction (residues 3147-3157,3 3 59-3 367). The second basic region 
is homologous to the apo E receptor binding domain (residues 142-150), having the 
consensus sequence Arg-X-X-Arg- Lys-Arg-X-X-Arg/Lys (Knott et aL, 1985). 
Genetic analysis of apolipoprotein B-100 
Cloning of the apo B cDNA and gene revealed several sequence heterogeneities. 
Comparison of 4 complete and several partial cDNA and gene sequences revealed 60 
"' were predict A apparent nucleotialc SUIDStALUILIOns, of -VVIIIIch 39 Led to cause amino acid 
substitutions (Ludwig et al., 1987). Data compiled by Yang et al. (1989) increased these to 
75 sequence differences. Most of these were due to sequencing errors Yang et al. (1989). 
However, 12 were probably genuine sequence polymorphisms, of which 10 were predicted 
to result in amino acid substitutions. 
A polymorphism is 'a Mendelian trait that exists in the population in at least two 
phenotypes, neither of which occurs at a frequency of less than I%' (Vogel & Motulsky, 
J Rajput- Williams Ph. D. Thesis Page 44 
1979). At the DNA level, a polymorphism is a neutral mutation or change in base sequence 
which occurs every 100 to 200 bases, and has no discernible effect on the phenotype 
(Francomano, 1986). In the past, genetic polymorphisms were detected immunologically 
(e. g., the antigenic system of LDL) or by electrophoresis (isoelectric focussing; e. g. apo E 
variants). Polymorphisms at the DNA level can now be detected by techniques such as 
sequencing, comparison of cDNA sequences from different libraries, or by restriction 
fragment length polymorphism (RFLP) analysis (Gusella, 1986; Francomano, 1986). 
Genetic variation in the form of RFLPs at the candidate genes may contribute to the 
risk of CHD, and also to the determination of inter-individual plasma lipid concentrations. 
RFLPs are variations in the DNA sequence between genomes of different individuals, 
which may arise as a result of gene deletions or point mutations (Cooper & Clayton, 1988; 
Francomano, 1986). They occur as varying lengths of gene fragments, and are identified by 
the digestion of genomic DNA with restriction endonucleases, which are bacterial 
enzymes that cleave at specific recognition sequences in the DNA. The pattern of 
restriction fragments produced is detected by Southern blotting (Southern, 1975), whereby 
the fragments are separated according to length by electrophoresis in an agarose gel, 
blotted on to a filter and then detected by hybridisation with a radioactive probe. The 
pattern of inheritance of these fragments through families is used in linkage and or 
association studies. Linkage (Vogel & Motulsky, 1979), i. e., location of two genes on the 
same or on homologous chromosomes is demonstrated when they fail to segregate 
-I- __ ----------II, A independentli-Y, d_I-IU U-Ile -inherited togetlie-I On 'LlIC S-U-1-11C chromosome as a hapiotype. A 
haplotype is the pattern of genes or markers on a particular chromosome and can be defined 
as 'a group of closely linked alleles which are inherited together as a unit' (Connor & 
Ferguson-Smith, 1991). When linked alleles occur together in a population more 
frequently or less frequently than expected by chance, the alleles are said to be in linkage 
disequilibrium (Vogel & Motulsky, 1979). When alleles at any pair of linked loci become 
randomised between the two homologous chromosomes by repeated recombination, the 
J Rajput- Williams Ph. D. Thesis Page 45 
alleles reach a state of linkage equilibrium, although this may require several generations 
to happen. Generally the smaller the distance between two linked genes, the greater the 
number of generations required to bring about linkage equilibrium. The existence of 
linkage disequilibriurn between an allele and a disease, or a marker allele and a 
susceptibility allele, is the basic requirement for population association studies in 
unrelated individuals. In the absence of linkage disequilibriurn any association would 
disappear. 
RFLPs are inherited as Mendelian traits, but the majority are in the noncoding 
region of the genes, and therefore are inherited without any effect on the phenotype 
(Luqmani et al., 1985). Some RFLPs in the coding region of the genes result in structural 
and or functional changes in the protein, whilst others represent genetic markers which 
may be in linkage disequilibriurn with a mutation in the gene which has a significant effect 
on metabolism. The association of a given RFLP with a particular phenotype may arise due 
to the sequence changes in an RFLP that result in an amino acid change, thus altering the 
metabolism of the candidate protein; or alternatively the sequence change would not be 
directly related to the phenotype, but would be in linkage disequilibriurn with another 
unknown functional change. Availability of cDNA and gene probes has made feasible the 
analysis of DNA sequence differences of various candidate genes (e. g. apo B, apo E) 
which may be related to changes in lipid and lipoprotein concentrations and the risk of 
CHD. In the apo B gene various restriction enzyme marker sites have been used for 
association Studies with CHI) and plasma HpILL concentrations. 
As previously mentioned, in single gene defects such as familial 
hypercholesterolaernia it is relatively simple to analyse and define the gene defect 
precisely, usually by segregation analysis or by association with a marker RFLP, followed 
by location of the precise defect. However, with polygenic diseases, the precise gene 
defect and the number of genes involved are more difficult to determine. As with single 
gene defects, polygenic diseases can be studied by looking for associations either in 
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population or family studies, between a particular phenotype and the candidate gene(s) of 
interest (Humphries et al., 1988). Once an association between a disease phenotype and 
the marker RFLP at the candidate gene is established, linkage studies may be used to map 
the region of mutation. 
The existence of numerous RFLPs at the apoprotein B locus has enabled an 
examination of the association of the various RFLPs with a defined clinical phenotype such 
as CHD and hypercholesterolaernia. Such association studies have shown that genetic 
variation at the apo B gene does indeed influence the plasma concentration of cholesterol 
as well as the risk of CHD. This will be discussed in more detail below. 
Restriction fragment length polymorphisms 
Restriction enzyme digestion of apo B DNA followed by Southern blotting has 
revealed many different RFLP variants. Some of these variants represent point mutations 
occurring in the exons, the introns and the regulatory regions. For example, the Xbal, 
3'Mspl, EcoRl polymorphisms represent point mutations in the Ycoding region (Priestley 
et al., 1985a, b, c, d; Huang et al., 1986; Barni et al., 1986). Both 3'Mspl and EcoRl are 
predicted to result in an amino acid change, whilst the Xbal RFLP represents a neutral 
change. The 3'MspI polymorphism in exon 26 arising from a loss of the restriction site at 
codon 3611 results in the predicted substitution of glutamine (Gln) for arginine (Arg) 
(CGG4CAGýý",, ____ý_7 1088), wililst the EcoRT. polymo-hism in exonlo --Ifý ; - kýk. --r, ,, -1. ,III -- I I- Y ... F...... 
the predicted substitution of (lysine) Lys for glutamic acid (Glu) (GAA-+AAA). Variants at 
the 5'end include the Hincll and the Pvull polymorphisms (Darnfors et al., 1986), which 
have been located to intron 4 (see section on' Restriction Mapping'). An Mspl RFLP has 
also been detected in the 5' flanking promoter region (Jones et al., 1989) (see section on 
'5'Mspl promoter site'). 
In the 3' flanking sequence is the AT-rich hypervariable region (within 200 bp of 
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polyadenylation site) which consists of a variable number of tandem repeats (VNTRs) 
(Knott et al., 1986c, Huang et al., 1987). Each repeat is 15 bp long and by high resolution 
analysis, at least 14 have been distinguished, containing between 25 and 52 copies of the 
repeat (Ludwig et al., 1989). The hypervariable region polymorphisms can be analysed 
using various restriction enzymes such as Xbal, and Mspl. An Xbal RFLP detects an AT 
rich hypervariable minisatellite region locatedjust Yof the second polyadenylation signal, 
which represents the Yallele system varying in length by -300 bp (Huang et al., 1987). In 
addition, sequence heterogeneity has also been detected within alleles of apparent similar 
length. An insertion-deletion polymorphism detected by Mspl in the region Yof the apo B 
gene has been reported by Hegele et al. (1986). 
Genetic mutations, coronary heart disease and hyperlipidaernia 
The association of apo B genetic polymorphisms with lipid and lipoprotein 
concentrations and also with CHD has been studied in various population association 
and/or case- control studies. Most of the results so far reported are contradictory. They also 
differ with respect to the sex, age, number and health status of the patients, ethnic 
heterogeneity, statistical methods and geographic location. 
For example, RFLPs of EcoRl and Xbal (RI and X1 alleles representing loss of the 
site) and the AT-rich minisatellite polymorphism the region downstream of the 3' end of 
the gene (detectable as an DIVIspi Inselt-101-11-UCICL1011 pulyrriorphism) kriegele et al., 1986) 
have been associated with myocardial infarction, although not with LDL cholesterol 
concentrations or apo B concentrations. These alleles occurred at a greater frequency in 
cases than in controls. A correlation between the hypervariable element alleles (HVE) 44- 
52 (these alleles arise due to the variation in the number of repeats of a 15 bp hypervariable 
element (HVE) in the hypervariable region (HVR) downstream of the Yend of the apo B 
gene and probably correspond to the insertion deletion (IDI) alleles described by Hegle et 
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al., 1986) and CHD has been supported by an Austrian study, which found a greater 
frequency of the HVE alleles 3 8,44,46 or 48 in I 10 CHD patients (5 5 years age) than in 
117 matched normal controls (Friedl et al., 1990). 
Xbal has also been associated with peripheral artery disease (Monsalve, 1988). 
However, contradictory results have been reported in age-matched cases and controls, 
when there was no association of angiographically proven atherosclerosis at extracoronary 
sites with the Xbal alleles or the genotype frequencies (O'Connor et al., 1987a). A similar 
study in patients with angiographically proven coronary artery disease did not show any 
association of Xbal RFLP and EcoRI RFLP with coronary atherosclerosis (O'Connor et 
al., 1987b). The Xbal RFLP has also associated with determination of plasma lipid 
concentrations in normal individuals (Law et al., 1986a; Talmud et al., 1987) and also with 
the presence of Type III hyperlipidaemia. Jenner et al. (1988) found X+ allele (presence of 
the site) was also associated with significantly increased plasma concentration of 
triglycerides (28%). Although the frequency of the El allele (presence of the site) was 
significantly increased in hypertriglyceridaemia, there was no difference in the frequency 
of EcoRl RFLPs between the hyperlipidaemics and controls. The numbers employed in the 
study were small (n=22); these findings require confirmation in a larger sample from the 
same population to eliminate the possibility of spurious associations, and to increase the 
power of detection of possible differences in the frequency of the RFLP between controls 
and hyperlipidaernics. If the rare allele frequency is low, the power to detect significant 
differences can be increased either by JUDIC-1-C-U-N-JUDIg 'Llic s-a-i-nple -size, or by studying a marker 
that is associated with a greater increase in risk (of CHD or hyperlipidaemia) in one 
population compared to another. In the condition of familial defective apolipoprotein 13- 
100, an autosomal codominant disorder, affected heterozygotes have a CpG mutation at 
amino acid 3500 in one allele. This substitution of glutamine for arginine (CGG-CAG) has 
been associated with hypercholesterolaemia and defective binding of LDL to the low 
density lipoprotein receptor (Soria et al., 1989). 
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Genetic mutations and hypolipidaernia 
Homozygous hypobetalipoproteinaernia, an autosomal codominant disorder is 
characterised by reduced levels of apo B-containing lipoproteins and a virtual absence of 
plasma apo B. An abnormal apo B-37 (mwt 203,000) is present in VLDL of affected 
subjects (Young et al., 1987a) along with apo B-1 00 and apo B-48. Two abnormal alleles 
were identified (Young et al., 1987c) with this condition. The B-37 variant arises from a 4- 
bp deletion in one of the abnormal alleles (Young et al., 1988) which results in a frameshift 
encoding for new amino acid valine, followed by a premature stop codon. A normal gene 
and a normal size message (although greatly reduced) are present (Ross et al., 1988). A 
mutation in the coding portion of the gene was suggested to lead to an abnormal protein and 
apo B mRNA stability. 
Other truncated variants have also been characterised in unrelated patients with 
hypobetalipoproteinaernia (Collins et al., 1988). One variant detectable in the plasma at 
low concentrations (in LDL and VLDL; predicted length 1794 amino acids) results from 
deletion of aG nucleotide from the leucine codon replacing it with Met, thus resulting in a 
frameshift translation which added four amino acids and a stop codon. The other variant 
not detectable in plasma (predicted 1305 amino acids long) resulted from a C-T transition 
in the CpG dinucleotide of the arginine codon converting it to a stop (CGA-TGA). 
T--- 
--- -- -- ---- -I* --II. 
r,. I. - 
immunogenetic polymorphisms oi apolipoprotein Ls 
In addition to DNA variants, apo B also has protein variants, which are detectable 
immunologically by monoclonal antibodies. The protein variants termed the antigenic 
group system (Ag), have been suggested to represent various antigenic forms of LDL. 
These were first detected by the use of antiserum from repeatedly transfused patients. Five 
different allelic variants of LDL have been identified, [Ag(x)-Ag(y), Ag(al)-Ag(d), Ag(c)- 
J Rajput- Williams Ph. D. Thesis Page 50 
Ag(g), Ag(t)-(z), Ag(h)-(i)]. This antigenic variation in LDL is genetically determined, 
and some of the variants have been correlated with RFLPs. Ag(c/g) epitopes are 
recognised by the apo B monoclonal antibodies, MB19 (Robinson, 1986) and BIP-45 
(Dunning et al., 1988). Based on the difference in binding affinities for MB 19 and BIP-45, 
a common genetic polymorphism was identified in the LDL. Thus LDLs from different 
individuals bound to MB 19 and BIP-45 with either strong, weak, or intermediate affinity 
(Young et al., 1986). Ag(c) allele corresponds to high binding affinity, and Ag(g) 
corresponds to low affinity (Tikkanen et al., 1987). In a Finnish family both alleles were 
transmitted in codominant fashion. 
Genetic linkage has been demonstrated between the immunogenetic variants of LDL 
and the apo B RFLPs (Berg et al., 1986), as shown by cosegregation of the Ag(x) alleles and 
apo B Xbal polymorphism. The Ag has thus been assigned to the same region as apo B on 
chromosome 2 (p23 -p24), (Robinson et al., 1986). 
Since the Xbal RFLP arises due to a silent mutation at the threonine codon 2488 
(C-+T change), the Ag(x) must represent a variant distinct from, and in strong linkage 
disequilibrium with, Xbal. A haplotype study (Ma et al., 1988) showed that Xbal was in 
linkage disequilibrium not only with Ag(x/y) site but also with Ag(c/g) site. This study 
showed no significant difference in either plasma cholesterol or plasma apo B 
concentrations between the haplotypes generated for the Ag(x/y), Ag(c/g) and Xbal RFLP. 
The protein polymorphism detected with both MB 19 and BIP-45, corresponding to the Ag 
(cIIg) epitope, was not associated With significant udn'turences in serum lIpIU concentrations 
either in Finnish men aged 18-22 years (Tikkanen et al., 1987) or in 53 French people 
(males and females, age 43 years). However, significantly higher apo B concentrations 
were associated with the intermediate (c+g) phenotype than either of the two homozygous 
groups (Tikkanen, 1987a). However, a study (Tikkanen et al., 1988) of young children (9 
years old) did show that genetic variation associated with the Ag(c) epitope was associated 
with significantly increased concentrations of both apo B and LDL. Young et al. (I 987b), 
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on the contrary reported negative associations of MB19 allotypes with CAD, 
hypercholesterolaemia and lipoprotein lipid concentrations, although in this Californian 
cohort the association may have been masked by geographic, ethnic and age differences. 
The Ag(t/z) epitope has been shown to be associated with the EcoRl RFLP of apo B 
(Ma et al., 1987), although it remains to be proved that the amino-acid alteration 
representing the EcoRl RFLP is actually the Ag(t/z) epitope. 
The epitope for Ag(a/d) was localised to a 26 amino acid stretch spanning nucleotide 
1950-2028 of apo B gene (Wang et al., 1988). This represents a single base substitution of 
T for C in individuals with Ag(dd), at nucleotide 198 1, resulting in an amino acid change of 
valine to alanine (GTT4GCT). This change results in the creation of a restriction site for 
Alu I in individuals homozygous for the Ag(dd) antigen. 
Genetic mutations and coronary heart disease in animals 
Various animals (rabbits, hamsters, mice, rats, pigs and non-human primates) have 
been used as models for the study of atherogenesis and disorders of plasma lipoproteins. In 
pigs, mutations of the apo B gene known as Lpb5 have been associated with 
hypercholesterolaemia and atherosclerosis. The Lpb5 mutation is associated with 
increased plasma cholesterol. Lpb5 gene in combination with the rare alleles LPu'and LPrI 
is associated with a more than 3-fold increase in plasma cholesterol. These pigs, in spite of 
- Ca 1; et I being fed a 1W. V, . -t d. 1 L, aa. so had -extensive Latty streaking and f1barn cel 1, sin their, "k". onal Y 
arteries (Rapacz, et al., 1986). The hypercholesterolaernia in these pigs was due to elevated 
LDL, which had reduced affinity for the LDL receptors. Although on sequence analysis, 
the Lpb5 allele from these mutants Lpb5.1 did not reveal any differences around the 
putative binding site that might explain the phenotype in these pigs (Maeda et al., 1988). 
Restriction enzyme polymorphisms of the apo B gene have been detected in mice 
(Lusis et al., 1987) and pigs (Maeda et al., 1988). 
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Aims 
There is considerable evidence that genetic variation at the apo B gene is associated 
with alterations in plasma cholesterol concentration, and with the occurrence of CHD. 
However most studies have produced results which have been inconsistent, possibly 
owing to small sample sizes, ethnic heterogeneity and non-random sampling. A 
preliminary study by our group (Law et al., 1986a) showed that variation at the apo B gene 
was associated with alteration of plasma cholesterol and triglyceride concentrations. These 
results prompted us to undertake a larger study to seek further associations with CHD and 
some of its risk factors, using different polymorphic markers and in a larger population. 
The study was designed to overcome some of the above mentioned problems by studying a 
large random sample of ethnically homogeneous Welsh men in a defined area within a 
defined age range. To obtain maximum information, haplotypes (haploid genotype) were 
determined for five genetic markers, and their associations sought with several variables, 
including serum cholesterol, LDL cholesterol, CHID, HDL cholesterol, body mass index 
(BMI) and serum triglycerides. 
The questions to be addressed were: 
1) Is genetic variation at the apo B candidate gene locus associated with plasma 
lipid and lipoprotein concentrations in a random sample of a middle-aged Welsh male 
population and, if so, to what extent? 
2ý Is genetic V"_1_.; U_U; 0n at the a-po BB locus associated with Ihe riisk m +11i, L11 LL1%1 I 13A V1 %_'L I" I U1113 
population? 
3) Is genetic variation at the apo B locus associated with other risk factors for CHD 
such as obesity, cigarette smoking and plasma triglyceride concentrations? 
4) What was the proportion of phenotypic variation that is attributable to the 
genetic variation, if any? (i. e. average allele effect. ) 
To address the above questions, genotypes and haplotypes (haploid genotype) of 
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apo B were determined by the technique of Southern blotting, using five restriction 
enzymes (Hincll, Pvull, Xbal, Mspl and EcoRI), and an attempt was made to identify 
specific RFLPs and haplotypes which might be associated with the different phenotypes. 
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Subjects, Materials and Methods 
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Selection of the Caerphilly subjects 
The Caerphilly cohort was a random sample of 2512 white men, aged 49-65 years, 
who were drawn from electoral wards and general practioners' lists in and around 
Caerphilly, South Wales. The nature of this cohort has been previously described (The 
Caerphilly and Speedwell collaborative group, 1984; The Caerphilly Collaborative Heart 
Disease Studies, 1985). These men attended the clinic of Caerphilly Collaborative Heart 
Disease Study, and were recruited to take part in a prospective study to determine risk 
factors for coronary heart disease (CHD). Of the 2512 men, a random sample of 290 men 
was drawn consecutively for the present haplotype study. The men were requested to fill in 
medical questionnaires on dietary habits, smoking history and alcohol consumption, and 
the London School of Hygiene and Tropical Medicine (LSHTM) questionnaire on chest 
pain. Anthropometric measurements were made (without shoes, jacket, shirt and watch). 
Height was measured to the nearest millimetre with a Holtain Stadiometer. Weight was 
measured to the nearest 5 g. Skinfold thickness was measured using Harpenden calipers. 
Body mass index (BMI) was calculated as the ratio of weight(kg)/height(metre)2 . 
Blood 
pressure was measured, and a resting (electrocardiogram) ECG was recorded on a 
Cambridge VS4 single channel machine. ECG tracings and chest pain questionnaires were 
used to define Possible and Probable CHD according to the Minnesota convention into two 
classes as in the Whitehall Study (Reid et al., 1974; Reid et al., 1976). The following were 
taken -- s- e vi den. %- e ou. LC %'-' HLI I D: - an gin ak' Ca -3 -3 es -0 e al 1- +1, - T QLT'F? k4 -L--+ U. Y LII%ý 1ý0111iVl %, IIL;; 3t PaIll LJUFý3LIVIaiane), 
myocardial ischaemia (from ECG records), history of myocardial infarction (MI) (from 
chest pain questionnaire and other medical history), or a combination of these. According 
to the Minnesota convention, definitions for CHD were as follows: Possible CHD defined 
as 1-3 (minor Q waves), 4-1 4-2 4-3 4-4 (ST wave changes), 5-1 5-2 5-3 5-4 (T wave 
changes) and 7-1 (left bundle branch block). Probable CHD defined as 1-1 1-2 (major Q 
waves), angina and or history of MI and/or probable ECG ischaemia. 
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A 12-hour fasting blood sample was drawn with minimal stasis from each subject in 
supine position for DNA analysis (genotyping and haplotyping), lipid and lipoprotein 
determinations. Blood for DNA was collected into tubes containing Na, EDTA as 
anticoagulant at a concentration of I mg/ml of blood. A5 ml aliquot of plasma was snap 
frozen for determination of total cholesterol, total triglycerides and HDL cholesterol. LDL 
cholesterol concentrations were calculated using the Friedewald formula: LDL cholesterol 
- total cholesterol - HDL cholesterol - (triglyceride/2.22) (Friedewald et al., 1972). All the 
samples were given a computer code. 
Statistical methods 
Cholesterol, LDL cholesterol and triglyceride distributions were checked by 
20 mainframe computer. applying thc'Shapiro-Francia Wtest for non-normality on a DECý 
The distributions were normalised by log transformation using the Minitab statistical 
computing system (Ryan, 1976). Analysis of variance was used to assess differences 
between the phenotypic means for the genotype distributions. If a significant difference 
was found between the three genotype groups, the data were analysed further to find where 
the difference was by comparing two groups at a time. 
Genotype frequencies and allelic frequencies were calculated for each RFLP. All 
RFLPs were checked for Hardy- Weinberg equilibrium. 
The contributions to phenotypic variance of cholesterol concentrations attributable 
to the MspI RFLP and EcoRl RFLP were analysed as described by Sing and Davignon 
(1085). Average allele effects were calculated using the formulas applied by Sing and 
Davignon (Sing and Davignon, 1985). 
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Isolation of genomic DNA from blood leucocytes 
All methods, unless otherwise stated were procedures adapted from Maniatis et al., 
(1982). Leucocyte DNA was prepared by the method of Kunkel et al., 1977; Bell et al., 
198 1). Five ml of whole blood (or 2.5 ml of cell suspension) was mixed with 45 ml of sterile 
lysis buffer (0.32 mol/I sucrose, 10 mmol/l Tris-HCL (pH 7.5), 5MMOl/l MgC'21 I% Triton 
X- 100) in 50 ml Falcon tubes and left on ice for ten minutes for the cells to lyse. The nuclear 
pellet was separated from the supernatant containing the lysed cell debris and plasma, by 
centrifuging at 4'C in a Sorvall RT6000 (Dupont) at 800 g for five minutes. The 
supernatant was discarded and the pink nuclear pellet resuspended in 2.75 ml of 75 mmol/l 
NaCl, 25 mmol/l EDTA, (pH 8.0). To release the DNA from the associated proteins, 0.25 
ml of 5% w/v (weight/volume) sodium dodecylsulphate (SDS) (0.5% w/v, final 
concentration) and 2 mg/ml proteinase K (0.1% w/v, final concentration; from BDH 
Ltd, Poole, UK) were added to the pellet and incubated at 3 7'C overnight. 
Extraction of DNA with phenol/chlorofonn: isoamylalcohoI 
Recovery and purification of DNA from the digested proteins of the nucleus 
involved extraction with an equal volume of Tris-saturated phenol, pH 8.5 (Rathburn 
Chemicals Ltd), containing 0.1% v/v (volume/volume) hydroxyquinoline as an 
antioxidant and 0.2% (v/v) B-mercaptoethanol as a reducing agent, for 30 min to Ih by 
gentle inversions on a rocker mixer (Ames). An equal volume of 
chloroform: isoamylalcohol (CHCI,: IAA), (24: 1) was added and the sample extracted for 
another 30 min to I h. The upper aqueous phase containing the DNA was then separated 
from the lower organic phase (phenol /CHCI,: IAA) and the protein interface by 
centrifuging in a Sorvall RT6000 at 800 g for 5 min. The DNA phase was transferred to a 
fresh tube using a glass pasteur pipette, the tip of which had been cut off to widen the bore. 
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The above extraction step was repeated to purify the nucleic acid further. The final 
extraction was with an equal volume of CHCI,: IAA, to remove any traces of phenol from 
the nucleic acid. The sample was centrifuged to separate the aqueous and organic phases. 
The DNA in the aqueous phase was precipitated by mixing with 0.25 ml (one-tenth 
volume) of 3 mol/I sodium acetate, pH 5.0 (final concentration 0.3 mol/1) and 5.0 ml (2 
volumes) of ice-cold absolute ethanol. The tube was inverted gently several times, and the 
precipitating white strands of DNA were spooled on to a pasteur pipette which had been 
hooked at the tip by melting in flame. The DNA was squeezed against the side of the tube to 
remove as much ethanol as possible, then dissolved in 1.0 ml of 10 mmol/l Tris-HCI, (pH 
7.5), 1 mmol/I EDTA at 4'C for several days. 10 ml of blood yielded on average 200-5 00 
VgDNA. 
Detection and quantification of genornic DNA on agarose gels 
The DNA samples were electrophoresed on a 0.6% (w/v) agarose gel in 0.89 mol/I 
Tris-borate, 0.089 mol/l boric acid, 0.002 mol/l EDTA (IxTBE) to check for physical 
integrity and quantity. Semi-quantitation was achieved by comparing the intensity of 
fluorescence emitted by the test DNA sample to the fluorescence emitted by DNA 
standards of known size (lambda/Hindlll or phiX I 74/Haelll) electrophoresed alongside. 
Ethidium bromide (EtBr) intercalates into the DNA molecule and fluoresces at 250 to 3 10 
im in tMe presence ofultra violet (U'V) III I 11 1 light. The in+ i ty kJ1 11 UkJI 16 P1 kJPVI UU11al 
to the amount of DNA. (As little as I to 5 ng DNA is detectable by this method. ) 
All DNA samples were quantified spectrophotometrically at 260 nm in a Pye 
Unicam SP8- 100 UV spectrophotometer. A standard curve was constructed with sonicated 
salmon sperm DNA (I mg/ml) in the range of 0 to 50 ýtg/ml with Tris-EDTA, (pH 7.5) as 
diluent. All the samples were standardised to a concentration of 200 [tg/ml either by further 
dilution or concentration (precipitating the samples with ethanol and redissolving in an 
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appropriate quantity of 10 mmol/I Tris (pH 7.5), 1 mmol/I EDTA. 
The purity of the DNA was determined by calculating the ratio of optical density 
readings at 260 nm and 280 nm (for pure DNA, the ratio is 1.8; contamination causes a 
reduction in the ratio). 
Restriction endonuclease digestion of genomic DNA 
The genomic DNA was digested with five restriction enzymes (Hincll, Pvull, Xbal, 
Mspl and EcoRl) for apo B restriction fragment length polymorphism analysis. The 
reaction digest consisted of 4 [tg of DNA (20 [d), 3 VI of I OX restriction enzyme buffer to 
give a final concentration of IX buffer, 3 VI of I mg/mI nuclease free bovine serum albumin 
(BSA), Bethesda Research Laboratories (BRL) (final concentration, 0.1 mg/ml), 24 units 
of the restriction enzyme (6 units per microgram), and sterile water to make a final volume 
of 30 pl in a 0.5 ml Eppendorf tube. The reaction was mixed and incubated at 37'C 
overnight. The reaction was stopped by the addition of one-tenth volume of 4xTBE stop 
(0.25% bromophenol blue, 25% Ficoll, 0.1 % SDS, 0.25% xylene cyanol in 4X TBE buffer 
(0.356 mol/I Tris borate, 0.356 mol/I boric acid, 0.008 mol/I EDTA). The digest was then 
electrophoresed. 
Gel fractionation of digested DNA fragments 
The digested DNA fragments were size fractionated by horizontal gel 
electrophoresis on 0.8% (w/v) agarose gels. Agarose, BRL Ultrapure (250 ml of 0.8% 
(w/v) concentration) prepared in IxTBE (0.089 mol/I Tris-borate, 0.089 mol/I boric acid, 
0.002 mol/I EDTA) was melted in a microwave oven, cooled to 50'C, mixed with 10 
mg/ml ethidium bromide (EtBr) to give a final concentration of 0.5 Vig/ml, and poured in a 
horizontal gel mould (15 cmx25 cm), which was sealed at the ends by tape. Because of the 
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length of the gel, it was possible to load 40 samples per gel (i. e., one 20 well comb was 
inserted into the gel at the top of the tray and a second comb was inserted half way (12.5 cm) 
from the top). After setting, the gel was loaded with the 30 pI apo B DNA digests and 
electrophoresed overnight (-16-17 h) in a Biorad Subcell (containing 1.5 litres (1) of 
IxTBEwith EtBratafmal concentrationof 0.5 ýtg/ml) at a constant voltage of 20 volts (I- 
1.5 volts/cm) using an LKB 2197 power supply. Lambda/HindlII DNA standard was 
loaded as a size marker in one well on each gel. Since EtBr was mixed with the gel, it was 
possible to view the DNA on a UV transilluminator without staining the gel. The gel was 
photographed with a Polaroid MP4 Land Camera (0.5 second exposure) using a polaroid 
film Type 667. The DNA fragments in the gel were then transferred to a nylon membrane 
by an alkaline blotting method (Reed and Mann, 1985). 
Alkaline transfer of apo B DNA fragments on to nylon membrane 
Prior to transfer, the gel was depurinated in 0.25 mol/I hydrochloric acid (HCI) for 20 
min to hydrolyse the DNA partially and aid in transfer of large fragments. The DNA 
fragments were transferred on to the nylon membrane (Zetaprobe, Biorad) in the presence 
of 0.4 mol/I sodium hydroxide, which caused denaturation. Once on the membrane, the 
fragments bind covalently, thus eliminating the need for vacuum baking. The assembly of 
the alkaline blot was similar to the Southern blot (Southern, 1975). 
Th. - cyol I ai A Iflat on a Pieceof33 M. I- chr('lA7', -tman"aper-a-ed across - gl- .. -A ý" AA-, AA. -A) - _J'Fý "ýl -00 " EAuaa 
plate, with the ends of the paper dipped in a tray containing 0.4 mol/I NaOH. A nylon 
membrane (Zetaprobe, Biorad) cut to the size of the gel and pre-soaked in 2X SSC (0.33 
mol/I sodium chloride, 0.03 mol/I sodium citrate, pH 7.0) was laid on top of the gel. A piece 
of parafilm was laid all around the outer edges to prevent bypass. Three or four pieces of 3 
mm Chr (Whatman) paper pre-soaked in 2X SSC were laid on top of the membrane. 
Approximately 200 Kleenex Professional Wipes (I vertical box) were laid on top of this. 
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The whole assembly was covered with Saran wrap (Dow Chemical Company Ltd. ), and a 
weight of approximately 1.5-2.0 kg placed on the top, and transfer allowed to occur 
overnight. The filter was then rinsed in 2xSSC (0.33) inol/I sodium chloride, 0.03 mol/I 
sodium citrate, pH 7.0) to wash off any agarose adhering to the filter, blotted dry on a piece 
of 3 mm Whatman filter paper, baked at 8O'C for '10 min under reduced pressure in a 
vacuum oven (Gal lenkamp), and stored at room temperature, until it was hybridised. 
Prehybridisation, hybridisation and dehybridisation of filter-bound DNA 
To block non-specific binding, the filter was prehybridised with 10 ml 
prehybridisation solution (containing 5xSSC (0.825 mol/I sodium chloride. 0.015 mol/I 
sodium citrate, pH 7.0), 1.0% SDS, 0.5% (w/v) blotto (Marvel milk powder), 0.5 mg/mI 
denatured sonicated sperm DNA) at 65'C overnight (-16h) in a shaking water bath 
(Kotterman). 
The filter was hybridised with 10 ml hybridisation solution (containing IxIO' 
counts/min/ml of 32P_01igo labelled denatured probe (specific activity - IxIO' cprn/ýtg), 
5xSSC, 1.0% SDS, 0.5% blotto, 0.5 m,, /ml denatured sonicated salmon sperm DNA) at 
65'C overnight (-16- 17 h) in a shaking waterbath (Kotterman). 
The filter was then given two washes of 20 min each at lower stringency conditions 
(2xSSC, 1.0% SDS) at room temperature, followed by a higher stringency wash (0.5xSSC, 
1.0% SDS) at 50uC for20min. A final very stringent wash (U. IxYsu (U. UIOD' mol/I sodium 
chloride, 0.0015 mol/I sodium citrate). 0.1% SDS) at 50'C was performed, until the 
background radioactivity registered 2-3) coutits/second onthe Geigercounter. 
All Mspl filters that had been hybridised with apo B Yprobe pABI were 
dehybridisedas follows, then rehybridised with the apo B 5'Mspl promoter probe (pl2x). 
The filters were stripped by two 20 min washes in a solution of OAX SSC (0.0165 
mol/I sodium chloride, 0.00 15 niol/I sodium citrate), 0.5% SDS at 95'C, according to the 
J Rajput- Williams Ph. D. Thesis Page 62 
BioRad instruction manual. To ensure that the filters were dehybridised, an X-ray film was 
exposed to them overnight. If the procedure was complete, no bands would appear on the 
film when developed. 
Autoradiography 
The DNA filter was blotted dry on a3 mm filter paper, wrapped in a Saran Wrap, and 
exposed to an X-ray film (Kodak) with a calcium tungstate-phosphor intensifying screen 
(Dupont Cronex Lightening Plus) at -80'C for five to seven days. The x-ray film was 
developed in an x-ray film processor (Fuji RGII, 240 V, 1.5VA, 50HZ). If the bands were 
faint after this time, the filter was exposed for a further seven to fourteen days, depending 
on the intensity ofthe bands. 
Oligolabelling of DNA fragments using random primers 
The method of Feinberg and Vogelstein (1985), which labels DNA to a very high 
specific activity, was used for oligolabelling. 
Approximately 60 ng of cDNA fragment (template) which had been denatured 
(boiled for 90 s in an Eppendorf tube and snap-cooled on ice) was mixed with I [d bovine 
serum albumin (BSA) (10 mg/ml nuclease free, BRL), 10 [d "P- dCTP (100 ýWi, 3000 
Ci/mmol, NEN, Dupont, West Germany), 11.4 [tl labelling solution (25 [il of I mol/I Hepes 
(pH 6.6), 25 ýtl of DTM, 7 [d of oligolabel), 0.5 ýtl Klenow (2.5 U large fragment of DNA 
Polymerase I, BRL). The final volume was made up to 25 pl with sterile water, mixed and 
the reaction allowed to proceed at room temperature overnight. 
The ingredients in DTM were 100 ýtrnol/l each of dATP, dGTP, dTTP, in TM (250 
mmol/I Tris-HCI, (pH 8.0), 25 MMOI/l 
MgC'2,50 
mmol/I B-mercaptoethanol). The 
oligolabel consisted of I mmol/I Tris, pH (7.5), 1 mmol/I EDTA, 90 units per ml 
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oligodeoxyribonucleotide hexamers, which act as random primers. The hexamers bind 
to the denatured template at random positions and prime the synthesis of a radiolabelled 
strand complementary to the template. 
Purification of radiolabelled probe 
The labelled cDNA probe was separated from the unincorporated free nucleotides by 
molecular sieve chromatography by passing through a column (a glass pasteur pipette, 6 
inches) packed with Biogel P60 (Biorad) dissolved in elution buffer (10 mmol/l Tris HCI 
(pH 8.0), 5 mmol/l EDTA, 100 mmol/l sodium chloride, 0.2% SDS). An equal volume (25 
pl) of bromophenol blue (BPB) (to act as a marker) was added to the reaction mix, and this 
was loaded on to the column and eluted with the elution buffer. 
The mixture resolved into two peaks, the first peak corresponding to the labelled 
cDNA probe, the second peak corresponding to the unincorporated nucleotides, as 
monitored by the counts/sec on the Geiger counter (Mini- Monitor G-M Metre Type 5.10). 
The eluate was collected in 1.5 ml Eppendorf tube. Two microlitres of the purified labelled 
cDNA probe was mixed with 5 ml scintillation fluid (Liquiscant, National Diagnostics) 
and the beta particle emission determined in a beta counter for 30 sec. The counts/min/ýd 
were calculated from this (counts/30 sec X2 divided by 2 microlitres). This procedure 
usually yielded stable labelled fragments with high specific activities (greater than or equal 
to Ix 109 counts/min/ ýig). 
Description of apo B clones used for hybridisation 
The EcoRl, Xbal and 3'Mspl filters were hybridised with a YcDNA probe pAB I 
spanning the carboxy terminal thrombolytic pepticle T2. Plasmid pAB I was amplified (see 
section on Midiprep) and then digested with the restriction enzymes BamH I and HindIll to 
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yield six fragments (0.315kb, 0.432kb, 0.508kb, 0.540kb, 0.560kb, 2.9kb) which were 
isolated (as described in a later section) to be used as hybridisation probes. 
The Pvull filters were hybridised with a 5'cDNA probe, pABF, spanning from exon I 
to exon 26. The plasmid pABF was amplified (see section on Midiprep) and digested with 
restriction endonucleases Pstl and Bglll, to yield four fragments (0.9 kb Pstl/Bglll; 
0.545kb Bglll/Bglll; 0.595kb Bglll/Pstl; 1.503kb Pstl/Bglll). The 0.9kb Pstl/Bglll 
fragment encoding exon 4 to exon 10 was used as a hybridisation probe. Details of the 
isolation of clones pABF and pAB I have been described previously (Knott et al., 1985). 
The Hincll filters were hybridised with a genomic subclone pl2x (3.4kb), in the 
vector pUC 13 (2.9kb) and spanning from the promoter region to the EcoRl site at the end 
of intron 3. This was digested with EcoRl to be used as a hybridisation probe. 
The 5'Mspl filters were hybridised with a 1021bp Pvull fragment spanning apo B 
promoter (-899 to + 12 1), cloned into EcoRl site of Bluescript pks+ (Jones et al., 1989). 
Amplification of recombinant plasmids - midiprep 
An overnight culture was grown by either inoculating 2 ml of TY broth containing 
ampicillin (50 ýLg/ml) with a single colony of E. coli containing the desired plasmid or by 
inoculating 2.5 ml TY broth with 200 [tl of glycerol stock (pABI/pABF). This was grown at 
37'C overnight in a shaker incubator (Kotterman) until it reached late log phase. For a 
midiprep, 2.5 ml of the overnight culture was inoculated in to a one litre conical flask 
containing 200 ml TY medium (containing 50 ug/ml ampicillin) and amplified overnight at 
37'C in a shaking incubator until the optical density (O. D. ) reached 0.4 to 0.5. The cells 
were then harvested by centrifugation at 5000 g in GSA Sorvall rotor at 4'C for 15 min, the 
supematant discarded and the resulting pellet resuspended in 8 ml of solution 1 (50 mmol/l 
glucose, 25 mmol/l Tris HCI (pH 8.0), 10 mmol/l EDTA, 5 mg/ml lysozyme added just 
before use). This was left at room temperature for 10 min for the bacterial cells to lyse, then 
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16 ml of freshly prepared solution 11 (0.2 mol/I sodium hydroxide, 1% SDS) was added, 
mixed, and left on ice for 5 min. This was followed by the addition of 8 ml of solution 111 (5 
mol/I potassium acetate, pH 4.8 [60 ml of 5 mol/I potassium acetate, 11.5 ml glacial acetic 
acid, 28.5 ml water]) and left on ice for 15 min. It was then centrifuged for 5 min in a Sorvall 
SS34 rotor at 27000 g. The supercoiled plasmid DNA in the supernatant was precipitated 
by adding 0.6 volumes (19.2 ml) of isopropanol, mixed, and allowed to stand at room 
temperature for 5 min, then centrifuged in an SS34 rotor at 8000 g for 5 min. After 
discarding the supernatant, the plasmid pellet was washed with 70% ethanol, air dried, and 
suspended in 8 ml TE (10 mmol/I Tris, I mmol/I EDTA), pH 8.0. The covalently closed 
circular plasmid was further purified by extraction with equal volumes of tris-saturated 
phenol (pH 8.5) and chloroform: isoamylalcohol followed by a final chloroform: isoamyl 
alcohol extraction, ethanol precipitation, spinning and resuspending in 2.0 ml TE (10 
mmol/I Tris, I mmol/I EDTA, pH 8.0). After addition of RNase (100 [tg/ml) the mixture 
was incubated at 60'C for 30 min, followed by phenol chloroform extraction and ethanol 
precipitation and resuspension in 2. Oml TE (10 mmol/I Tris, I mmol/I EDTA pH 8.0). 
Isolation of DNA fragments from recombinant plasmid clones 
DNA fragments were isolated by the method of Dretzen et al. (1981). The 
recombinant plasmid containing the required cDNA insert was cleaved with the 
appropriate restriction endonuclease according to the manufacturer's instructions (Paisley 
UK). The restricted fragments were resolved by horizontal gel electrophoresis on a 1.0- 
1.5% agarose gel (15cmxl4.5cmxO. 3cm) in IxTBE (0.089 mol/I tris-borate, 0.089 mol/I 
boric acid, 0.002 mol/I EDTA) at 150 volts for 4-5 h. (For small fragment sizes, 1.5% gel 
was used whilst for larger fragment sizes, 1.0% gel was used, whilst an intermediate 
concentration was used for intermediate sizes. ) The gel was prepared (described in a 
previous section) contained EtBr at a final concentration of 0.5 ýtg/ml. The resolved 
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fragments were viewed under long wave UV, recovered on to strips of DEAE cellulose 
paper (DE81 ion exchange paper, Whatman, England) (2cmx2cm strips soaked in 2.5 
mol/I NaCl for 4 h, then rinsed several times in water and eventually soaked in I xTBE), 
which were inserted into slits made above and below the bands of interest. Electrophoresis 
was then continued until the DNA band had moved on to the bottom DEAE strip. The upper 
strip would catch any contaminating DNA from the bands above. 
After the fragment had transferred on to the paper, the strips were rinsed in sterile 
water, blotted dry with filter paper, and the DNA was eluted in 200-500 ý11 of a high salt 
buffer (20 mmol/l Tris-HCI (pH 7.5), 1 mmol/l EDTA, 1.5 mol/lNaCl) for 2h at 37'C or30 
min at 60'C. The paper was squashed with a syringe needle to form a homogeneous mesh, 
then filtered through 2-3 layers of Glass Microfibre filter discs (Whatman GFC) placed in 
the bottom of a 1.0 ml syringe. The eluted fragments were purified further by 
phenol/chloroform extractions, ethanol precipitation, followed by resuspension in 100 [tl 
of TE, pH 7.6 (10 mmol/l Tris, (pH 7.5), 1 mmol/I EDTA). 
Phenol/chloroform extraction and ethanol precipitation of DNA fragments 
The fragments were extracted from the eluate with equal volumes of phenol and 
chloroform: isoamylalcohol (24: 1 v/v), mixed gently and then centrifuged for 10 min in an 
MSE microcentrifuge (13000xg). The upper aqueous phase was transferred to a clean 
EppenClort'tubje-, Land the extraction repeatedl. The fi-mal extraction vVa-S pCir-IrOb-1111CUA ýWvltfil a-1-1 
equal volume of chloroform: IAA. 
The DNA in the aqueous phase was precipitated by mixing with 2 volumes of 
absolute ethanol and leaving at -70'C for 2 h, followed by centrifugation for 10 min in a 
microcentrifuge (13000g). The ethanol was discarded and the DNA pellet washed with 
70% ethanol, followed by another 10 min spin and removal of ethanol. The pellet was air 
dried and resuspended in 100-200 ýtl TE, pH7.6 (10 mmol/l Tris (pH7.5), I mmol/l EDTA). 
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A2 pl aliquot of the dissolved fragment was electrophoresed in a 1.0% agarose (50- 
100ml in I xTBE) minigel (6.5cmx9. Ocm) to check for its presence and to quantify it by 
comparing with a known amount of molecular weight marker (Lambda/Hindlll or 
phiX I 74/Haelll) run alongside. 
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Results I: Restriction Mapping 
J Rajput-Williams Ph. D. Thesis Page 69 
Mapping of apolipoprotein B Hincll and Pvull polymorphisms 
Although Hincll and Pvull polymorphisms have been detected using cDNA probes 
from 5'end of apo B (Darnfors et aL, 1986), the precise location has not been mapped. 
To determine the precise location of polymorphic sites for Hincll and Pvull, single 
and double restriction endonuclease digestions were set up with DNA from individuals 
homozygous for both the presence and the absence of the polymorphic site. The restriction 
fragments were detected by Southern blotting (as described previously). The sizes of the 
bands produced by the various digestions were used to deduce the order of the fragments 
and determine the location of the Hincll and Pvull sites on the map. 
For Hincll mapping, the following restriction enzymes (Hpal, Hincll, Bglll+Hincll, 
Avrll+Hincll, EcoRI+Hincll, Pstl+Hincll) were used for digesting the DNA according to 
the manufacturer's instructions. For Pvull mapping, the restriction enzymes used were: 
EcoRV +Pvull, Pvull, Sphl+Pvull, Sphl, Pvull+Hincll, Kpnl+Pvull, Xmnl+Pvull. 
The probes used for hybridisation were pl2X for Hincll mapping and 0.9 kb 
Pstl/Bglll pABF cDNA fragment for Pvull mapping. The restriction fragments in the 
digests were electrophoresed (I % agarose gel), blotted and hybridised as described above. 
A restriction map of the 5' end of the apo B gene is shown in Figure 2 and the 
fragment sizes generated by the polymorphic Hincll, Pvull, and 5'Mspl restriction 
enzymes are shown. The results used to map the positions of the polymorphic Hincll and 
PVUII SItLCs are explained bbelow. 
Mapping of Hincll polymorphism 
The various restriction enzyme digests with the resultant fragments are shown in 
Figures 3 and 4. A restriction enzyme map of these fragments is shown in Figure 5. Hincll 
digestion gave an invariant band of 5.4 kb, 1.3 7 kb band in HZ++ (presence of the site), and 
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1.85 kb band in HZ-- (absence of the site). Partial bands of 6.77 kb and 7.25 kb were 
present in HZ++ and HZ-- respectively, due to the slow cutting Hincll site in intron 3. 
Hpal digest (Figures 3 and 5) gave the most informative result. As Hpal has the same 
recognition sequence as Hincll, the polymorphic site must also be a Hpal site, thus giving 
identical bands to the Hincll digest (1.37 kb band in HZ++ and a 1.85 kb band in HZ--) 
(Figures 3 and 5). A Bglll/HinclI double digest (Figures 3,4 and 5) generated fragments of 
sizes 1.11 kb and 5.4 kb for the 1- IZ++ and HZ-- 1.59 kb and 5.4 kb for the HZ--, the 
difference arising due to the presence of the polymorphic Hincll site. Since the band sizes 
were constant 5' of Bglll site, and varying 3' of the Bglll site the polymorphic Hincll site 
must lie Yof the BgllI site in intron 3. 
Avrll/Hincll digest (Figures 4 and 5) yielded invariant bands of 0.85 kb, 1.7 kb, and 
2.4 kb for both HZ++ and HZ --. The 1.7 kb and 3.1 kb bands (not shown in Figure 5) are 
probably generated due to an AvrII site in the unsequenced region in intron 2. HZ++ digest 
yielded a 0.54 kb band. In the HZ-- individual absence of the site would yield 0.85 kb band, 
which it did. This suggested that the site was Yof the Avrll site in intron 3. All bands 5'of 
the Avrll site were of a constant size; therefore the polymorphic site must be Yof this site. 
The EcoRI/Hincll digest (Figures 4 and 5) gave identical bands for both HZ++ and 
HZ-- (5.4 kb, 1.07 kb, and 6.0 kb). The 6.0 kb band was probably a partial band due to the 
slow cutting Hincll site in intron 3. Since EcoRl site lies Yto the Avrll site in intron 3 and 
did not yield bands of differing sizes the polymorphic Hincll site must be 3' of this. 
The Pstl/Hincll digest (Figures 4 and 5) similarly yielded identical fragment sizes 
for both HZ++ and HZ-- (0.90 kb, 0.80 kb, 0.39 kb, and 1.70 kb). By similar reasoning to 
above, the polymorphic Hincll site must lie Yof the Pstl site in exon 4. 
By use of Hpal, the site was located 171 bases Yinto intron 4, since Hpal and Hincll 
recognise the same sequence. The site resulted from a single base substitution of C4A 
(GTTAcC4GTTAaC). This result is in confirmation with the elucidation of this site by 
Huang eta/. (1990). 
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Figure 2. Restriction Map of 5'end of Human Apo B-100 Gene. 
The 5' flanking region and 5' end are shown. Polymorphic restriction enzyme sites 
are in parentheses ( ); restriction fragments produced by digestion with HincIl (H I, H2, 
H3, H4), Pvull (P I, P2) and MspI (M I, M2) are shown. Fragment sizes are in kb pairs. 
i 
represents CAP site 
A= 1021 bp Pvull genomic fragment used as a probe for 5'Mspl; B=pI 2x 
genomic probe for Hincll; C=0.9 kb Pstl/Bglll fragment of pABF, the 5'cDNA probe 
for Pvull. 
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Figure 3. Restriction Digestion Products for Hincll Mapping -I 
Complete and partial double digestion products of genomic DNA with various 
restriction enzymes; lanes A to D represent DNA from an individual homozygous for 
the absence of the Hincll polymorphic site; lanes E toH represent DNA from an 
individual homozygous for the presence of the Hinell polymorphic site; lanes A and E 
(Hpal), lanes B and F (Hinc 11) - incomplete digestion; lanes C and G (Hincll), lanes D 
and H (Hincll/Bglll). Fragment sizes are in kb. 
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Figure 4. Restriction Digestion Products for Hincll Mapping - 2. 
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Complete and partial double digestion products of genomic DNA digested with various 
restriction enzymes; lanes A to D represent DNA from an individual homozygous 
for the absence of the HincII site; lanes E to H represent DNA from an individual 
homozygous for the presence of the site; lanes A and E (Hincll/Bglll), lanes B and F 
(HincII/Avrll); lanes C and G (Hincll/EcoRI); lanes D and H (Hincll/Pstl). Fragment 
sizes are in kb. 
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Figure 5. Restriction Map Determination of Hinell. 
Complete and partial fragments of various Hincll digests. Fragment sizes are in kb. 
11 = Hincll, B= Bglll, A= Avrll, P= Pstl. 
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Mapping of Pvull polymorphism 
The bands generated from the various double digestions with Pvull and a restriction 
map of the corresponding fragment sizes are shown in Figures 6 and 7. Pvull digestion of 
genomic DNA yielded a 5.2 kb band in HZ++ and 7.3 kb band in HZ--. An invariant band of 
0.76 kb was also detected (not shown). An EcoRV/PvuII digest yielded invariant bands 
(2.18 kb and 0.76 kb) and varying bands of 3.32 kb for HZ++ and 5.5 kb for HZ--. The 
constant band of 2.18 kb is 3' of the EcoRV site in intron 7. Therefore the polymorphic 
Pvull site must lie 5' to the EcoRV site between the invariant Pvull site in intron 4 and 
EcoRV site in intron 7. An Sphl digest yielded identical fragments for both HZ++ and HZ-- 
(3.8 kb, and 3.1 kb). An SphI/PvuII digest produced an invariant band of 2.1 kb and varying 
bands of 3.5 kb for HZ++ and 3.8 kb for HZ--. The 3.8 kb band is produced by the Sphl site 
in intron 4 and the Sphl site in intron 7. The polymorphic Pvull site must lie within this 
region. If the 3.5 kb band extends upstream from the Sphl site in intron 7, then the Pvull 
polymorphic site would appear to be in intron 4. If however it extended downstream from 
the Sphl site in intron 4, then the polymorphic site might lie in intron 6. HincII/PvuII 
digestion yielded invariant bands of 1.70 kb and varying bands of 4.2 kb for HZ-- and 2.18 
kb for HZ++. The 4.2 kb band results from Hincll site in intron 4 and Hincll site in exon 7, 
therefore the polymorphic site lies within this region. If the 2.18 kb band extends upstream 
of the Hincll site in exon 7, then the polymorphic Pvull site would be located in the 
unsequenced region of intron 4. If however the 2.18 kb band extended downstream of the 
Hincll site in intron 4, the polymorphic site would still be in the unsequenced region of 
intron 4. As this intronic band would not be detected by the 0.9 kb cDNA probe, the 2.18 kb 
band must extend upstream of the Hincll site in intron 7. 
From the above results the polymorphic Pvull site appears to be located in the 
unsequenced region of intron 4. Huang et al. (1990) have also reported the location of this 
change to occur in intron 4, located precisely within an Alu sequence, 523 bp 5'to exon 5. 
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Figure 6. Restriction Digestion Products for Pvull Mapping. 
Double digestion products of genomic DNA with various restriction enzymes; 
lanes A to H represent DNA from an individual homozygous for the absence of the 
Pvull polymorphic site; lanes I to 0 represent DNA from an individual 
homozygous for the presence of the Pvull site; lane A (lambda/HindIll 
marker); lanes B and I (Pvull/EcoRV); lanes C and J (Pvull); lanes D and K 
(Pvull/Sphl); lanes E and L (Sphl); lanes F and M (Pvull/Hincll); lanes G and N 
(Pvull/Kpnl - incomplete digestion); lanes H and 0 (Pvull/Xmnl - incomplete 
digestion). Fragment sizes are in kb. 
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Figure 7. Restriction Map Determination of Pvull. 
Pvull/Sphl 
Sphl 
I 
Pvull/Hincil 
Digestion fragments of various Pvull digests. Fragment sizes are in kb. N. D. 
not detected. 
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Results 11 : Restriction Enzyme Polymorphisms of Apolipoprotein B Gene 
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Restriction fragment length polymorphism used for genotype and haplotype analysis 
In this study five restriction enzymes (Hincll, Pvull, EcoRl, Xbal and Mspl) 
spanning a distance of 43 kb from the 5'end to the 3' end of the apo B gene were used for 
genotype and haplotype analysis. A restriction enzyme map of the apo B gene is shown in 
Figure 8. The polymorphic sites and the restriction fragments corresponding to the 
restriction enzymes 5'Mspl, Hincll, Pvull, Xbal, 3'Mspl, EcoRl are shown in Figures 9 and 
10. The corresponding bands detected by Southern blotting and autoradiography are shown 
in Figures II to 16. 
The Xbal RFLP produces an invariant band of 2.8 kb plus an 8.6 kb fragment in the 
absence of the site, and a 5.0 kb fragment in the presence of the site. Homozygous 
individuals for genotype XIXI have 8.6/8.6 kb bands, whilst X2X2 individuals have 
5.015.0 kb bands (Figures 10 and 11). Heterozygotes have 8.6/5.0 kb bands. The Xbal 
RFLP arises due to a single base change of C->T in the third base of the threonine codon 
2488 (ACC->ACT) in exon 26 of the apo B gene. This is a silent mutation without affect on 
the amino-acid sequence (Berg et al., 1986). 
The EcoRl RFLP results from a single base substitution of G->A in codon 4154, thus 
altering the apo B protein sequence from glutamic acid (GAA) to lysine (AAA) (Berg et al., 
1986). Homozygotes lacking the site (EIEI) produce fragment sizes 14.0/14.0 kb. 
Individuals homozygous for the presence of the site (E2E2) produce 12.0/12.0 kb bands. 
Hetero--go, ------ Juce 1-11 1- fragments i F; - -- 10 -A12 
.' 6-ý F. ýý111 . 1.12.0/1114.0 
k1b a k. L 16ul %ýa Iv "Ilu 
The 3'Mspl RFLP is generated by deamination of cytidine to thymidine (C->T) on the 
non-coding strand, resulting in a substitution of arginine (CGG) to glutamine (CAG) in 
codon 3611 (Huang etal., 1988). Homozygotes forthe absence of the site (MI MI) produce 
fragments of 8.8/8.8 kb, while M2M2 homozygotes (presence of the site) produce band 
sizes 5.6/5.6 kb. Heterozygotes produce both 8.8 /5.6 kb bands (Figures 10 and 13). 
The Hincll site is generated in the fourth intron of the apo B gene, 0.171 kb 
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downstream of exon 4 (unpublished - section on mapping). The RFLP (Figures 9 and 14) 
results from a single base substitution of a C4A, creating a recognition sequence for Hincll 
(GTTAcC4GTTAaC). Since this is an intronic change, it does not alter the sequence of the 
mature protein. The fragment sizes generated by an individual homozygous for the absence 
of the site (H IH 1) are 1.8 5/1.8 5 kb whilst homozygotes for the presence of the site (1-121-12) 
generate 1.37/1.37 kb bands. The heterozygote produces both the 1.85/1.37 kb bands 
(Figures 9 and 14). 
The Pvull RFLP (Figures 9 and 15) is generated in intron 4 (unpublished- section on 
mapping), but the precise location has not been mapped because it lies in the unsequenced 
region. Homozygotes for the presence of the site (P2P2) produce band sizes 5.2/5.2 kb, and 
homozygotes for the absence of the site (PIPI) produce fragments of sizes 7.3/7.3 kb. 
Fragment sizes 7.3/5.2 kb are produced by the heterozygotes (Figures 9 and 15). 
The 5'Mspl promoter RFLP arises from a C4T transition 265 bases upstream of the 
cap site, resulting in the loss of Mspl site CcGG to CtGG (Jones et al., 1989). Homozygotes 
for the loss of the site produce bands of 0.77/0.77 kb, and homozygotes for the presence of 
the site produce bands of 0.598/0.598 kb. Heterozygotes have band sizes 0.77/0.598 kb 
(Figures 9 and 16). 
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Figure 9. Restriction Map of 5'end of Human Apo B-100 Gene. 
11 
The 5' flanking region and 5' end are shown. Polymorphic restriction enzyme sites 
are in parentheses ( ); restriction fragments produced by digestion with Hincll (HI, H2, 
H3, H4), Pvull (P 1, P2) and Mspl (M 1, M2) are shown. Fragment sizes are in kb pairs. 
I 
represents CAP site 
A= 1021 bp Pvull genomic fragment used as a probe for 5'Mspl; B=pI 2x 
genomic probe for Hincll; C=0.9 kb Pstl/Bglll fragment of pABF, the 5'cDNA probe 
for Pvull. 
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Figure 10. Restriction Map of the 31 end of the Human Apo B-100 Gene. 
Shown are the positions of the cDNA probe AB I; the sites of restriction 
endonuclease cleavage for Mspl(M), Xbal(X) and EcoRI(E); _3 )'HVR 
(hypervariable 
region) is shown; polymorphic sites are in parentheses solid bars are exons and 
lines are introns. Fragment sizes are in kb. 
J Rajput- Williams Ph. D. Thesis Page 84 
w "o l4W up ow 
1" 
8.6 kb 
$0 4w 5.6 kb 
Op 40 
Figure 11. Southern Blot Analysis of Xbal Polymorphism Detected with the 
3'cDNA Probe AM 
Fragment XI=8.6 kb; Fragment X2 = 5.6 kb 
J. Rajput- Williams Ph. D. Thesis Page 85 
"0 
41W 4m 
0» g» m* geo 40 
14.0 
12.0 
low ico, 40 
ýAwwm, jumbak. - AJOWIML --P' 40'*W "RIPPROW '140w 
Figure 12. Southern Blot Analysis of EcoRl Polymorphism Detected with the 
YcDNA Probe ABI 
Fragment EI =14.0 kb; Fragment E2 = 12.0 kb 
J Rajput- Williams Ph. D. Thesis Page 86 
%*110 4& goem 
0 
W 10 - VP '4*- 8.8 kb 
5.6 kb 
OW 4040 OW 5, 
Figure 13. Southern Blot Analysis of 3'MspI Polymorphism Detected with the 
YcDNA Prohe AB1 
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Fragment MI=8.8 kb; Fragment M2 = 5.6 kb 
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Figure 14. Southern Blot Analysis of Hinell Polyrnorphism Detected with the 
pl2x Probe. 
Fragment HI=1.8 5 kb; Fragment H2 = 1.3 7kb 
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Figure 15. Southern Blot Analysis of Pvull Polymorphism Detected with the 0.9 kb 
PstI/BgIIl Fragment of Plasmid pABF. 
Fragment PI=7.3 kb, Fragment P2 = 5.2 kb. 
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Figure 16. Southern Blot Analysis of 5'MspI Polymorphism Detected with 
the 1021 bp Pvull Fragment spanning the Apo B Promoter 
Fragment MpI =0.77 kb; Fragment Mp2 = 0.59 kb 
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Results Ill: Linkage Disequilibrium 
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Apoprotein B gene and linkage disequilibrium 
A measure of linkage disequilibrium D' was calculated for all pairs of RFLPs as 
previously described (Cox et al., 1988). Haplotype frequencies calculated for the entire 
data set were used in the calculation of the linkage disequilibrium, D', as follows: 
D'=D/Dmax where D=h(l I)-pq; h(l 1)= the estimated number of haplotypes with 
allele I at locus I and allele I at locus 2; p and q are frequencies of allele I at locus I and 
allele I at locus 2 respectively. D'ispositive whenthe rarer alleles at each of thetwo loci are 
associated and as negative when the rarer allele at locus I is associated with the more 
common allele at locus 2. 
Dmax=min[pq, (l -p)(I -q)] for D<O or min[p(l -q)(I - p)q] for D>O. 
The significance of the disequilibriurn was assessed by determining whether D 
varied significantly from 0; 
[DýNN(p(I-p)q(l-q))]'=Xi 
D' provides information on linkage disequilibrium. relative to the maximum (or 
minimum) possible for a pair of loci. D'is independent of the frequency of the alleles that 
are associated, as opposed to other methods of assessing disequilibrium. 
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Table 3. Standardised Linkage Disequilibrium Values for Apolipoprotein B 
Restriction Enzyme Sites 
5'Mspl Hincll PvUll Xbal 3 Mspl 
(Prornoter) 
Hinell 4 1.0 *** ---- 
Pvull + 0.88 *** + 0.89 
Xbal - 0.77 *** + 0.89 *** -4- 0.89 *** 
3 Mspl - 0.78 *** - 1.0 *** - 1.0 ** - 1.0 *** 
EcoR1 +0.31 *** + 0.29 *** - J. () *** + 0.96 *** - I'() *** 
p<0.01; that is, D' is significantly different from zero 
p<0.001, that is, D' is significantly different from zero 
The standardised linkage disequilibrium value (usually denoted D') provides an 
indication of the linkage disequilibrium relative to its theoretical maximum. Thus a 
value of +0.29 indicates that the EcoRl and Hincll show 29% of their theoretical 
maximum disequilibrium. The sign of D' indicates whether the common alleles at 
the two RFLPs are associated H or whether the common allele at one locus is 
associated with the rarer allele at the other locus (-). 
The standardised linkage disequilibrium D' is not sensitive to the frequencies of the 
associ, 9ted alleles. 
The disequilibrium D'between 5'Mspl and Hincll is +1.0 (frequencies being 0.79 
and 0.85, respectively) whereas Ubetween 5'Mspl and EcoRl is +0.31 (frequencies 
being 0.79 and 0.84, respectively). Although the frequencies are similar for both 
pairs, the value of D' differs considerably, hence D' is not dependent on the allelic 
frequencies. 
There was no relationship between the magnitude of D' and the physical distances. 
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Discussion 
Extensive linkage disequilibrium existed between all the five RFLPs (Hincll, Pvull, 
Xbal, Mspl and EcoRI). All pairwise D values were significantly different from zero 
(p<0.001) (Table 3). This great extent of the disequilibrium would explain the observation 
of only a limited variety of haplotypes: 15 of a possible 32 haplotypic combinations were 
observed in a total of 468 chromosomes (234 individuals). The linkage disequilibrium 
implies that the RFLP sites are close to each other (i. e. the genetic distance between the 
sites is relatively small). Hence the frequency of recombination events is likely to be low. 
As a consequence, this would result in a reduced frequency of certain haplotypes. A study 
by Fems et aL (1988), however, showed that Xbal and EcoRl were in linkage equilibrium, 
despite the loci being quite close together (approximately 8 kb apart) (n=28). In Myant's 
study (1989), Xbal was in linkage disequilibrium with EcoRl and Pvull, but there was 
linkage equilibrium between Pvull and EcoRl. This may be a reflection of the sample sizes 
used to calculate the disequilibrium parameter, D (146 individuals). It is possible that 
much larger numbers would be required to detect a linkage disequilibrium, if it exists. 
Because of linkage disequilibrium between the markers, mutations which arise in any one 
of these haplotypes becomes fixed with that haplotype and is observed as a statistical 
association of the haplotype with the phenotype of interest. It is generally considered that 
linkage disequilibrium and physical distance are inversely correlated, but some studies 
have reported an inconsistent relationship between linkage disequilibrium and physical 
distance (Borresen et aL 1988). In a small region of 20 kb on chromosome 2, no consistent 
relationship was found between the magnitude of linkage disequilibrium and physical 
distance between pairs of seven RFLPs (Litt & Jorde, 1986). Because the region is small, 
recombination is unlikely, therefore factors suggested to influence such a relationship are 
mutation, genetic drift, selection, all of which may overpower the effects of recombination 
and therefore affect linkage disequilibrium (Litt & Jorde, 1986). It should be noted that 
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with extensive disequilibrium in a particular region, the amount of additional polymorphic 
information will be reduced, but with moderate disequilibrium, this will increase the 
frequency of the haplotypes and therefore the polymorphic information. Some methods 
used for calculating linkage disequilibrium are dependent on frequencies of the associated 
alleles, in which case it is difficult to make comparisons. The ability to detect deviation 
from zero disequilibrium is quite sensitive to the frequencies of the alleles that are 
associated (Cox et aL, 1988) i. e. there is less power to detect disequilibrium when an allele 
with a frequency of 0.09 is associated with an allele with a frequency of 0.88 in the Chinese 
population (Rsal and Taql RFLPs in the insulin/insulin-like growth factor 11 gene region) 
compared to an allele with a frequency of 0.46 being associated with a frequency of 0.87 in 
the Caucasian population. 
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Results IV: Genotypes of Apolipoprotein B Gene and Plasma Lipids 
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Genotype and allele frequencies 
The clinical characteristics of the total cohort of Caerphilly subjects are presented in 
Table 4. The clinical characteristics of the subsample of the Caerphilly cohort (total 290 
men) are presented in Table 5, and represents the number of men for whom the genotype 
data was available. The numbers of individuals genotyped was variable, and limited by the 
availability of the sample. Genotyping was performed on these men using six restriction 
enzymes (5'Mspl, Hincll, Pvull, Xbal, Mspl and EcoRl). Results for genotyping the 
Caerphilly men for the various RFLPs are presented in Table 6. (See Appendix for raw 
data). 
Genotype frequencies and allele frequencies were calculated by the gene counting 
method. All the genotype frequencies were in agreement with those expected by the Hardy- 
Weinberg equilibrium (Table 6). There was statistically no significant difference between 
the observed and the expected gene frequencies. The constancy of the frequencies has been 
maintained from generation to generation, and hence all were in Hardy-Weinberg 
equilibrium. 
For haplotype analysis, five restriction enzymes were used (Hincll, Pvull, Xbal, 
Mspl and EcoRl) and complete data for all five RFLPs was available for 234 individuals. 
Comparison of genotype and allelic frequencies derived from the complete haplotype data 
set comprising 234 individuals were similar to the frequencies derived from the total 
(actual) 
-R-FLP-, qrnri-d 
fnr i-nrh f-n7vmi- ti-yrhiti; nn '; 'Mcnh Thic!; mnI; tfj f nt a - ----- 11-i-plied tha-F-sibilit. 7 
of a bias was eliminated in the analysis of the haplotype data set of 234 RFLPs, and would 
thus be reflective of the whole of the Caerphilly cohort recruited for this study. Thus, the 
final haplotype analysis would be unbiased despite a proportion of the individuals missing. 
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Table 4. Clinical Description of the Caerphilly Cohort: Plasma Lipid and 
Lipoprotein Concentrations 
Variable 11 Mean ± SEM 
Total Cholesterol (nirnol/1) 300 5.52 A. 01 
Triglycerides (ininol/1) 300 1.87 0.06 
HDL Cholesterol (nirnol/1) 299 1.03 Oý01 
Age (years) 100 5.2 :t0.27 
Height (metres) 299 1.72 0.0 1 
Weight ft) 299 77.9 0.63 
BM I (kg/rn) 299 26.4 ýi- 0.19 
n number of subjects 
Table 5. Characteristics of the Subsample of the Caerphilly Cohort. 
Clinical Characteristics 
Total Cholesterol > 6.5 minol/I 
Total Cholesterol < 4.8 mmol/I 
BMI > 26.0 k g/1112 (obese) 
CHD Cases 
Individuals (ratio) 
17.1 (40/234) 
18.8 (44/234) 
53.9 (125/232) 
24.0 (56/233) 
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Analysis of variance 
Associations were sought for between the various apo B genotypes and plasma lipid 
concentrations. One-way analysis of variance was performed on the log-transformed 
cholesterol and triglyceride data for each RFLP to test the null hypothesis that allelic 
variation at the apo B locus does not affect the phenotypic variation. The geometric means 
of plasma cholesterol, LDL cholesterol and triglyceride for the various apo B RFLP 
genotypes are presented in Table 7. 
The genotypic means of plasma cholesterol, LDL cholesterol and triglyceride for 
each RFLP were compared using the one-way analysis of variance procedure on the 
statistical programme, Minitab. Comparisons were made among the three genotypic 
means and also between each of the two genotypic means (Table 8). Analysis done on the 
residuals from a regression of age, height and weight confirmed that concomitant variables 
(age, sex, weight) did not contribute significantly to variance in cholesterol and 
triglyceride concentrations. Part of the reason for this could be that the data were 
representative of males only within a narrow age range (49-65 years). Therefore, analysis 
was done on unadjusted cholesterol concentrations. 
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Table 8. One-way Analysis of Variance for Total and LDL Cholesterol 
Total Cholesterol LDL Cholesterol 
Enzyme Genotype F-ratio P DF F-ratio P DF 
HincIl HIHI/H2H2/HIH2 0.43 0.65 2 0.48 0.619 2 
HIHI/H2H2 0.72 0.40 1 0.80 0.372 1 
HIHI/H2H2 0.23 0.63 1 0.24 0.625 1 
H2H2/HIH2 0.34 0.56 1 0.43 0.514 1 
PvuI1 PIPI/P2P2/PIP2 2.08 0.13 2 2.02 0.135 2 
PIPI/P2P2 4.00 0.047* 1 3.59 0.059 1 
PIP I /PI P2 0.11 0.74 1 0.37 0.544 1 
P2P2/PIP2 3.97 0.052* 1 3.78 0.058 1 
Xbal XIXI/X2X2/XIX2 2.67 0.070 2 4.05 0.019* 2 
X1XI/X2X2 3.71 0.056 1 3.94 0.049* 1 
XIXI/XIX2 0.37 0.54 1 0.02 0.888 1 
X2X2/XIX2 3.89 0.049 1 7.67 0.006* 1 
3'Mspl MIMI/M2M2/MIM2 4.49 0.0 12* 2 4.98 0.008* 2 
MIMI/M2M2 4.19 0.042* 1 6.13 0.014* 1 
MIMI/MIM2 1.56 0.217 1 3.33 0.074 1 
M2M2/M I M2 5.34 0.022* 1 4.38 0.037* 1 
EcoRI EIEI/E2E2/EIE2 2.88 0.058 2 2.87 0.058 2 
EIEI/E2E2 3.03 0.083 1 2.89 0.091 1 
EIEI/EIE2 1.43 0.235 1 1.34 0.250 1 
E2E2/EIE2 3.20 0.075 1 3.31 0.070 1 
5'Mspl MpIMpl/Mp2Mp2/Mp2Mp2 0.40 0.670 2 0.89 0.412 2 
MpiMpl/Mp2Mp2 0.51 0.48 1 0.75 0.388 1 
MpIMpI/MpIMp2 0.24 0.63 1 0.24 0.625 1 
Mp2Mp2/MpIMp2 0.39 0.53 1 1.22 0.270 1 
* significant difference (P < 0.05) 
DF, degrees of freedom 
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5'Mspl promoter site polymorphism 
The details of the polymorphism have been described in the report by Jones et al. 
(1989). The frequency of the polymorphism was determined in 270 individuals of the 
Caerphilly cohort. A C->T transition 265 bases upstream of the cap site results in the loss of 
a recognition site for Mspl (CcGG-CtGG). The rare allele (MP 1) representing the loss of 
the site is 770 bp, occurs with a frequency of 0.21. The common allele (MP2) having the 
site present is 598 bp, occurs with a frequency of 0.79 (Table 5). 
An analysis of variance was done to test the hypothesis that phenotypic variation of 
concentrations of plasma total cholesterol and LDL cholesterol were not influenced by the 
genetic variation at the MspI locus in the promoter region of apo B. The three genotype 
groups did not differ significantly in the mean concentrations of either total cholesterol or 
LDL cholesterol (Table 8). This indicated that the variation in the apo B promoter due to 
this RFLP does not seem to alter the phenotypic expression. Because the RFLP is in the 
regulatory region (promoter), the chances of it influencing the phenotypic expression 
would be expected to be higher than if it were in the non-regulatory region. However, there 
is evidence (Pullinger, et al., 1988) that the rate of transcription of the apo B gene is not the 
regulator of apo B synthesis; neither is apo B mRNA translation. It appears that it is the rate 
of degradation of intracellular apo B that determines apo B secretion rate. Thus, the above 
data are consistentwith promoter region mutations having little effect on apo B production 
rate, or therefore on LDL cholesterol and total cholesterol concentrations. 
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3'Mspl, Xbal, EcoRl, Pvull and Hincll polymorphisms 
For the 3'Mspl RFLP the results showed a statistically significant difference in the 
means of plasma total cholesterol (p=0.012,2df) and LDL cholesterol (p=0.008,2df) 
among the three genotype groups (Table 8). The association for LDL cholesterol was much 
stronger than that for plasma total cholesterol. This is not surprising, as LDL is the major 
carrier of plasma cholesterol. The absence of the site (MI) seemed to be associated with 
significantly higher concentrations of plasma total and LDL cholesterol. The M2M2 
genotype had the lowest and the MIMI genotype the highest means for plasma total and 
LDL cholesterol. A further comparison of the means between each of the two genotype 
groups indicated that the significant variability in plasma total cholesterol means was 
attributable to the differences in MIMI /M2M2 (p=O. 042), and that in LDL cholesterol to 
differences in MIMI/M2M2 (P=0.014) and M2M2/MlM2 (p=0.037). However, there 
were only four individuals homozygous for MIMI (1/70), and this may considerably 
weaken the association between the groups. At least five times as many individuals would 
be required to get a statistically valid number for analysis. 
For the Xbal RFLP, comparison of plasma cholesterol means among the three 
groups did not reveal a significant difference, although there was a trend. Further analysis 
showed borderline significant differences between the means for the genotype groups 
XlXl/X2X2 (p=0.056) and X2X2/XIX2 (p=0.049) (Table 8), suggesting that the 
C tice offhe site 'I'V, )'% ated pr se ýý ýX L11%., 31L was asSOCiaUýU VVILII IIIgIIVI plasmacholeste-iol concentrations. 
Analysis of LDL cholesterol, however, showed a significant difference (p=O. 0 19) among 
the three genotype groups, providing further support for the Xba I site in the determination 
of plasma cholesterol and LDL cholesterol concentrations. The presence of the site seemed 
to be associated with significantly higher concentrations of LDL cholesterol. The 
difference seemed to exist between XI XI /X2X2 (p=0.049) and X2X2/X I X2 (p=0.006). 
A borderline significant difference (p=0.058,2df) (Table 8) existed amongst the 
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plasma cholesterol nicans of FcoRI RFLP. Plasma cholesterol concentrations were lowest 
in absence of the restriction site (E IFI) representing the Lys allele and highest in presence 
ofthe restriction site (E2E2) representing the Glu allele. 
Similarly for Pvul La significant borderline difference existed between the plasma 
cholesterol means for groups PIPI /P2 1`22 (p=0.047) and P2P2/P I P2 (p=0.052) (Table 8). 
Homozygotes for the presence of the site (P2) had higher cholesterol concentrations, 
although account must be taken of the small number of individuals (n=4) representing the 
P2P2 genotype. 
There was no statistically significant phenotypic variation associated with genetic 
variation for plasma total cholesterol or LDL cholesterol at the loci for HinclI. Analysis of 
variance to compare the means of triglycerides amongst the genotypes of each apo B RFLP 
did not show any statistically significant difference (results not shown), implying that this 
genetic variability does nothiflue-iice plasma triglyceride concentrations. 
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Discussion: Xbal Polymorphism and plasma lipids 
(i) Plasma cholesterol and triglycerides 
This study did not show a significant association between the Xbal polymorphism 
and plasma cholesterol or triglyceride concentrations. Although there was a tendency 
towards an increased concentration of plasma cholesterol and triglyceride in individuals 
with the X2 allele (X2X2>XIX2>XIXI), this difference did not reach statistical 
significance. In agreement with these results, Leren etal. (1988) showed that homozygotes 
and heterozygotes for the presence of the X2 site had higher concentrations of plasma 
cholesterol and triglyceride, although this was not statistically significant. In contrast, a 
previous study (Law etal., 1986a) performed on subjects from northwest London showed a 
highly significant association between the Xbal genotypes and lipid concentrations, in 
which the presence of the restriction site (X2X2 and XI X2) was associated with increases 
in both triglyceride (36%) and cholesterol (8%) concentrations. However, the lipid 
analysis in that study was performed on non-fasting sera. Results from a dietary 
intervention study (Tikannen et al., 1990) suggested that the response to diet is influenced 
by the genotype of an individual. Depending on their Xbal genotype, subjects showed a 
differential response to reductions in total plasma cholesterol and LDL cholesterol when 
put on a low fat, low cholesterol diet. The magnitude of reduction in subjects possessing the 
X2 allele (X2X2) and (X I X2) was greater than in those lacking the site. The reduction in 
LDL cholesterol is probably due to upregulation of hepatic receptors during the low 
cholesterol diet. This in turn increases the rate of clearance of LDL cholesterol from the 
circulation. In addition to the confounding factor of non-fasting lipids, there Xare other 
possible explanations for this discrepancy between the Caerphilly and London subjects, 
such as geographical, social and ethnic differences. Other factors which may be 
responsible are: 
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Selectionof individuals: The Caerphilly cohort was probably a homogeneous, stable 
based group with a relatively constant gene pool. In contrast, the north-west London group 
was probably more heterogeneous, even though all the individuals recruited were 
Caucasian. Furthermore, the London group had a selection bias, as all the recruits were 
from a food processing firm, compared to the Caerphilly cohort, who were randomly 
recruited from electoral registers and general practitioners' lists. As it is likely that the 
London group was under rather similar environmental stresses, associations within that 
group may be less representative of the population as a whole. 
Allele Frequencies: Although the allele frequencies were similar in the Caerphilly 
and London groups, the phase of linkage may be different, i. e. perhaps the X2 allele occurs 
frequently with the wild type variant in the Caerphilly group, and with the mutant variant in 
the London group. 
(e) Linkage Disequilibrium In the London study Xbal was suggested to be in linkage 
disequilibriurn with the mutant variant. However, differences in the degree of 
disequilibriurn between the marker and the mutant between these two groups may mask 
certain associations. It is possible that in the Caerphilly group the Xbal RFLP is associated 
with a variant which offers a selective advantage. If so, it may weaken any associations of 
the marker with plasma cholesterol and triglyceride. 
(f) Size of the groups: There were three times as many individuals (264 men) in the 
Welsh group as opposed to 83 men in the north-west London group. Greater numbers 
would tend to give a more accurate assessment of small real differences and also yield more 
convincing results. Despite a lack of clear significant association in the Caerphilly group, 
the results did tend to suggest that the presence of the site (X2 allele) was associated with 
elevated concentrations of plasma cholesterol. Variation at this locus may be involved in 
the genetic determination of plasma cholesterol concentrations by being in linkage 
disequilibriurn with the susceptibility variant responsible for this effect. Since Xbal is a 
silent mutation (Berg et aL, 1986) causing no change in the amino acid sequence, this 
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RFLP cannot be directly related to the phenotypic variation. 
The triglyceride concentrations in the three genotype groups were not significantly 
different, and these results are supported by similar findings in a study of 170 Norwegian 
males (age 47 years) (Myklebost et al., 1990) To ensure uniform distribution of lipid 
concentrations, subjects were selectedboth fromthe lowerandthe upper distribution of the 
lipid concentrations. Since these results were in contradiction to the findings of Law et al., 
(1986a) it is likely that the effect observed in Law's study may not be real and possibly 
explained by the non-fasting status of triglycerides. However other explanations can be 
postulated i. e. the mutant variant may not exist in the Welsh group and might have arisen 
independently in the London group, thus being in linkage disequilibrium with the Xbal 
allelic change; or the Welsh group may have had such an association when the mutant 
variant first arose, but because of the existence of possible recombinational 'hotspots' 
between the mutant variant and the RFLP, this association weakened or ceased to exist. 
The association of Xbal polymorphism with slightly increased plasma cholesterol, and 
lack of association with triglycerides could be interpreted as being due to reduced 
catabolism of LDL rather than increased production of VLDL, the precursor of LDL. 
(ii) Plasma low density lipoprotein cholesterol 
With respect to LDL cholesterol, this study showed a significant difference in LDL 
cholesterol concentration annong +MCILIM-ce r, ý, IIUL. YFU rIVUP3. Individuals homozygous anu 
heterozygous for the presence of the restriction site (X2X2 and XI X2) had significantly 
higher concentrations of LDL cholesterol compared to the individuals homozygous for the 
absence of the restriction site (XIXI). These observations are in agreement with other 
studies, showing the association of the X2 allele and elevated plasma cholesterol 
concentrations (Law et al., 1986a; Talmud et al., 1987; Houlston et al., 1988). Contrary 
results showing a negative association of the X2 allele and elevated LDL cholesterol 
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concentrations have also been reported (Genest et al., 1990). Xbal polymorphism also 
influences plasma LDL cholesterol levels in familial hypercholesterolaernia patients 
(Aalto-Setala et al., 1989), although this may be a cumulative effect due to reduced 
fractional catabolic rate (FCR) and defective receptors. This is of interest, as there is wide 
variation in LDL cholesterol in familial hypercholesterolaemia, even within the same 
kindreds who presumably have the same mutations affecting the LDL receptor. Studies 
such as this may provide clues as to how apo B mutations and LDL receptor mutations 
interact to determine the final phenotype in familial hypercholesterolaemia. 
Since plasma apo B concentration and plasma LDL cholesterol concentration are 
positively correlated, it is possible that the association of apo B gene with LDL cholesterol 
would also reflect its association with plasma apo B concentrations. Hence, individuals 
with the restriction site (X2 allele) might have higher concentrations of plasma apo B than 
those lacking the site (X I allele). Since plasma apo B concentrations were not measured in 
the present study, this assumption remains to be confirmed. However, Law's study (I 986a) 
showed apo B levels to be 10% higher in individuals possessing the restriction site than in 
those lacking it (X IX 1). Leren et al. (1988) found a statistically significant association of 
apo B concentrations with the Xbal RFLP (p<0.05): genotype X2X2 (presence of the site) 
was associated with significantly higher concentrations of apo B compared to genotype 
XIXI (absence of the site). In one study, the average effect of the X+ allele on plasma apo 
B and LDL cholesterol concentrations was to raise them by 3-4 mg/dI (Deeb et al., 1992), 
while the X- all-III r-rI-s1d the... b A__1A1 IL -y ... 6/ýX. XL LX1UO UFfJI"10 L11"LYVU"JL polyino. ph, sm acts 
to increase LDL cholesterol concentration. A plausible explanation for this would be 
linkage disequilibrium of the Xbal polymorphic site with a mutation in the apo B gene 
which increases the synthesis rate of LDL or reduces its LDL-receptor mediated 
catabolism. 
In support of the latter possibility, Houlston et al. (1988) and Demant et al., (1988) 
showed that the fractional catabolic rate (FCR) of LDL apo B was reduced in subjects 
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possessing the restriction site (X2). The increased FCR in the XIXI subjects has been 
suggested to be due to an alteration in the apo B which presumably affects binding to the 
LDL receptor (Demant et al., 1988). But contrasting results have been reported, showing 
elevated binding and degradation in vitro of LDL from X2X2 individuals (Vilella et al., 
1992) which would not explain the elevated concentrations of LDL cholesterol observed in 
those Spanish subjects. Also, there was no difference in the LDL receptor activity of 
derepressed blood lymphocytes. 
(iii) General discussion 
Observations reported by Leren et al. (1988) are in agreement with this study, i. e. the 
presence of the site (X2) was associated with higher concentrations of plasma cholesterol, 
although this did not achieve statistical significance. However, it should be noted that the 
subjects recruited for Leren's study were all middle-aged (50-59 years) (n= 62) non- 
familial hypercholesterolemics, and were also ethnically different from the present 
subjects. Similarly, higher concentrations of both total and LDL cholesterol, although not 
statistically significant, were observed in X2X2 group of 106 fasting male patients with 
CHD and 118 healthy men of Austrian descent (cf XIXI and XI X2) (Paulwebber, 1990). 
A Finnish study (Aalto-Setala, 1988) of 176 healthy subjects also detected no significant 
difference in plasma cholesterol, triglyceride or LDL cholesterol concentrations between 
the Xbal genotypee g-r-oups- for either ma-less or fen. alles. 'Iffiesee fiindl J, ngs are in agreenm tt "idi 
the Caerphilly results, except for LDL cholesterol, and also it should be noted that in the 
Finnish study a significant association existed between elevated plasma cholesterol 
concentrations and the X2 allele when both the sexes were combined. It should also be 
noted that in the presence of the appropriate environment, a differential response can be 
produced by specific genotypes, as shown in the study of Tikkanen et al. (1990) where 
individuals with the X2 site showed greater reduction in plasma cholesterol, LDL 
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cholesterol and apo B concentrations than those lacking the site. 
An association study on 62 normolipidaemic Caucasians (versus hyperlipidaernics 
Types 11,111, IV, V) from London (Talmud et al., 1987) showed significantly higher 
concentrations of plasma cholesterol and triglyceride in the X2X2 (presence of the site) 
genotype group. However the numbers in this study were smaller than in the Caerphilly 
cohort, and also the association seen was in a mixture of males and females. Also the age 
range for this group was very broad (20-65 yrs), hence the association may not be 
maintained if the subjects were divided into two groups. 
Contrary to most studies of Caucasians, a Japanese study (Aburatani et al., 1988) of 
107 normo- and hyper-lipidaernic males and females showed no association of either Xbal 
or Pvull genotypes with plasma cholesterol, triglyceride or apo B concentrations. The 
genotype frequencies were not significantly different between the normo- and the hyper- 
lipidaernic groups. However, the age range was fairly wide (19-62 yrs) and the analysis 
was done on pooled data from both sexes. The frequency of the XI allele was 0.96 
compared to 0.47 of the Caerphilly population. This large difference may be due to 
inherent ethnic differences within the two populations I- or perhaps the mutation arose as an 
independent event in the Japanese. 
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Results V: Haplotypes of Apolipoprotein B Gene and Plasma 
Cholesterol 
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Apolipoprotein B haplotype analysis ýF 
As already mentioned, haplotype analysis was performed only on the complete data 
set for all five RFLPs (Hincll, Pvull, Xbal, 3'Mspl and EcoRl) available for 234 
individuals. Haplotype frequencies were calculated using the myriad haplotypes algorithm 
of MacLean and Morton, (1985) using a Fortran computer programme. Subgroup analysis 
was also performed on the complete data set. Phenotypic subgroups for which the 
haplotype frequency was determined and compared were as follows: 
Normal cholesterol concentrations between 5th and 90th centiles (4.0-6.5 mmol/1) 
versus elevated cholesterol concentrations, > 90th centile (> 6.5 mmol/1) 
Normal cholesterol concentrations between 25th and 90th centile (4.9-6.5 mmol/1) 
versus low normal cholesterol concentrations, <25th centile (<4.9 mmol/1) 
plasma HDL cholesterol concentrations (-, -0.9 mmol/l versus> 0.9 mmol/1) 
plasma triglycerides(<=1.5 mmol/l versus> 1.5 mmol/1) 
Obesity (BMI<26.0 versus BMI> 26.01) 
History of angina, myocardial infarction (MI), or abnormal ECG versus normal on 
all these variables 
Cigarette smoking (ever smoked versus never smoked and currently non-smoker 
versus currently smoker) 
Alcohol consumption <200ml/week versus > 200ml/week 
Alcohol consumption <400mi/week versus > 400ml/week 
Evidence for differences between the two subgroups in the distribution of estimated 
haplotype frequencies was assessed using a likelihood ratio heterogeneity chi- square. 
Subgroups which showed significant heterogeneity in the overall distribution of the 
estimated haplotype frequencies were further investigated to determine the minimum 
subset of RFLPs, which preserved the observed haplotype frequency differences. 
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Haplotype frequencies 
Haplotypes were determined for 468 (234x2) chromosomes. Theoretically 32 
possible haplotypes would be expected by the five RFLPs. However, only fifteen different 
haplotypes were observed in this population, designated A to 0. Under conditions of no 
linkage disequilibrium (Table 9), the discrepancy in the estimated and expected would be 
accounted for by the existence of linkage disequilibriurn between these RFLPs. Linkage 
disequilibrium would reduce the chances of recombination between marker RFLPs, hence 
reducing the expected variety of haplotypes. 
The most frequently occurring haplotypes in this population were B, C, D, and E. Just 
over 80% of the individuals are represented by one of these haplotypes. 
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Table 9. Estimated and Expected Haplotype Frequencies 
Hincll Pvull Xbal 
A 1 1 1 
B 1 1 1 
C 1 1 1 
D 1 1 2 
E 1 1 2 
F 1 2 1 
G 2 1 
H 2 1 1 
I 2 1 1 
J 2 1 1 
K 2 1 2 
L 2 1 2 
M 2 2 1 
N 2 2 1 
0 2 2 2 
3'Mspl EcoRl Expected Estimated 
Frequency Frequency 
(n=234) (n=234) 
1 1 0.006 0.000 
2 1 0.053 0.090 
2 2 0.268 0.221 
1 2 0.036 0.106 
2 2 0.307 0.409 
2 2 0.027 0.009 
1 1 0.001 0.000 
1 2 0.006 0.000 
2 1 0.010 0.062 
2 2 0.049 0.011 
1 2 0.007 0.003 
2 1 0.011 0.000 
1 2 0.001 0.000 
2 2 0.005 0.083 
2 2 0.006 0.005 
I represents the absence of a restriction site 
2 represents the presence of a restriction site 
The above table shows estimated and expected haplotype frequencies assuming no 
linkage disequilibrium. 
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Apolipoprotein B haplotypes and plasma cholesterol 
The estimated haplotype frequencies for the two subgroups of plasma cholesterol 
concentrations between 5th and 90th centiles and > 90th centile (Table 10) showed 
borderline significant difference (X2=14.827,9df, 0.1>p>0.05). Haplotype D (1 121 2) 
best differentiated the group with respect to cholesterol concentrations and is the same as 
the haplotype which best differentiates the groups with respect to coronary heart disease 
(Table 15). This haplotype was increased (0.1 >p >0.05) in frequency in subjects with 
plasma cholesterol concentrations above 6.5 mmol/l (frequency 0.2) compared to those 
with plasma cholesterol concentrations below 6.5 mmol/l (frequency 0.085). The Mspl 
RFLP alone was sufficient to detect this effect. Although thi s haplotype showed significant 
heterogeneity at the conventional level, the significant heterogeneity disappeared at the 
corrected level (when the number of haplotypes was taken into account). 
Haplotype frequencies were also examined for subjects with plasma cholesterol 
concentrations between the 25th- 90th centile and below the 25th centile (Table 11). A 
significant difference existed in the frequency distribution of subjects with normal and low 
cholesterol concentrations (P<0.05). The minimum locus which still maintained this 
difference was the EcoRl RFLPI, which alone was sufficient to detect this effect. 
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Table 10. Estimated Haplotype Frequencies in Subjects with Normal and 
Elevated Plasma Cholesterol 
HincII Pvull Xbal 3'MspI EcoRl Normal Elevated 
Cholesterol Cholesterol 
(4.0-6.5 mmol/1) (>6.5 mmol/1) 
(n=194) (n-40) 
A I I I I 1 0.000 0.000 
B I 1 1 2 1 0.094 0.072 
C I 1 1 2 2 0.233 0.163 
D 1 1 2 1 2 0.085 0.200 
E 1 1 2 2 2 0.417 0.374 
F 1 2 1 2 2 0.006 0.028 
G 2 1 1 1 1 0.000 0.008 
H 2 1 1 1 2 0.000 0.000 
1 2 1 1 2 1 0.058 0.065 
1 2 1 1 2 2 0.012 0.011 
K 2 1 2 1 2 0.005 0.000 
L 2 1 2 2 1 0.003 0.000 
M 2 2 1 1 2 0.004 0.000 
N 2 2 1 2 2 0.087 0.084 
0 2 2 2 2 0.000 0.013 
Likelihood ratio heterogeneity XI = 14.827,9 df, 0.1 >p>0.05 
Most of the differences between these groups can be attributed to a single RFLP, 
MSpl (X2 = 8.44,1 df, p<0.05). Discrepancy in the estimated frequencies for 
haplotypes A and H are due to lack of cholesterol results. 
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Table 11. Estimated Haplotype Frequencies in Subjects with Normal and Low- 
Normal Plasma Cholesterol 
HincIl PvuII Xbal 3'Mspl EcoRI Normal Low-Normal 
Cholesterol Cholesterol 
(4.9-6.5 mmol/1) (<4.9 mmol/1) 
(ný150) (n-44) 
A I I I I 1 0.000 0.016 
B I 1 1 2 1 0.084 0.123 
C I 1 1 2 2 0.263 0.139 
D 1 1 2 1 2 0.083 0.062 
E 1 1 2 2 2 0.410 0.443 
IF 1 2 1 2 2 0.004 0.014 
G 2 1 1 1 1 0.003 0.000 
H 2 1 1 1 2 0.000 0.006 
1 2 1 1 2 1 0.049 0.104 
1 2 1 1 2 2 0.014 0.000 
K 2 1 2 1 2 0.000 0.017 
L 2 1 2 2 1 0.000 0.000 
M 2 2 1 1 2 0.000 0.002 
N 2 2 1 2 2 0.090 0.063 
0 2 2 2 2 2 0.000 0.012 
Likelihood ratio heterogeneity yl = 17.017,9 df, p<0.05 
Most of the differences between these groups can be attributed to a single RFLP, 
EcoRl (Z' = 4.91,1 df, p<0.05). Discrepancy in the estimated frequency for 
haplotype L is due to lack of cholesterol results. 
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MspI - EcoRl RFLPs and plasma cholesterol 
Since the Mspl and EcoRl RFLPs were sufficient to detect an altered plasma 
cholesterol concentration, genotypes generated from alleles (Table 12) defined by the 
Mspl - EcoRl RFLPs were further analysed in relation to their cholesterol concentrations 
(Table 13). The Mspl variant was designated apo B (Arg36H4 Gln). The EcoRl variant was 
designated apo B (Glu,,,, -+ Lys). 
Table 12. Haplotype Frequencies for the "Alleles" of MspI-EcoRI RFLPs 
3'Mspl EcoRl Allele Frequency 
I I Gln/Lys 0.000 
2 1 Arg/Lys 0.162 
1 2 Gln/Glu 0.104 
2 2 Ariz/Glu 0.734 
The Gln/Lys allele was found at zero frequency. 
The six double heterozygotes were assumed to have the 1,2 (Lys/Arg) and 2,1 
(Glu/Gln) haplotypes (since the alternatives of 1,1 (Lys/Gln) and 2,2 (Glu/Arg) are 
impossible with the zero haplotype frequency of 1, I). Usually this would lead to an 
overrepresentation of haplotypes containing two or more alleles, especially if the 
assignment of the haplotypes in the population is equivocal. The assignment of the 
six double heterozygotes should not differ significantly from the expected. 
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Table 13. Plasma Cholesterol Concentrations Stratified by the Alleles of Mspl- 
EcoRl Haplotype Pairs 
Genotype n Relative Total Cholesterol 
Definition Frequency Mean ± SEM 
(mmol/1) 
Arg/Lys, Arg/Lys (2 12 1) 6 0.022 5.03 ± 2.27 
Arg/Lys, Arg/Glu (2 12 2) 72 0.259 5.44 ± 0.65 
Arg/Glu, Arg/Glu (2 22 2) 146 0.525 5.59 ± 0.47 
Arg/Lys, Gin/Glu (2 11 2) 6 0.022 5.77 ± 2.60 
Gln/Glu, Arg/Glu (1 22 2) 44 0.158 5.87 ± 0.91 
Gln/Glu, Gin/Glu (1 21 2) 4 0.014 6.45 ± 3.74 
Total 278 5.60 ± 0.72 
n, number of individuals 
Six different genotypes (haplotype pairs) were observed as defined by the alleles of 
Mspl-EcoRl RFLP. The average total cholesterol and number of individuals for 
each genotype are shown in Table 13. 
Analysis of variance was performed on the mean plasma cholesterol concentrations 
of the six genotype groups to test the hypothesis that genetic variation defined by 
these haplotype pairs did not affect phenotypic variation. Significant heterogeneity 
existed in the average plasma cholesterol concentrations among the six genotype 
groups (F-ratio = 2.50,5 df, p<0.03). The Arg/Lys, Arg/Lys had the lowest mean 
(5.03 mmol/1) whilst the Gln/Glu, Gln/Glu had the highest mean (6.45 mmol/1). 
Genotypes containing the Arg/Lys allele had an average plasma cholesterol of 0.24 
mmol/l lower than those not having this allele. There was a tendency towards an 
increase in the total cholesterol concentration down the Table, from Arg/Lys, 
Arg/Lys to Gln/Glu, Gln/Glu. The loss of an Mspl site was associated with 
increasing cholesterol concentrations, whereas the loss of an EcoRI site was 
associated with decreasing cholesterol concentrations. 
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Average effect of Mspl - EcoRl haplotypes on plasma cholesterol 
By applying the techniques of Sing and Davignon (1985), it was possible to calculate 
the average effect of the Mspl - EcoRl and MspI alleles on plasma cholesterol 
concentrations (Table 14). The average effect of the allele is the amount by which a 
particular variable (e. g. serum cholesterol) in a population differs from the mean value of 
that population. The average effect of the Arg/Lys (2,1) allele was to lower plasma 
cholesterol by 0.195 mmol/l; and of the Gln/Glu (1,2) allele to increase plasma 
cholesterol by 0.317mmol/l. 
Table 14. Estimates of the Average Effect on Plasma Cholesterol of the Three 
Common Functional Alleles of Apolipoprotein B 
Allele Mutation Average Effect of the Allele 
Frequency (mmol/1) 
Arg/Lys (2 1) 0.000 -0.195 
Arg/Glu (2 2) 0.162 -0.004 
Gln/Glu (1 2) 0.104 +0.317 
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As already mentioned in a previous section, the genotypes containing the MI allele 
were associated with a significant increase in plasma cholesterol concentrations. These 
concentrations were higher than the population mean of 5.52±1.01 mmol/l 
(MIMI=6.45±. 36), (MIM2=5.85±0.13). Despite there being only a small number of 
individuals with the MI allele, there seemed to be an increasing trend in plasma cholesterol 
concentrations associated with the MI allele across the three genotype groups 
(MlMl>MlM2>M2M2), suggesting that the MI allele was influencing the plasma 
cholesterol concentrations. The average effect of MI allele on plasma cholesterol was to 
raise it by +0.31 mmol/l and that of M2 was to lower it by -0.004 mmol/l. However, as the 
frequency of MI allele was low in the population, its overall influence on population 
cholesterol concentrations would be relatively small. The proportion of phenotypic 
variance provides an indication of population variance in plasma cholesterol 
concentrations attributable to variation at the Mspl RFLP site. The proportion of 
phenotypic variance in cholesterol concentration attributable to genetic variation at the 
, N4spl RFLP locus was 2.4% in this population. The relatively small contribution of the 
N4spI locus may be a reflection of the sampling procedure for this population (representing 
a narrow age group of males only). Nevertheless, it suggests that genetic variation at this 
locus is influencing plasma cholesterol concentrations. Whether this structural change is 
involved directly or indirectly in the determination of plasma cholesterol concentrations is 
not known. 
, kpolipoprotem B haplotypes and plasma low density lipoprotein cholesterol 
Haplotype frequencies were estimated for individuals in LDL subgroups above the 
90th centile (5.3 31 mmol/1) and below the 90th centile (5.31 mmol/1). 
Comparison of the estimated frequencies between the two subgroups by the 
likelihood ratio heterogeneity chi square revealed a significant difference (X2 = 19.4,9df, 
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p<0.05). Most of the frequency differences were attributable to the Mspl RFLP (X2 = 8.9, 
1 df, p<0.05). This reflects the significant difference observed for plasma total cholesterol 
between the normal and the elevated subgroups. Mspl alone accounted for 2.8% ofthe total 
variance in LDL cholesterol concentration. 
Haplotype frequencies of EcoRl-Mspl differed significantly between the two LDL 
subgroups (normals and above the 90th centile). This was a reflection of the strong effect of 
Mspl on both total plasma cholesterol and LDL cholesterol concentrations. The EcoRl- 
Mspl haplotype accounted for -3.6% of the total variance in LDL cholesterol 
concentration, whilst the Mspl alone accounted for 2.8% of the total variance in LDL 
cholesterol concentration. 
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Discussion 
Seventeen percent (40/234) of the Caerphilly cohort were hypercholesterolaemic (> 
6.5 mmol/1), whilst 18.8% (44/234) were hypocholesterolaemic (<4.8 mmol/1). 
Although the proportion of hypercholesterolaernics was large, this was not so 
surprising in view of the age range of the men (49-65 years), cholesterol levels increasing 
with age (Miller, 1984b; The Lipid Research Clinics Epidemiology Committee, 1979). As 
familial hypercholesterolaemia is rare (I in 500), an increased prevalence of that disorder 
can be discounted as an explanation (Goldstein & Brown, 1989). Gross 
hypercholesterolaernia can also be caused by mutation of the apo B gene which reduces 
the fractional catabolic rate of LDL (Houlston et al., 1988; Demant et al., 1988), but again 
this is relatively rare. Most of the individuals in the Caerphilly cohort are likely to have a 
polygenic basis to their hyPercholesterolaemia. This would mean that there are several 
genes exerting an effect on LDL metabolism, with inheritance of a combination of some of 
these predisposing to hypercholesterolaernia. In addition to the effect of the polygenes, 
certain dietary and lifestyle factors predispose to hypercholesterolaernia. As the age range 
of the men was 49-65 years in 1978 when recruitment started, they were born during the 
1920's and 1930's. Exposure to poor dietary habits in their childhood may have made them 
susceptible to development of hyperlipidaernia in their later years. Besides dietary and 
socio- economic factors, evidence from single RFLP analysis and haplotype analysis has 
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of cholesterol concentration in the Caerphilly cohort. The present study showed 
associations between haplotypes of apo B and altered total cholesterol and LDL 
cholesterol concentrations. Most of the differences in haplotype frequency between the 
groups were attributable to Mspl for both increased total and LDL cholesterol, and to 
EcoRl for low plasma cholesterol concentrations. For comparison purposes, the 'control' 
group was drawn out of the same population sample. This eliminated the need to match 
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separately for race, age, sex, geographical location. The criteria for the definition of the 
'control' group for each of the variables was based on the levels encountered in the total 
cohort; and on the basis of absence or presence of CHD. An analysis done on the residuals 
from regression of age, height, and weight confirmed that these variables did not influence 
the final results. Haplotypes constructed with the EcoRl and Mspl RFLPs showed a 
significant difference in frequency distribution in the two groups for LDL cholesterol 
below and above the 90th centile, indicating possible linkage with a mutation that may be 
close to or between these sites. The genetic variance for LDL cholesterol accounted for by 
the Mspl-EcoRl haplotype was greater, 3.6% compared to 2.8% accounted for by Mspl 
alone, illustrating the greater resolving power of haplotypes compared to single RFLP 
analysis. Stratification of plasma cholesterol concentrations by haplotype pairs of Mspl- 
EcoRl showed a significant difference in cholesterol concentrations between the genotype 
pairs, the loss of the Mspl site being associated with relatively high cholesterol 
concentrations and the loss of EcoRl site with relatively low concentrations. Variation in 
cholesterol concentrations attributable to the 3 alleles (defined by the EcoRI/MspI RFLP) 
was responsible for 3.5% of the total phenotypic variance in the Caerphilly population. 
Although the percentage of variance explained by these alleles was small, it does not 
necessarily imply that the effects are unimportant. Since most of hypercholesterolaernia in 
the general population has a polygenetic basis (Motulsky, 1976), even a small effect on 
cholesterol concentrations might make an important contribution to the overall population 
variance. If several other alleles were discovered. each with a small effect, the combined 
effect, together with their interaction with environmental factors, would be greater. 
The total phenotypic variance attributable to the Mspl alone was 2.4%. The average 
effect of the MI allele (frequency = 0.10) was to raise plasma cholesterol by 0.31 mmol/l, 
whilst the M2 allele (frequency 0.90) lowered it by 0.004 mmol/l. Although, the effect of 
this RFLP on cholesterol concentrations was small, it provides evidence that variability at 
the apo B locus is associated with variation of plasma cholesterol concentrations in this 
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South Wales group, though the overall impact is of course small. 
In contrast to these data, a case-control study (Hegle et al., 1986) of 84 pairs of 
Caucasians with and without CHD (matched for age and sex, but not for smoking, diabetes 
or hypertension) showed no significant association between genotypes of Xbal, EcoRl or 
Mspl and plasma cholesterol, triglyceride, LDL or apo B. However, because the 
population was heterogeneous there was a possibility that small, real differences were 
obscured by confounding variables. A similar finding was applicable to the alleles of these 
RFLPs. A study of Norwegian males (mean age, 47 years) free of CHD also showed no 
significant association of either Mspl or EcoRl with plasma cholesterol (Myklebost et al., 
1990). 
Besides allelic variation at the apo B gene determining plasma concentrations of 
cholesterol, it has been suggested that the within-individual variability of cholesterol may 
also be determined by genetic variation. For example, Monsalve et al. (199 1) have shown 
that individuals heterozygous for EcoRl or Xbal RFLP show significantly greater within- 
individual variability over time compared to individuals of other genotypes (5 to 10 repeat 
cholesterol measurements over a year). It should also be noted that genetic variability 
associated with the haplotypes contributed much more to the variance of the cholesterol 
concentrations than did the Mspl RFLP alone. 
In comparison to the effect of apo E alleles, which explained about 7% of the 
variance in plasma cholesterol (adjusted for age, sex, height, and weight) in a random 
sample of a Canadian population (Sing and Davignon, 1985), the proportion of variance 
attributable to the Mspl-EcoRl RFLPs in Caerphilly was small. In the Canadians 
concomitant variables, such as age, sex, height and weight, accounted for another 7% of 
the variance in plasma cholesterol concentrations, which was statistically significant at 
p<0.01. In contrast, in the Caerphilly sample, no contribution from any of these 
concomitant variables was demonstrable. 
The genetic contribution to the phenotypic variance of cholesterol concentrations 
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has been discussed by Sing and Boerwinkle (1987). These authors concluded that 50% of 
the variance could be explained by genetic factors as follows: (1) Polymorphic blood and 
plasma markers account for I% of the variance. (2) FH accounts for another 1%. (3) A 
locus influencing apo AI levels may account for another 1%. (4) Variance in the apo E loci 
explains 7%. (5) Apo A IV explains another 3 %. (6) The Xbal RFLP in the apo B accounts 
for 14% of the variability in normolipidaernic adults in London (Humphries, 1987). All the 
above together account for 27% of the total genetic variance. (7) Residual polygenes 
account for the rest 23%. The total genetic contribution would increase to 30.5% by 
considering the 3.5% contribution from the EcoRI/MspI RFLPs in the Caerphilly 
population. 19.5% would therefore be accounted for by residual polygenes. However, all 
these figures are representative of different populations, and therefore the contribution of 
each marker may vary within each population. 
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Results VI : Haplotypes of Apo B Gene and Coronary Heart Disease 
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As already mentioned, the number of men for whom complete haplotype data was 
available was 234, but only 233 individuals had data available on the status of coronary 
heart disease. Haplotype frequencies were estimated in subjects with possible and 
probable CHD versus subjects without CHD. The distribution of estimated apo B 
haplotype frequencies was significantly different between the groups with and without 
CHD (X2=1 8.734,9 df, p<0.05) (Table 15). The haplotype which best differentiated the 
groups regarding heart disease was D (112 12). 
The minimum haplotype necessary for detection of apo B association with CHD was 
the RFLP pair Xbal-Mspl (likelihood ratio heterogeneity X2=6.34,2df, p<0.05) (Table 
16). The haplotype MIA2 (absence of the Mspl site and presence of the Xbal site) was 
increased in frequency in cases compared to controls (15.1 % versus 9.7%), and therefore 
seems to be more strongly associated with the disease. The association was not detected 
with the MspI alone. This is interesting because as noted previously genotype comparisons 
of the mean values of plasma cholesterol have shown a significant association with MI 
(absence of the site) (p=O. 0 12), whilst X2 (presence of the site) shows a tendency towards 
elevated plasma cholesterol. The association of haplotype Mspl-Xbal with CHD and the 
RFLP genotype results would suggest that there is a relationship between cholesterol 
levels and occurrence of CHD and that the predisposing mutant variant is in linkage 
disequilibriurn with these RFLP marker sites. 
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Table 15. Estimated Haplotype Frequencies in Subjects With and Without 
Coronary Heart Disease 
Hincll Pvull Xbal 3'Mspl EcoRl No CHD CHD 
(n=177) (ný56) 
A I I I I 1 0.000 0.000 
B I 1 1 2 1 0.082 0.116 
c I 1 1 2 2 0.230 0.200 
D 1 1 2 1 2 0.089 0.153 
E 1 1 2 2 2 0.403 0.424 
F 1 2 1 2 2 0.012 0.000 
G 2 1 1 1 1 0.000 0.008 
H 2 1 1 1 2 0.000 0.000 
1 2 1 1 2 1 0.067 0.028 
1 2 1 1 2 2 0.014 0.000 
K 2 1 2 1 2 0.004 0.000 
L 2 1 2 2 1 0.004 0.000 
m 2 2 1 1 2 0.004 0.000 
N 2 2 1 2 2 0.095 0.059 
0 2 2 2 2 2 0.000 0.012 
The discrepancy in the estimated frequency for haplotypes A and H is due to lack of 
evidence of CHD status. Likelihood ratio heterogeneity Z'= 18.734,9 df, p<0.05 
Both possible and probable CHD were considered in these analyses. Equally 
significant results were obtained if only probable CHD was examined. Most of the 
differences between the groups can be attributed to haplotypes consisting of the two 
RFLPs Mspl and Xbal (see Table 16) 
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Table 16. Minimum Apolipoprotein B Haplotype Showing an Association with 
Coronary Heart Disease 
Haplotype No CHD CHD 
Mspl - Xbal 
12 0.097 0.151 
21 0.482 0.428 
22 0.421 0.421 
Likelihood ratio heterogeneity yl = 6.34,2 df, p<0.05 
J Rqjput- Williams Ph. D. Thesis Page 131 
Discussion 
Almost quarter (24%) of the Caerphilly cohort had heart disease. The haplotype 
associated with the RFLPs Mspl- Xbal showed statistically significant differences in 
frequency distribution between the cases and controls (p<0.05). The minimum haplotype 
necessary for detection of CHD was the RFLP pair MI -X2 (absence and presence of the 
sites, respectively) which was increased in cases compared to the controls (15.1 % versus 
9.7%). An association was not detected with Mspl alone. This would indicate that although 
Mspl represents an amino acid change, this alone does not predispose to coronary heart 
disease. A mutant variant in linkage disequilibrium with the haplotype Mspl-Xbal may be 
the predisposing variant. Since the MspI change at residue 3611 resides close to the 
postulated receptor binding domain, the haplotype Mspl-Xbal may be in linkage 
disequilibrium with a mutant variant in this region. which may influence predisposition to 
CHD either through receptor binding, thus resulting in elevated plasma cholesterol 
concentrations, or through other risk factors. A study by Myant et al (1989) showed 
significantly (p<0.02) higher frequencies of E- and X- alleles in subjects with CHD and 
normal plasma cholesterol concentrations compared to controls. This is in contrast to the 
present study where the X2 allele (presence of the site) was associated with the minimum 
haplotype necessary for detecting CHD. Since the Xbal polymorphism was the variant 
common to both studies, the variant predisposing to CHD probably lies very close to Xbal 
site, and probably in linkage disequilibrium with both Mspl and EcoRl sites. Contrary 
results have been presented for a negative association between the X- allele and CHD in 
both a Japanese study (Abrutam, 1987) and a study by Deeb et al. (1986) in Caucasians. 
In a group of patients with peripheral artery disease (PAD) (Monsalve et al., 1988), 
there were no significant differences in the concentrations of cholesterol, triglyceride or 
apo B for the Xbal genotypes, although there was an increasing trend in cholesterol 
concentrations (X2X2>XIX2>XIXI). The allelic frequencies XI (absence of the 
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restriction site) and R2 (absence of the EcoRl restriction site), and the haplotype frequency 
XlR2, were significantly increased in the patients compared to the controls, suggesting 
that genetic variation at the apo B locus was involved in the development of the 
atherosclerotic disease. This was in contrast to the Caerphilly result, where the haplotype 
associated with CHD (not PAD) was Mspl-Xbal. This suggests that CHD and PAD may be 
under independent genetic control. Despite the apparent inconsistencies, the results overall 
suggest that genetic variation at the apo B gene is associated with the determination of 
CHD not only in Caerphilly but also in the other populations. An earlier report (Monsalve 
et aL, 1986) also showed a similar significantly increased frequency of XI allele in patients 
with PAD and CHD compared to the controls. Both the study by Monsalve and the present 
study showed Xbal RFLP to be associated, either singly or as a haplotype, with CHD and 
PAD, therefore suggesting that the variant(s) predisposing to these conditions is/are close 
to the Xbal site possibly located in the putative LDL receptor binding domain (AA 3147- 
3370). The observed association between Xbal and LDL cholesterol, and the association 
between Xbal and CHD, may be mediated by the same variant. Fems (1988) however 
found no significant association of Xbal with prevalent myocardial infarction, but Hegele 
(1986) found the XI (absence of the site) allele to be significantly more common in CHD 
survivors than in controls. This in contrast to our study where the opposite allele (X2) was 
associated with CHD. Although a significant association was found with myocardial 
infarction, the authors suggested that the heterogeneous nature of the population (84 pairs 
of Caucasians, matched for age and sex) made it uncertain if the observed allelic 
differences were really due to genetic variation. In addition, the absence of matching for 
smoking, hypertension and diabetes would tend to influence associations, since these are 
also risk factors for CHD. In agreement with this study, Genest et aL (1990) found an 
increased frequency of the MI allele (absence of cutting site) in patients with premature 
CHD. 
In our study an association was observed between Mspl- EcoRl (M IR I) haplotype 
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and plasma cholesterol concentration. It is possible that the changes induced in plasma 
cholesterol concentration by this haplotype are related to increased risk of CHD in subjects 
with the Mspl-Xbal allele. 
About 17.0% of the Caerphilly cohort were hypercholesterolaernic, having plasma 
cholesterol > 6.5mmol/I whilst 24.0% had CHD. Most cases of CHD have plasma 
cholesterol concentrations centered around the population mean (Rose, 1981; Shaper et 
al., 1985). Therefore, in the Caerphilly population only some of the 
hypercholesterolaernics (of the 17%) would be expected to develop CHD, whilst most 
would probably be unaffected, even though they are at an increased risk. In the rest of the 
cases, other risk factors (known, and unknown) besides hypercholesterolaernia must be the 
predisposing factors. 
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Results VII : Haplotypes of Apo B Gene and Obesity 
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The total number of individuals with the complete haplotype data set was 234, but 
the number of individuals for whom the obesity data was available was 232. 
From Table 17 it can be noted that the most frequently occurring haplotypes are B, C, 
D, and E which account for over 80% of the individuals. These account for about 83% and 
81% of chromosomes in obese and non-obese people respectively. It should be noted that 
over 50% (53.9%) of the Caerphilly cohort is obese, having a BMI > 26.0. Haplotype 
frequencies were compared betweenthe two groups BMI>26.0 versus BMI<26.0. 
A significant difference existed in the overall distribution of estimated apo B 
haplotype frequencies between the obese (BMI>26.0) and the non-obese (BMI<26.0) 
groups. Further examination of individual haplotypes showed haplotype C (I 1 12 2) to be 
significantly different in frequency between the two subgroups, the frequency being higher 
in obese (25.4% versus 17.9%). 
The havlotype was reduced further to find the minimum number of loci which would 
still maintain the group difference. The RFLP pair Pvull-Xbal constituted the minimum 
subset of RFLPs (haplotype) required to detect a significant association of apo B locus with 
obesity (Table 18). A likelihood heterogeneity chi-square showed the distributions of 
obese and non-obese groups were significantly different (p<0.01,3df) for the haplotypes 
defined by Pvull-Xbal RFLPs. However, an analysis of variance among genotypes defined 
by these two RFLPs (Pvull-Xbal genotypes or haplotype pairs) showed no significant 
differences in BMI among these genotypes (results not shown). Pvull change is intronic 
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functional variation in this region which affects obesity would not be easily detected by 
these RFLPs. A difference did exist in the frequency distribution of BMI when haplotypes 
of Pvull-Xbal were analysed (Table 18). This indicated that haplotype analysis was more 
informative than single RFLP analysis, and that, although the frequency of distribution 
between the groups might differ, the absolute levels of a particular parameter may not 
differ significantly. 
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Table 17. Estimated Haplotype Frequencies in Obese and Non-Obese Subjects 
Haplotype 
Hindl PVUII Xbal 3'Mspl EcoRI Obese non-Obese 
(n=125) (ný107) 
A I I I I 1 0.000 0.000 
B I 1 1 2 1 0.090 0.094 
c I 1 1 2 2 0.254 0.179 
D 1 1 2 1 2 0.104 0.111 
E 1 1 2 2 2 0.384 0.433 
F 1 2 1 2 2 0.000 0.020 
G 2 1 1 1 1 0.000 0.000 
H 2 1 1 1 2 0.000 0.000 
1 2 1 1 2 1 0.066 0.056 
1 2 1 1 2 2 0.022 0.000 
K 2 1 2 1 2 0.000 0.006 
L 2 1 2 2 1 0.000 0.000 
m 2 2 1 1 2 0.000 0.000 
N 2 2 1 2 2 0.080 0.091 
0 2 2 2 2 2 0.000 0.011 
Discrepancies in the estimated frequencies for haplotypes A, G, H, L and M are due 
to lack of results for the obesity index. Likelihood ratio heterogeneity ZI = 27.538,9 
df, p<0.005 
Most of the differences between the groups can be attributed to haplotypes 
consisting of the two RFLPs Pvull and Xbal (see Table 18) 
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Pvull - Xbal haplotype and obesity 
Table 18 shows that PI- X2 is the most common haplotype in both obese and non- 
obese subjects. Haplotype PI-XI (absence of the polymorphic sites) seems to show the 
strongest disease association. 
Table 18. Minimum Apolipoprotein B Haplotype Showing an Association with 
Obesity 
Haplotype non-Obese Obese 
Pvull - Xbal 
11 0.312 0.426 
12 0.567 0.498 
21 0.115 0.071 
22 0.006 0.005 
Likelihood ratio heterogeneity yl = 12.61,3 df, p<0.01 
Haplotype PI- X2 is the most common haplotype in both groups of obese and non- 
obese subjects. Haplotype PI - XI (absence of the polymorphic sites) seems to 
show the strongest association with obesity. 
J Rajput-Williams Ph. D. Thesis Page 138 
Discussion 
The association of obesity with haplotype Pvull-Xbal of apo B has not been reported 
previously. However, it should be noted that over 50% of the Caerphilly cohort is obese, 
which will increase the likelihood of demonstrating significant associations. The 
prevalence of excess overweight in the United Kingdom is known to be high, affecting all 
age groups. Approximately 5-20% of the 16- to 19- year old English population is 
overweight. This proportion increases with age, until by the 4th and 5th decade it affects 
40% of the men (James, 1985). A Dietary and Nutritional survey of British adults (16-64 
years old) in 1986/1987 showed that 45% of the men were either overweight or obese, and 
this proportion increased to 52% in the 1991 health survey (Department of Health, 1994: 
Coronary HeartDisease-An Epidemiologic Overview, London HMSO). 
Before this result of the present study is extrapolated to other populations, the 
characteristics of the subjects studied should be considered. Since they were of an older 
age, their mean body mass index will have increased over the years. If a younger age group 
had been selected for study, the haplotype association might not have been found, as most 
would not yet have become obese. 
If the association does exist in younger subjects, the haplotype could be used as a 
predictive risk marker for predisposition to obesity either directly or indirectly via effects 
on plasma lipid metabolism. Since the haplotype would not affect the primary structure of 
the Pic nzih-n --t, -tionwhi1, fP,,,, TTPPT Pic; ntrrwiioý flio I? PT P 
changes cannot be a direct cause of obesity. They may however be in linkage 
disequilibrium with a variant which is causally related. A variant mutant site might 
influence the folding of the apo B molecule and hence its conformation. Consequently, this 
may result in overproduction and/or increased secretion of VLDL, and hence increased 
lipolysis. It is also possible that the effect on obesity may be due to a different gene linked 
to the apo B locus or by genes involved in triglyceride metabolism (e. g., apo E, apo C). 
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A correlation coefficient of 0.228 was observed between BMI and plasma 
triglyceride concentration. However, whether obesity is secondary to abnormal lipid 
metabolism, or is a cause of hypertriglyceridaernia in the Caerphilly population is not 
possible to deduce from these results. 
Defective clearance of VLDL due to a mutant variant in VLDL apo B might result in 
a reduced fractional conversion to LDL, thereby prolonging the residence of VLDL in the 
circulation. A mutational defect in the apo B might also increase interaction with the 
lipoprotein lipase, increasing the efficiency of lipolysis to make excess fatty acids 
available for uptake by the adipose tissue. Apo B interacts with the glycosaminoglycans 
(GAG) in the arterial wall matrix via the heparin binding domains (Weisgraber, 1987; 
Camejo, 1982). A mutation either in or around the heparin binding domains might result in 
an increased electrostatic interaction with lipoprotein lipase, thereby enhancing release 
and deposition of fatty acids. Interaction of lipoprotein lipase with the endothelial cell is 
thought to occur via heparan sulfate, which is a surface component of endothelial cells 
(Olivecrona, 1978). 
The seven heparin-binding domains which span the length of apo B contain clusters 
of positively charged basic residues, which probably interact with heparin (Weisgraber, 
19 8 7). The se heparin-binding domains are thought to be di stinct from the receptor-binding 
domain. (Cardin et al., 1986). One of the heparin-binding domains (D) extending from 
residues 2016-2151 is close to the Xbal polymorphic site (2488). Codon 2058 (CGA, Arg) 
A 
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result in a charge alteration, which might affect the binding of apo B with heparan sulfate in 
the endothelial cell surface. The contribution of genetic influence to the determination of 
obesity has been demonstrated by adoption studies (Stunkard el al., 1986) and twin studies 
(Brook et al., 1975). In a study of Danish adoptees (mean age 42 years), it was shown that 
the weight class of the adoptees was highly related to the BMI of the biologic parents, and 
not to the BMI of the adoptive parents, suggesting a heritable component in the 
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determination of obesity. Heritability estimates (Brook et al., 1975) of body fatness in 
monozygotic and dizygotic twins have shown that an age-related genetic influence is an 
important determinant of body fatness in children over 10 years of age (0.91 for 
monozygotes and 0.84 for dizygotes). Below 10 years environmental influence was 
contributing more to variation in total body fat. Variability produced by environmental 
factors could be investigated by comparing the within-pair differences in variance of 
obesity between monozygotic twin pairs lacking and possessing the haplotype. If the 
difference is greater in the pairs lacking the haplotype than in those possessing it, it would 
suggest that the presence of the haplotype has a restrictive effect on the variability of BMI 
induced by environmental factors. 
The relevance of the present study results to the the cloning of the the mouse obese 
gene and its human homologue (Zhang et al., 1994) is not clear. The human obese gene has 
shown to be expressed specifically in the adipose tissue (Masuzaki et al., 1995). 
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Overall discussion on haplotypes of apolipoprotein B gene 
For CHD, plasma cholesterol, LDL cholesterol and obesity, haplotypes (Xbal-Mspl, 
Mspl-EcoRl, Mspl-EcoRl and Xbal- Pvull respectively) showed significant associations. 
It should be noted that most of the associations were of borderline significance, i. e. 
elevated plasma cholesterol concentrations (0.1>p>0.05), low plasma cholesterol 
concentrations (p<0.05). high LDL cholesterol (p<0.05), and CHD (p<0.05). The 
association with obesity was much stronger (p<0.005). 
However, some of the associations were not statistically significant when individual 
genotypes were considered for either CHD, plasma cholesterol or obesity, illustrating that 
haplotype analysis is more precise and informative. 
Whether these associations have aetiological significance in the development of 
either CHD, hypercholesterolaernia or obesity would have to be confirmed in other studies 
carried out independently in the Caerphilly and other populations. These haplotypes may 
be specific to the South Wales population, and it is possible that a study in another 
population may not yield similar results. The South Wales group is fairly homogeneous, in 
that there has probably been little interbreeding with other ethnic groups. Therefore, the 
probability of new haplotypes being introduced in the population would be small. Certain 
combinations of haplotypes are more frequent than others, which may be a reflection of the 
age of the haplotypes, the recent ones occurring at a lower frequency, and the more frequent 
ones be.;. -.,,, older in evolutionary terms. It may also I- rdnwd w tho- 1-ploty- .YY FIO 
conferring a selective advantage to the population. Recombination frequency is likely to 
influence the variety and frequency of the haplotypes. When marker sites are close to each 
other, the chances of recombination are reduced. Hence certain haplotypes will be more 
frequent than others. The presence of recombinational hotspots' between marker sites can 
account for the variety of haplotypes observed. 
It should be noted that the associated haplotypes are probably not causally related to 
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the traits (e. g. elevated plasma cholesterol concentration, CHD, obesity). It is the 
difference in the frequency distribution which is associated with the variables, and which 
distinguishes individuals who are likely to be at a risk of acquiring a particular trait. Since 
these haplotypes are present in individuals both with and without the trait, the RFLPs 
comprising the haplotypes cannot be sequence changes which are uniquely responsible for 
the altered phenotype. The haplotype probably requires a predisposing agent (genetic 
or/and environmental) for the disease phenotype to be expressed. In these individuals there 
may be an unidentified mutant(s) variant, which predisposes to the altered phenotype, and 
which may be absent in individuals without the trait. Alternatively, it may be present but its 
effect suppressed by another dominant gene variant which offers a selective advantage. 
Mutant alleles can be characterised at the molecular level to identify the change (if any) 
responsible for the observed phenotype. Since each of the phenotypic traits is associated 
with a different haplotype, this would seem to indicate that each is under independent 
genetic control (i. e., the presence of one would not necessarily lead to the occurrence of the 
other). It should be noted that for CHD and hypercholesterolaernia there is a common 
contribution by the Mspl polymorphism, suggesting a possible link between the two. 
If each haplotype had a distinct mutation associated with it, it might reflect the 
polygenic character of these traits (hyperlipidaemia, CHD), i. e. each haplotype would be 
associated with a different set of genes, each of which has a differential effect on 
predisposition to elevated plasma cholesterol concentrations and/or CHD. For the B- 
thalassaemiias each IA 11 t' oty-eis associated will ni ff-- -tat .y Fe dit-e-m-tion, although 
dian 
one mutation may be found in some of the haplotypes (Hill & Wainscoat, 1986). Cloning 
and sequencing of the genes associated with each haplotype has allowed the identification 
of the many point mutations associated with B- thalassernia (Orkin et al., 1982). 
Since there is extensive disequilibrium between the RFLPs, and there is a significant 
association between Mspl and plasma cholesterol, one might expect that similar 
associations will exist between all the other RFLPs and cholesterol (i. e. the genetic 
J Rajput- Williams Ph. D. Thesis Page 143 
variation associated with the Mspl which influences plasma cholesterol concentrations 
would also be associated with genetic variation exhibited by the other RFLP sites). 
However, this was not observed. A possible explanation for this may be that the 
disequilibrium between the RFLPs and the mutant variant is not large enough to be 
detected with the sample sizes used for this study. This would be particularly important in 
situations where allele frequencies are small and the linkage disequilibrium is negative 
(the rarer allele at one locus is combined with the common allele at the other locus) 
(Thompson et al., 1988; Cox et al., 1989). Inadequately small samples might fail to show 
significant associations, since the disequilibriurn may be of a negative type. With the 
knowledge of the marker frequency in the general population, the susceptibility locus 
frequency and the magnitude of linkage disequilibrium between the two, it would be 
possible to determine the sample size necessary to detect significant associations (Cox et 
al., 1989). 
Since the associations demonstrated are of borderline statistical significance, no firm 
conclusions can be drawn from the present study. It does however suggest strongly that 
variation at the gene is involved in determination of plasma cholesterol concentration, 
LDL concentration, predisposition to CHD and obesity. Although the associated 
mutations may contribute to variability of plasma cholesterol concentrations, and 
susceptibility to CHD, this does not imply they are necessarily causal. The weak nature of 
the associations suggests that these RFLPs are not contributing substantially to the 
poly-enic of h,, -erl;. -,.; daem. i-, - --nd CHD. Because of the extensive dJisemi; 1; kr; iim, .7b .7F 'I -... -. - 
further work on association studies is warranted. Since the associations have been found in 
a modest sample size, and the population is ethnically homogeneous, the chances of a 
spurious association are minimised. However, since the sample is from a restricted age 
group, these associations might disappear if there was a more representative sample. It is 
clearly important for the associations to be confirmed in other populations. In addition, 
unequivocal confirmation of the associations would require a greater level of significance 
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(e. g., at a level of I% or 0.1 %) in the same and other populations. 
Associations of genetic variation at the apo B locus with plasma cholesterol and 
CHD reported by other workers have been inconsistent (Berg, 1986; Monsalve et al., 1986; 
Deeb et al., 1986; Law et al., 1986a; Talmud et al., 1987; Abrutani et al., 198 8; Dunning et 
al., 1988; Jenner et al., 1988; Monsalve et al., 1988). The relevance if any of the 
associations in the present study to CHD susceptibility and elevated plasma cholesterol 
concentration is at present unclear. If confirmed in other studies, future investigations 
would need to address the biochemical role of these mutations in the causation of 
hyperlipidaernia and CHD. To answer these questions, one would need to isolate the alleles 
associated with the disease, and identify the sequence changes responsible for the 
mutations. It is possible that the associated mutations may cause functional and structural 
changes in the apo B molecule. There are no unique or predominant haplotypes associated 
with the disease conditions in the Caerphilly population. The numbers are too small to 
draw firm conclusions. Repeat studies on this or the other populations would be required 
for definite conclusions regarding specific haplotypes. Family studies would be most 
useful for identification of disease- specific haplotypes. 
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Results VIII : CpG Mutations Around the LDL Receptor Binding 
Domain 
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Introduction 
(i) Mutations of CpG dinucleotide 
It is known that the cytosines of the CpG dimer in the eukaryotic DNA are frequently 
methylated, which may be hotspots for mutation, resulting in spontaneous dearnination of 
cytosine to thymine (Barker et al., 1984). Mutations in the CpG dinucleotide account for 
35% of the single base-pair coding region changes which cause human genetic disease. 
Over 90% of these involved transitions of C4T or G4A (Cooper & Youssoufian, 1988). 
These codon changes give rise to an altered protein, which in turn produces the disease. For 
example, in familial dysbetalipoproteinaernia (Type III hyperlipoproteinaemia), 
characterised by increased cholesterol and triglyceride concentrations (B-VLDL), 
clinically affected patients are at an increased risk of premature CHD. This disorder is 
associated with the apo E phenotype E2/E2 which results from such a structural mutation 
in the apo E gene (Mahley et al., 1984). A C->T transition in the apo E gene changes 
arginine- 15 8 to cysteine, thereby reducing the binding of apo E to the LDL receptor, thus 
resulting in an increased VLDL concentration and therefore increased risk of CHD. Other 
rare apo E variants also associated with this disorder involving arginine to cysteine 
substitution occur at codons 142 and 145 (Mahley, 1988). In apo B, mutations influencing 
CpG in the arginine codon around the receptor binding-domain have been associated with 
elevated plasma cholesterol concentrations for the variants 3611 (nrPQ, -nt Qtudxlý qnfi '1'; AA 
(Soria et al., 1989). It is possible that similar substitutions of C-*T or G4A may occur 
around the receptor binding domain in the hypercholesterolaernic individuals and affect 
the binding of apo B to the LDL receptor, thereby resulting in reduced clearance and 
accumulation of cholesterol. Some CpG dinucleotide mutations affecting the arginine 
codon cause hypobetalipoproteinaernia by the production of premature termination codons 
at residues 1306 (Collins et al., 1988) and 2058 (Young et al., 1989) that lead to the 
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formation of truncated variants of apo B. A missense mutation of CpG has also been 
reported causing a transition of arginine to tryptophan at residue 4019 (Ladias et al., 1989). 
Some of these variants can be detected by restriction enzyme analysis. However, not all the 
CpG variants are represented by restriction enzyme sites. Thus, such mutations require 
identification by techniques other than RFLP analysis. One could isolate the alleles from 
these individuals and sequence these, but this can be very time consuming since it involves 
cloning. A quicker, accurate and reliable method is to screen them bv means of the 
polymerase chain reaction (PCR) and allele-specific synthetic oligonucleotide (ASO) 
probes, which can detect single base-pair mismatches between the wild-type and mutant 
genes. Synthetic oligonucleotides have also been used to detect single base mutations in 
the B- thalassemia gene, using DNA prepared either from blood leukocytes or amniotic 
fluid cells (Orkin et al., 1983; Piratsu et al., 1983, Thein et al., 1985), and also for the 
detection of sickle cell allele 13, in both sickle cell trait and sickle cell disease (Conner et al-, 
1983). 
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(ii) Objectives of the CpG dinucleotide screening study 
The results from the Caerphilly study showed that the CpG mutation, namely the 
MspI polymorphism near the postulated LDL receptor-binding domain (extending 
between aminoacids (AA) (3147-3157 and 3357-3367) representing a C-*T transition of 
positively charged arginine to negatively charged glutamine at codon 3611, was associated 
with altered plasma cholesterol concentrations (Figures 17 and 18). The percentage of total 
phenotypic variation in plasma cholesterol concentrations attributable to MspI was 2.4%. 
Whether the change in charge for the MspI polymorphism from positive to negative 
influences the binding of apo B to the receptor, and thus affects clearance of LDL 
cholesterol, is not known. It is known that chemical modification of positively charged 
lysine and arginine residues in both apo B and apo E inhibit their binding to the LDL 
receptor. In apo Ka domain enriched in basic amino acids (residues 136-158) has shown to 
be crucial for binding to the LDL receptor using apo E variants designed by site-specific 
mutagenesis (Lalazar et al., 1988). Substitution of neutral amino acids for the basic 
residues at positions 136,140,143 and 150 all displayed reduced binding activity. Apo B 
also has eight distinct domains enriched in basic amino acid residues. Seven of these 
domains bind heparin. The basic regions between residues 3134-3209 and 3356-3489 have 
the highest density of positive charge and the greatest affinity for heparin (Weisgraber & 
Rall, 1987). It is possible that mutations around these basic regions might affect the 
binding of apo B to the LDL receptor ow, to the nftlii- qrtprx7 lx7q]] qnd t: ' -11 t.. 7 -. 7 
therefore increase the cholesterol concentrations by affecting LDL clearance. 
From Figure 17, it is noted that there are three domains which contain the epitopes for 
the monoclonal antibodies which completely block the binding of the apo B to the LDL 
receptor. The Mspl RFLP andthe 3500 mutation lie within this region (between amino acid 
residues 2980 and 3780) which has been mapped for the monoclonal antibodies which 
completely block the binding of apo B to the LDL receptor (Milne et al., 1989) (Figure 17). 
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Because both mutations involve the positively charged basic residue arginine and are 
associated with increased cholesterol concentrations, there is a possibility of other 
mutations occurring around this region which might have a similar effect on cholesterol 
concentrations. Because of the high mutation rate associated with CpG dinucleotide, we 
decided to screen for arginine codons around the putative LDL receptor binding domain. 
The codons selectect for screening were at residues 3480,3500,3531,3611 and 3676 
(Figure 17). The subjects selected for screening were hypercholesterolaernic patients from 
the Northwick Park Hospital lipid clinic since the likelihood of finding mutations 
associated with elevated cholesterol concentrations is higher in these patients than 
normolipidaemics. 
It should also be mentioned that the observed population association of the Mspl 
RFLP with altered cholesterol concentrations (haplotype section) would not arise unless 
the marker (Mspl) is in linkage disequilibriurn with the variant/(s) responsible for the 
change in plasma cholesterol concentrations. This therefore provides further support for 
screening for mutations around the putative receptor binding domain. 
Therefore, we set up a study using PCR and allele-specific oligonucleotide (ASO) 
probe hybridisation technology (Saikiet al., 1986; Saikiet al., 1988) to screen for potential 
mutations of CpG dinucleotides (in the arginine codons) (Figures 17 and 18) around the 
putative LDL receptor-binding domain of the apo B gene and which might contribute to 
hypercholesterolaemia either via mutations which affect heparin binding or receptor 
bind; J specific U Ing. Fhe procedure of PJLCR Involves in villro amplification of DNA usi 
oligonucleotide primers which flank the target sequence to be amplified. The primers 
anneal to the complementary strands of the DNA and in the presence of a DNA polymerase 
catalyse the extension of target sequence. The template-directed extension product of one 
primer can serve as a template strand for the other. Repeated cycles of denaturation, primer 
annealing and primer extension result in the exponential accumulation and production of a 
101 fold increase of the target sequence (Saiki et al., 1986). 
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Figure 17. Proposed structure of the putative LDL receptor binding domain of apo 
B-100 
The boundary of the thrombolytic peptides (T3 and T2) is shown at residue 3249; the 
disulphide bridge S-S links T3 and T2 via the two cysteines at residues 3167 and 3297; 
open boxes represent the positively charged basic amino acids sequences (3147-3157 
and 3357-3367); basic region 3357-3367 shows primary and secondary structural 
homology to the LDL receptor binding domain of apo E; Zig-zag represents the proline- 
rich amphipathic P-sheets; solid boxes represent monoclonal antibody epitopes that 
block binding of apo B-100 to the LDL receptor; arrows show established (3500 and 
3611) and possible (3480,3531 and 3676) mutations. Adapted from Milne et al., 1989. 
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Figure 18. CpG-Dinucleotide Containing Codons Around the Putative Receptor 
Binding Domain 
Portion of exon 26 showing relative positions of arginine codons containing 
CpG dinucleotides around the receptor binding domain. Filled boxes represent putative 
receptor binding domain extending from nucleotides 9648-9680 and 10284-103 10. 
Open boxes represent PCR primers 4A (nucleotides I J5467 - 10576), F (nucleotides 
10835 - 10856), G (nucleotides 10806 - 10829), H (nucleotides 11267 - 11288). 4A and 
G are 5'primers. F and H are Yprimers. Amino acid positions 3480,3500,3531,3611 
and 3672 represent arginine codons which were screened for mutations of the CpG 
dinucleotide. 
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Subjects, materials and methods 
(i) Selection of subjects 
Patients from the lipid clinic at Northwick Park Hospital, who had high total serum 
cholesterol concentrations were considered suitable for screening for potential mutations 
of CpG codons (coding for arginine) around the receptor-binding domain. 
Hypercholesterolaemic patients (n=298) with serum cholesterol concentration above the 
90th percentile of 6.5 mmol/l were selected. A 10 ml blood sample was collected after an 
overnight fast for determination of serum cholesterol and triglyceride. Another 20 ml 
blood sample was collected into disodium- EDTA tubes (I mg/ml) and frozen at -70'C for 
DNA analysis. These subjects were compared with a consecutive series of subjects (n=286, 
and who had their ýzenotvpes and haplotypes determined as described previously in the 
present study) drawn from a random sample attending the clinic of the Caerphilly 
Collaborative Heart Disease Study. 
(ii) Amplification of genomic DNA 
A modified PCR procedure of Saiki et al. (1985) was used to amplify target 
sequences defined by 5' ends of the two oligonucleotide primers hybridised to 
I LU Lvý. -In. - complementary Krand'soffthetemplate. Tnatotal -1- e-flOOýi1ofthePCRreactionmix 
was added I ýtg genomic DNA, 10 ýtl of I OX PCRbuffer (to give a final concentration of 50 
mmol/l KCI, 10 mmol/I Tris HCI (pH 8.3), 1.5 mmol/l MgCl,, 0.0 1% gelatin, 200 [tmol/I of 
each of deoxynucleoside triphosphates (Pharmacia)), approximately 300 ng each of the 3' 
and 5'oligonucleotide primers. 
The initial cycle consisted of denaturing the DNA at 94'C for 20 min, cooling to 
65'C for 5 min for the primers to anneal to the target sequence, adding two units Taq 
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polymerase (diluted in the PCR buffer (New England Biolabs)), overlayering with 100 PI 
mineral oil (Sigma Diagnostics), mixing and allowing primer extension of DNA to occur 
at 65'C for 5 min in an automated Perkin- Elmer Cetus thermal cycler. A further 30 cycles 
of amplification were performed, consisting of denaturation at 92'C for I min, and 
annealing and extension at 65'C for five minutes. Three ýd of the PCR product were loaded 
on to a 1% agarose mini-gel and electrophoresed alongside molecular weight markers 
(Lambda / Hindlll, PhiXl 74 / HaellI) to check for the presence of the appropriate sized 
bands. Assuming a minimum of 50 ng of the amplified sequence per 3 ýtl of the reaction 
product, the final quantity of the amplified sequence in 100 ýtl final volume was 
approximately 1.6 ýtg DNA. 
(iii) Slotblotting of amplified DNA 
Five [tl (50 ng) of the amplified DNA was denatured with 50 ýil 0.4 mol/I NAOH, 25 
mmol/l EDTA for 15 min, followed by neutralisation with 165 [tl 0.8 mol/I Tris (pH 7.5), 
1.5 mol/I NaCl in a final volume of 220ýtl. The sample was mixed and applied immediately 
to the wells of a Schliecher and Schuell Minifold 11 slot blotter, containing a 0.20vtm 
cellulose nitrate membrane (Schliecher and Schuell, BA83,0.2um 63x228nm), pre-wetted 
in 20xSSC (3.3 mol/I NaCl, 0.3 mol/I NaCitrate, (pH 7.0)). The samples were blotted on to 
the membrane according to the manufacturer's instructions. After vacuum suction of the 
sample through the filter, each well was washed with 500 I_1120xSSC and left for 5 min to 
dry, then baked for I hour in a vacuum oven at 80'C and stored at room temperature until 
hybridisation. Three replicate filters were prepared for each sample (one filter per one of 
the three allele specific oligonucleotides (ASO)). 
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(iv) Analysis of amplified DNA 
Design and description of oligonucleotide probes 
The allele specific oligonucleotide probes (ASO) of fifteen nucleotides (15 mer) 
were designed to include the dinucleotide CpG. The predicted mutation was placed in the 
middle of the probe. Five such CpG sites were selected. The probes were synthesised on the 
DNA synthesiser (Applied Biosystems Model 380). For each CpG codon chosen, three 
variants were produced, one resembling the wild type and the other two representing either 
a sense C-*T change and an antisense C->T change. The oligonucleotide probes used are 
listed in Table 19. These probes were endlabelled with 7_ 31P-ATP (6000 Ci/mmol specific 
activity) by T4 polynucleotide kinase (PNK) (Pharmacia, U. K. ) forward reaction (see later 
section) and used for the differential hybridisation of the amplified sequences. 
The probes were 15 nucleotides long and spanned the codons of the gene as follows: 
Probes for amino-acid 3480 spanned codons 3478-3482 
Probes for amino-acid 3500 spanned codons 3498-3502 
Probes for amino-acid 3531 spanned codons 3529-3533 
Probes for amino-acid 3611 spanned codons3609-3613 
Probes for amino-acid 3676 spanned codons 3674-3678 
The probes were all complementary to the sense strand ofthe gene. 
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Table 19. DNA Sequence of Oligonucleotide Probes used for Allele Specific 
Hybridisation. 
W/M# Amino Acid Nucleotide Codon Sequence of Oligonucleotide 
Position Position Mutated 
W 3480 10647 CGG* CTT TCT CGG GAA TAT 
Leu Ser Arg Glu Tyr 
M 3480 10647 TGG TGG 
Trp 
M 3480 10647 CAG CAG 
Gln 
W 3500 10707 CGG* AGC ACA CGG TCT TCA 
Ser Thr Arg Ser Ser 
M 3500 10707 TGG TGG 
Trp 
M 3500 10707 CAG CAG 
Gln 
W 3531 10800 CGC* CTC CAA CGC ATA TAT 
Leu Gln Arg Ile Tyr 
M 3531 10800 TGC TGC 
Cys 
M 3531 10800 CAC CAC 
His 
W 3611 11040 CGG* GAA GTC CGG ATT CAT 
Glu Val Arg Ile His 
M 3611 11040 TGG TGG 
Trp 
M 3611 11040 CAG CAG 
Gin 
W 3676 11235 CGT* CAT CTT CGT GTT TCA 
His Leu Arg Val Ser 
M 3676 11235 TGT TGT 
Cys 
M 3676 11235 CAT CAT 
His 
M indicates probes complimentary to the potential mutant alleles of apo B 
W indicates probes complimentary to the normal apo B allele. 
indicates wild-type codon; the respective amino acid sequences for each 
oligonucleotide are shown underneath. For each mutant oligonucleotide 
the changed amino acid sequence is represented below the mutated codon. 
Amino acid 3611 represents the 3'Mspl polymorphism. 
Amino acid 3500 represents the Familial defective apolipoprotein B-100 variant. 
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(v) Purification of the crude oligonucleotide probes 
After synthesis was completed on the DNA synthesiser, the crude probe was purified 
through the NENSORB PREP column (Nen Research Products, Dupont) according to the 
manufacturer's instructions. The column was activated by 10 ml HPLC grade methanol, 
pre-equilibrated with 5 ml 0.1 mol/I triethylammonium acetate (TEAA) pH 7.0, loaded 
with the crude oligonucleotide dissolved in 4 ml TEAA, eluted with 
acetonitrile/TEAA(12%CH, CN/88%TEAA) to remove the failure sequences, then 
washed through with 25 ml 0.5% trichloroacetic acid (TCA) to hydrolyze the trityl group 
of the resin-bound oligonucleotide and eventually eluted with 5 ml methanol: H20(35: 65 
v/v). Six I ml oligonucleotide fractions were collected in Eppendorf tubes, and the optical 
density (O. D. ) at 260 nm determined. The fractions containing the majority of the 
oligonucleotide were pooled and the concentrations calculated, assuming 1.0 O. D. unit at 
260 nrn = 37.0 ýLg/ml single stranded DNA. The oligonucleotides were Iyophilised in the 
Speedvac (S avant) then reconstituted with 0.1 ml water and stored at -8 O'C until required 
to be used as endlabelled probe for the differential hybridi sation. 
(a) Synthesis and purification 
The oligonucleotide primers were synthesised on a DNA synthesiser (Applied 
B io systems Model 38 OA) according to the manufacturer's instructions. 
(b) Sequence of PCR primers 
Primer 4A: 5' CTAAAGGAGCAGTTGACCACAAGCTTAGCTT 3' 
Primer F 3' GGTGAATGTCGATCTCCCGGAG 5' 
Primer G 5' TATTCCCTCTGGGAGCACAGTACG 3' 
Primer H 3' GGGGTTACCGATAAGTAAGAGG 5' 
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Primers 4A and F were used to prime the synthesis of a3 10 base pair stretch of apo B 
DNA spanning nucleotides 10546-10856 (amino-acid 3446-3550) 
Primers G and H were used to prime the synthesis of a 482 base pair stretch of apo B 
DNA spanning nucleotides 10806-112 88 (amino-acids 3533 -3 693) 
Primers 4A and G are complementary to the sense strand of the gene. Primers F and H 
are complementary to the antisense strand of the gene. 
Crude PCR primers were purified through a SEP-PAK C18 cartridge (Waters 
Associate s, Massachusetts, USA) according to the manufacturer's instructions. The 
compounds are separated chromatographically, based on their polarity, the more polar 
compounds eluting first. The cartridge was activated by 10 ml of methanol, followed by 
10 ml of sterile water. The crude sample was loaded dropwise into the cartridge and eluted 
with 5 ml water to remove the polar contaminating substances, then eluted three times with 
I ml methanol: H, 0(60: 40v/v) to collect the purified oligonucleotide fractions into I ml 
Eppendorf tubes. The fractions were dried in the Speedvac (Savant), reconstituted and 
pooled in 100[tl sterile water followed by phenol/chloroform extraction and ethanol 
precipitation (as described in a previous section), and resuspension in 100 Vtl sterile water. 
The concentration was calculated from the measured optical density at 260 nm. 
This procedure was used for purifying the PCR primers 4A and G. Since PCR 
primers F and H were only 22 mers, these were purified by denaturing polyacrylamide gel 
electrophoresis to attain a higher yield. 
(c) Purification of primers F and H 
Denaturing polyacrlyamide gel electrophoresis (PAGE) was used to purify primers 
F and H. A vertical polyacrylamide gel(13.5xl7.5cm) was cast between 2 glass plates 
(previously cleaned with methanol), separated by a3 mm spacer(Biorad) and sealed at the 
bottom by a tape. A 16% polyacrylamide gel mix (100 ml) was prepared using the Sequagel 
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reagents (National Diagnostics) as follows: 64 ml Sequagel concentrate (29: 1 
acrylamide: bisacrylamide. 8.3 mol/I urea), 26 ml Sequagel diluent (8.3 mol/I urea), 10 ml 
Sequagel buffer (50% urea (83 mol/1) in I OxTBE (1.0 mol/I Tris-Borate, 20 mmol/l EDTA 
(pH 8.3), 1 ml I 0%(V/V) ammoniumpersulphate(Koch-Light Ltd)). 
The above ingredients were mixed and filtered through a Nalgene filter, 50PI 
N, N, N', N'-tetramethylethylenediaii-line (TEMED, Koch-Light Ltd) added, the solutions 
mixed and poured into the vertical motild, and the well-former comb inserted at the top of 
the gel. 
After the gel had set, it was prerun at 25W for '30 min in I xTBE. Before loading the 
samples, the wells were flushed with I xTBE to wash off any urea using a 50 ml syringe. 
The sample (I O[tl crude oligonucleotide plus 90 ýLl deionised formamide) was then loaded 
into the wells using a Gilson Pippeteman 200. A 4ýLl aliquot of the tracking dye 
bromophenol blue (BPB), 'Xylene cyanol was 'loaded into one well. The gel was 
electrophoresed at 25W until the BPB reached the bottom of the gel. The gel was then 
transferred to a TLC (thin laver chromatography) plate and the bands of interest viewed by 
shadowing the short wave ultraviolet I ight on to it. The band of interest was sliced out using 
a scalpel blade, then squashed by passing through a2 nil syringe, mixed with 3 ml I mmol/l 
EDTA and left mixing on an Ames mixer overnight at 4'C. The squashed gel was filtered 
through 2-3 layers of Glass Microfibre discs placed in the bottorn of a 10 ml syringe. The 
oligonucleotides in the filtrate purified with the SEP-PAK C 18 cartridge, as outlined 
for oligonucleotide probe preparatioii (see earlier section). 
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(vi) Labelling and hybridisation of target sequences 
(a) Endlabelling using T4 Polynucleotide Kinase (T4 PNK) 
The allele specific oligonucleotide probes were labelled using T4 polynucleotide 
kinase J4 PNK). The T4 PNK catalysed forward reaction of labelling 5' ends of 
oligonucleotide probes involves the transfer of the 7 phosphate of (7-"P- ATP) to the 5' 
hydroxyl terminus of the oligonucleotide. 
A 10ýtl labelling reaction was set up containing 50 ng oligonucleotide (50 pmol 
dephosphorylated DNA, 5' ends), I pl of 10xkinase buffer (10 mmol/l MgCl,, 5 mmol/l 
DTT, 50 mmol/l Tris-HCL, (pH7.5), 50 pg per ml bovine serum albumin (BSA)), I 
Vtl(7units) of T4 PNK (Pharmacia), 5 Vtl (7- "P-ATP (specific activity 6000 Ci/mmol, NEN 
Research products, Dupont) and sterile water. The reaction mix was incubated at 37'C for I 
h, then stopped with I ýtl 0.5 mol/I EDTA. This was mixed with 200 41 of water and purified 
through the SEP-PAK C18 cartridge to separate the incorporated label from the 
unincorporated. The labelled fractions were collected in 1.5 ml Eppendorf tubes., 
Iyophilised in a Speedvac, and resuspended in I ml sterile water. An aliquot of 2 ýtl was 
mixed with 5 ml of Liquiscant and the counts per minute determined in a beta counter. The 
specific activity was calculated as cpm/[tg. The labelled probes were then used for 
differential hybridisation. 
(b) Differential hybridisation 
The three replicated filters were hybridised with the three variants of each allele 
specific oligonucleotide probe (one variant per filter). Prior to hybridisation the filterswere 
prehybridised in polythene bags containing 20 ml of prehybridisation solution (5xSSC, 
5xDenhardt's (I x Denhardt's solution is 0.02% polyvinylpyrolidone, 0.02% Ficoll, 0.02% 
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Ficoll, 0.02% BSA), l%SDS, 0.5% non-fat dried milk (Blotto), 0.5 mg per ml denatured 
sonicated salmon sperm DNA) per bag, and left in a shaking waterbath at 37'C for one 
hour. Hybridisation was performed overnight at 3 7'C using 10 ml of hybridisation solution 
per bag. The hybridisation solution contained IX107 CpM of end-labelled 31P-ASO, plus 
5xSSC, 5xDenhardt's, l%SDS, 0.5% non-fat dried milk (Blotto), and 0.5 mg per ml 
denatured sonicated salmon sperm DNA. Since the ASO was single stranded, it did not 
require denaturation. The specific radioactivity of the ASO was lxlOlcpm/ýIg. The 
hybridisation temperature was worked out empirically, using the equation Td=4(G+C) 
2(A+T) as a guide (Suggs et al., 198 1). 
(c) Differential washing of nitrocellulose filters 
The procedure of Wood et aL (1985) was used for differential washing of the filters. 
The wash temperature was chosen 2'-5' below the Td (dissociation temperature at which 
half the oligonucleotide is dissociated). Three mol/I tetramethylammoniumchloride 
(TMAC)((CH, ), NCI) was used in the wash solution, since it eliminates the dependence of 
Td on the GC content of the probe (Jacobs et aL, 1988). Hence preferential melting of A-T 
base pairs is abolished in the presence of 3.0 mol/I (CH, ), NCI, since it binds selectively to 
these bases, thereby displacing the dissociation equilibrium and raising the melting 
temperature (Melchior et aL, 1973). Initially the filters were rinsed two times in 6xSSC at 
4'C for 30 min, with gentle shaking on the gyratory shaker. A rinse in 3.0 mol/I (CH3)4NCI 
(TMAC) wash solution (3.0 mol/I (CH3)4NCI, 50 mmol/l Tris-HCI (pH 8.0), 2 mmol/I 
EDTA, 0.1% SDS) was followed by two washes of 20 min each in the same solution at 
room temperature to remove the residual SSC, and 2x2O min high stringency washes in 3.0 
mol/I (CH, )4NCI at 45-46'C, to differentially wash off the mismatched oligonucleotides 
until the background on the Geiger counter was less than 5 counts per second. An 
autoradiograph was obtained, by exposing the filter to an X-ray film at -70'C for Ih with 
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one cronex lightening Plus intensifying screen (DuPont). 
With the use of (CH, ), NCI the differential washing was solely dependent on the 
probe length and not on the base composition. Therefore a one basepair mismatch in a 
duplex would lower the Td; hence it would melt whilst at the same temperature a perfectly 
matched duplex would be stable. On the basis of this differential thermal stability between 
matched and mismatched duplexes it was possible to screen potential CpG mutagenic sites 
around the receptor binding domain of the apo B gene. 
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Results and discussion 
The second basic region of the postulated LDL receptor-binding domain of apo B 
(residues 3357 and 3367) lies close to the epitope for the receptor blocking monoclonal 
antibody MB47 (residues 3441-3569). The mutated CpG dinucleotides 1,2, and 3 lie within 
this epitope for MB47 at residues 3480,3500 and 353 1. Although they are close to the 
putative receptor-binding domain, no variants were detected for CpG dinucleotides 1 
(3480) or 3 (353 1). However, for CpG dinucleotide 2 at residue 3500,2/298 heterozygote 
variants were detected representing a change of CGG (Arg) to CAG (Gln) (Table 20 and 
Figure 19). This was also in confirmation with the sequencing results of Soria et al. (1989) 
which showed the variant to result from a substitution of the neutral amino acid, glutamine, 
for the acidic amino acid, arginine (nucleotide 10707). The charge change resulting from 
this mutation was suggested to be responsible for the altered binding of monoclonal 
antibody MB47 to the abnormal LDL of familial defective apo B- 100 (FDB) heterozygotes 
(Weisgraber et al., 1988). The disorder familial defective apolipoprotein B- 100 (Innerarity 
et al., 1987a) has been attributed to an abnormal LDL with a reduced binding affinity for 
the LDL receptor (Vega et al., 1986). Turnover studies in such patients have shown 
reduced clearance (lower FCR) of autologous LDL compared to homologous LDL, when 
both were injected simultaneously. Competitive receptor binding assays on cultured 
human fibroblasts have shown this abnormal LDL to have a 70% reduced binding affinity 
for the receptor. The defective allele is transmitted as an autosomal coulominant trait 
(Weisgraber et al., 1988). Because there is only one molecule of apo B per LDL particle, 
half the LDL in these individuals would have the normal protein and half would have the 
mutant protein. Since this change is close to the putative receptor-binding domain, it may 
influence the interaction of LDL with the receptor. A similar disruption of binding occurs 
in the apo E variants which have a substitution of basic amino acids arginine or lysine with 
the neutral amino acids at residues 142,145, and 146 ( Mahley et al., 1984). The region of 
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apo E which interacts with the apo B/E (LDL) receptor is enriched in basic amino acids 
around residues 140-150 of the niolecule. This region is horriologous to the postulated 
receptor-binding domain in the COOH-terininal of apo 13- 100. Since the change in the 
MB47 epitope has been correlated with defective receptor-binding of LDL, it is likely that 
mutations in this region may influence the interaction of apo 13- 100 with the receptor, 
possibly via conformational changes in the ligand-receptor corriplex. A small charge 
change such as that for variant 3500 nught disrupt a critical process in the formation of the 
secondary or tertiary confin, Liration of the apo B. which might be necessary for the 
formation of ligand-receptor coinplex and Subsequent endocytosis by the cell. In the 
present study only two individLiýds exhibited this chanoc. FLirther studies of isolating LDL 
from these patients and doing receptor binding studies would indicate whether these 
patients possess an abnormal L, 1)1.. In the present study besides the two heterozygous 
individuals, the rest of the hypercholesterolaemics -, vcre hornozygotis for the wild type 
allele. This indicated that besides the 3500 variant change. there are other factors 
responsible for the hyperlipidaciiiia in these Individuals. The frequency of this variant in 
this hypercholesterolaernic ('rOL1p ýWS 111LIC11 less (0.34%) than the frequency (2.7%) in 
hypercholesterolaernic subjects in MLinich (Schuster et a/., 1990). A study on Caucasians 
in the USA, Canada. Austria and Itak estiniated the frequency to be 1/500-1/700 (0.2%- 
0.14%) (Innerarity ei al., 1990). By use ofPCR anipffication. and digestion of the PCR 
product with restriction enzynic inarkers, the 3500 mutation was shown to cosegregate 
with a particular mutant haploLypc in all affected subjects studied in eight kindreds 
(comprising 85 individuals) (1, Lid\\ ig cl al., 1990). 
The CpG dinucleotides 4 and 5 Lit residue 3611 and ')676 respectively, are not within 
the MB47 epitope. No variants O1'('pG residue 3676 \\ cre obser\ ed with either of the two 
mutated allele specific oligoiniclcotidc probes I'Or residue 3670. 
However two variants, hoino/ygous for the CpG chanoc at residue 3611, were 
observed (Table 20 and Fi, ()L11'C -0). 
This chanoe corresponded to the previously reported 
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Mspl polymorphism (Huang et al., 1988) arising from a substitution of the neutral amino 
acid, glutamine, for the basic amino acid, arginine. With the use of the allele specific probe 
the change was confirmed to be CGG4CAG. 
A randomly drawn series of subjects selected from the Caerphilly sample were also 
included as controls to check the validity of the method. The results of the differential 
hybridisation using the allele specific oligonucleotide probes confirmed the results 
obtained by restriction enzyme digestion and genomic Southern blotting, indicating that 
the method of differential hybridisation using PCR samples is accurate.. 
Because of the statistically significant association of the Mspl polymorphism with 
elevated plasma cholesterol concentration in the Caerphilly sample, a hyperlipidaernic 
sample such as that from the Northwick Park clinic might be expected to show a higher 
frequency of the Mspl polymorphism. However, this was not observed. This may be due to 
ethnic and geographic differences, one sample being Welsh (located in the southwest of 
Britain) and the other being an ethnic mixture (white and non-white Caucasians) of a north 
London population. These probably have different gene pools and therefore any 
differences might be masked, unless both controls and hyperlipidaernics were compared 
within the same population. 
It is also possible that in the hyperlipidaernic population, Mspl is not in linkage 
disequilibriurn with the variant responsible for elevating the lipid levels. If this is the case, 
then Mspl is probably not a good marker for this population. Alternatively Mspl may be in 
linkage with the mutant variant in both the populations, but in the hyperlipidaernic 
population the disequilibrium is weak and requires greater numbers to be detected. 
The serum cholesterol concentrations were not different in the Gln/Arg,,,, 
heterozygotes and the Gln/Gln,,,, homozygotes in the hypercholesterolaernic subjects 
(Table 21). In the Caerphilly subjects, however, the cholesterol concentrations were 
significantly higher in the Gln/Gln,,,, homozygotes lacking the restriction site than in the 
Gln/Arg,,, , heterozygotes. 
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For the Mspl change at amino acid 3611 the allele frequencies in the Caerphilly 
population were slightly higher than the Northwick Park hyperlipidaernic population 
(1.4% and 0.67% respectively) (Table 20). However, the overall frequencies of the Arg36,, 
4 Gln were similar, 10.4% for the Caerphilly versus 8.77% for the hypercholesterolaernics. 
Since the apo B (Arg,,,, 4 Gln) was not increased in frequency in the 
hypercholesterolaernic population, this variant mav not be a major contributor to 
hypercholesterolaernia in this group. 
In summary, the common CpG mutations around the receptor binding domain did not 
contribute considerably to hyperlipidaernia in the Northwick Park Clinic group. However, 
there may be other CpG variants elsewhere in the gene which cause hyperlipidaemia. The 
other heparin binding domains would be worth investigating for such mutations. Variants 
without the CpG dinucleotide may also contribute to hyperlipidaemia. 
Table 20. Genotype Frequencies for Hypercholesterolaemic and Caerphilly Subjects 
Variant Genotype Hypercholestero I aern ic % Gin Caerphilly Subjects (n) % Gin 
Subjectss 0) Alleles Alleles 
Arg, 61, ->Gin CAG/CAG 2 0.67 4 1.4 
CGG/CGG 248 - 230 - 
CAG/CGG 48 8.1 52 9.0 
Ar93500 
4GIn CAG/CAG 0 -0- 
CGG/CAG 2 0.34 0 
CGG/CGG 296 - 286 
n number of subjects 
% Gln Alleles percent allele frequencies 
no alleles detected 
lotes (allele frequency 0.34%) were detected in the For the Ar, -3,,, (, -> Gln variant, two lieterozyg 
hypercholesterolaernic population, whereas no variants were detected in the Caerphilly population. 
The allele frequencies for the Ar,,,,,,,, 4 GIn were similar overall in both the populations: 10.4% in 
Caerphilly versus 8.77% for the hypercholesterolaemics. 
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Figure 19. Slot Blot of Arg3..,,, 4Gln3,,,,, FDB Mutation. 
Autoradiograph of slot blot amplified genomic DNA hybridised with 
"P-labelled allele-specific oligonucleotide (ASO) probes. Lane A 
(Arg,,,, ) was probed with the wild type ASO detecting the G base. Lane 
B (Gln .... ) was probed with ASO detecting the mutated G+A base. 
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Figure 20. Slot blot of Arg36,, 4 Gln361, Mutation. 
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Autoradiograph of slot blot amplified genomic DNA hybridised with "P-labelled 
allele-specific oligonucleotide (ASO) probes. Lane A (Arg,,,, ) was probed with the 
wild type ASO detecting the G base. Lane B (Gln,,,, ) was probed with the ASO 
detecting the mutated G->A base. 
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Table 21. Cholesterol Concentrations for the Arg,,,, -+Gln and Arg,,,,,, -3-Gln Variants 
Hypercholesterolaemics 
Caerphilly Subjects 
Hm homozygotes 
Hz heterozygotes 
All Gin/Gln Gln/Arg 
Subjects 3611 Hm 3611 Hz 
8.00±1.70 7.1012.40 8.20 1.90 
ný 298 ný2 n 48 
5.60+0.72 6.45 ± 3.74 5.85 0.96 
ný 286 n-4 n 52 
Results are presented as mean ± SID (mmol/1) 
* Significantly different from the Arg3,, I 4 Gln heterozygotes 
Gln/Gln Gln/Arg 
3500 Hm 3500 Hz 
- 9.60 1.60 
n-0n2 
n0n0 
This table shows the total cholesterol concentrations for the Arg,,,, 4GIn and 
Arg,,, 4GIn variants in both groups. The mean cholesterol concentration for 
hypercholesterolaernic group was higher (8.00±1.70 mmol/1) than for the Caerphilly 
subjects (5.60±0.72 mmol/1). The cholesterol concentrations for both the homozygotes 
(Gln/Gln) and heterozygotes (Gln/Arg) in the hypercholesterolaernic group were 
similar for the Arg36,, 4 Gln variant. However, the mean cholesterol concentrations for 
the same variant in the Caerphilly subjects were significantly different between the two 
groups, as mentioned previously. For Arg15104 Gln, the cholesterol concentrations for 
the two female heterozygotes were 11.2 and 8.2 mmol/l. 
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Raw data for genotyping and haplotyping of apolipoprotein B-100 
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Key: 
Angina 
Past History MI 
ECG Ischaernia 
IHD 
Age ý Years 
Smoking 
I= No Angina 2= Angina Not Known 
I= Negative 2= Positive Not Known 
I= None 2- Possible 3 Probable Not Known 
I =None 2= Possible ECG Ischaernia without history of MI or Angina 
3= Probable ECG Ischaernia and/or history of MI and / or Angina *= Not Known 
0ý Never I= Ex-Smoker, 10+ Years 2ý Ex-Smoker, 5-9 Years 
3= Ex-Smoker, 1-4 Years 4= Ex-Smoker, less than I Year 
5= Current Pipe / Cigar 6- 1-14 cigarettes/day 7= 15-24 cigarettes/day 
8= 25+cigarettes/day *= Not Known 
Alcohol Usual consumption in cc/week 
Height- Metres 
Weight - Kg 
Body Mass Index - Weight/(Height)' 
Plasma Cholesterol, Triglyceride, HDL Cholesterol - mmol/I 
Genotype Definition 
I= Homozygous for absence of restriction site 
2= Homozygous for presence of restriction site 
3= Heterozygous 
*- No Result 
EcoRl I =(-site) EIE1 2ý (+site) E2E2 
Hincll I =(-site) HIHI 2ý (+site) H2H2 
NISPI Iý (1-site) MIMI 2- (+site) M2M2 
Pvull I= (-site) PI PI 2ý (+site) P2P2 
Xbal I= (-site) XIXI 2= (+site) X2X2 
5' Mspl Promoter I= (-Site) MIM1 2- (+site) M2M2 
Not Known 
Not Known 
Not Known 
Not known 
Not Known 
3ý site) EI E2 
3= site) HI H2 
3ý site) MI M2 
3- site) PI P2 
3ý site) XI X2 
3= site) MI M2 
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